var title_f12_48_13056="Nasal dermoid radiograph";
var content_f12_48_13056=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Radiograph of a nasal dermoid (nasal pit)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 313px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sagittal MRI of nasal pit extending to the cribriform plate (indicated by arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_48_13056=[""].join("\n");
var outline_f12_48_13056=null;
var title_f12_48_13057="TEE PFO";
var content_f12_48_13057=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/78654/teepfonc_conv.mp4?title=TEE+PFO\" style=\"width:324px;height:236px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    TEE of PFO",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 256px; height: 420px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGkAQADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5Uooq1p+n3upT+Rp1pcXc2M+XBE0jY9cAUm0ldjSbdkVaKs31ldWFwYL62ntZxyY5oyjD8DzVahNNXQNNaMKKkEMrQtMsbmJThnCnaD6E1HTEFFWryxurNLd7u3khW4jEsRdceYh6MPUVVpJp6obTWjCiiimIfGjyyLHGrO7EKqqMkk9ABXcWUCaHpQjYkXM3zszIVIYD7oOO3Pcj8DXO6XaPFa/byhzuAifGQhB5Yj9B+PtT7yWS5+QypIeoBc56fl3oA2rrxKxO22AXk7jGxyeeoP8AT+fFZ8mr3Wo3WLidmXIPynp+Gf8APNYsTCHcdjMR6nofWrf9otGWIXAPB7bh3z/9agC3qOm3cluk6QOY+RvCkZ68/kDWUUO1NrMZCRnPAHtzWm/iC5WNY1J8vPAJzx6YPGOtOF5HcO0s42jrtRQc9+TjpwPz7dgDKmhcCSKQgspzkHjJ9z+FUyCCQRgjtWxfvay+WLZZIxsG/wCcuzMOvOB/hWbdbTIdmSBwSTnNAEFPikeGQPE7I46MpwR+NMooAt/2lff8/tz/AN/W/wAaP7Svv+f25/7+t/jVSigC3/aV9/z+3P8A39b/ABo/tK+/5/bn/v63+NVKKALf9pX3/P7c/wDf1v8AGj+0r7/n9uf+/rf41UooAt/2lff8/tz/AN/W/wAaP7Svv+f25/7+t/jVSigC3/aV9/z+3P8A39b/ABo/tK+/5/bn/v63+NVKKALf9pX3/P7c/wDf1v8AGvU/2Yb26m+OXhpJbmeRD9pyrSEg/wCjS9q8hr1X9lz/AJLt4Z/7ev8A0lloA8qr0/4Uz3S6DrNt/Yl7qWnXMkazSadNsuYmHK8Agsv6cHPWvMKfHI8Tbo3ZG6ZU4NYYij7anyf1+DRtQq+xnz/1+p7JeeHdNv8AxdqHhmS9mvby701HsZr+TfPZTKWbyGYe2SeuBxUuiaRoN54l8QW1hoolisjDZW90LX7XGjLkSO8YYEliDhumB27+T+HdbvPD+qLqGnGMXaKyo7ru27hgke+CfzrPWWRXZ1kcO3VgxBNcTwNV3jz6WX39Xb0S/E6/rlNWlya3f3dNfm/wPa4rWW28N+MNM03R9K1Oe21KMmCGN2j2leWC78gKQcc8c9cUy38OaYbW3g/sWybw0+kfaZdaOfNWbYSTv3cHdgbMV4skjxkmN2UkYO04yKN7+Xs3NsznbnjPrin9Qmr2nv69ku+/b9Q+ux0vD8u9+33ntthpem6reeFotTRJpI/DQktYHXeJZQxwNu5d/BJ25GfWuL+KmnWlnLpM1rpU2nTTROJle2FssjKR8yxb2K8HHXBxxXCA4IIODTpHeRi0jMzHuxya0pYOVOop8+i6ff5+ZnVxUalNx5Ne/wBwyrNjbi4m2sSEUbmwMnHtVdVLHCgk+grQiZrdRGqDcRk9c/ga7ziNT7Z5czRgmGN+QsZA2emfb/Gq1zeRzGNHRjgfLyAR+Pp7Vmrz8r7gDzyevpU1zgRqCCNp78/pQBDc7Q+Y33D19PpUBOOvJqUqQMh8r7ZpM7fmCEZ+6T2oAaUO0dOeeTUlvB5nRiP+A5FRnIGDj8CKt2F09sTtRSfXaCf1oAbcwpDtEZYt/FkHP1xVZgN2Op960Zz9pJYkAMOmMdO9Z7ckKOeOooAjZdp5ptSvluozx1qKgAooooAKKKKACiiigAooooAKKKKACvVf2XP+S7eGf+3r/wBJZa8qr1X9lz/ku3hn/t6/9JZaAPKq6WTwRr6eBo/F7WONAkn8hbjeuS2Sv3c5xkEZx1rmq92m+LfhWTw/e+Ff7E1BfDz6JHpkVyGHnmWP51laHf5Y/fM7ZBzjH0AB5Rrvg/xBoVxDBquk3UEstut0gC78xEAhsrkD7y5B5GQDio5fDOpiHTTBA9zc33mhLSCN2mQxuVYMu3rkE8Z464r1q5+Mli08upQXfiNNVl8LPowBZdttd/uMTRv5m7DGNizYDZC8Htm6B8TdES28Ir4hh1i7u9LtdTS6uVYMzT3MzSJLzIplHzHcrlcknr3APPbfwhq8mkeINQlg+ypoawNeQ3IaOUebIETCkepHXHFc9Xtfjz4q6J4g0XxJaWkGpm41LSNMsElmgijBltpzJI7BXOAR0xnnjAFeKUAFFFa/h3S31G8yUYwR/M5xx9OfzPtQBY0G1MUUl0xdHC5RguQvXr9fp3rOu5UdwFRQ4/iUjBzzXY6pCqxFRuA+6DgHt1weCO3P4Vx1xCFfaSQO2Oh/OgCIAlcNtUj8M09SVX5AARlT8vUfSmiNgoHBUng9M0jFlHJUk/mPrQAhDIdoUhsYxj9elIoYEgZb121LHtaLLEM+OBwB/OtHw/or63r2k6RCyQzahdRWkcjfdVpHCgnGTjJoAyDnaMj2HtT1Jd8bxz+RrqtP8F6je/EiXwdBNC19FfTWTzlmEQ8osHkJxnaAjN9KoeOPC194Q8VXuiagY5ZrcqRLCSY5FZQyspI5BBFAGKMfNggdhzn86QAFlY/N60ICACSfTC4pVHB+QEk4+b6elACSHzJN8jDPoD2psy7izgbe+OORU2C+CgOe5BzineX5zZCYCjkvQB1F98L/ABRZ+HF1uS0tnszYxamUju4mmS1k+7MYg28J2zjjB9DjEtvCXiC41DTbJNGv0udSlWG0WaFohMzYxhmwMc9c4A5PFeg+M/iwbvw9o2j6BZLbwL4ftNG1G5mhC3EwizvjRwxxEeOwJ5rp9Y+NPh0Wulpoltraiz1yz1VYpkRdkUQIkj83zGeRmBI3N1BwcdwDxSbwxrkWp32nHSL572xJFzFFC0hiwcEnaCMcdeh9aq2+j6nc2r3Vtp15NbIhkaWOBmRUBwWLAYABB5r3LSvjNolhd64qTa/tutXGr2t/JbRzTjKBfJeMzAbUxhTvPBPy84qnovxmsdOuvCiZ1ldN0/8Atb+0LaIIqXH2l5WhwgcK23zFznGMHGeKAPI9f8M6z4fg06bWLCW1i1C3W6tnYgiSNs4OQTg8H5Tgj05Faur/AA/13StJ0S8uYUabWFElpYxbnuWQ5w2wL0O3pnPIyK0fiN4ztfFnh3wnBHcasL7StPjsbi3uCDbsyFv3yHcSWYMAcqMBRya6qD4uWRvdHW6bWTZxeFToNxKjKZre4YsWuIQXwTjYuSVJGRxgUAeR/wBlaiJ54DYXfnwMElj8lt0ZJwAwxkEnjmn3Gi6rbacl/caZfRWL8JcyQOsbfRiMGvWdU+L9v9i8TJob6zZX93pmm6dY6grhLhzbOC8szq+VZ1yPl3ehNSaj8UfDkvwu1Dw5aW2sLeXmm21syTRpJGJ43VmkMzSFyp2nA2gL0A9ADyhfDeuM0Sro2pM0rMsYFrIS5UZIHHJA5NVrbStQurO4u7awu5rS3/100cLMkX+8wGB+Ne9an8erS41+8u7efxElnL4hsdSjiLgbbOJAJocCTALEfd+6e5FVdM+NGjW+kyWqwalYyRXeoSxGG1imW5iuZGfEgaRQjANtJw4wB6UAeIto+prYtetp14LNArNOYG8sBvuktjHPb1r0b9lz/ku3hn/t6/8ASWWtKb4t2culzaazaw2nN4Mi0FbVipiF6oQeds3424Vvmxu56Vm/suf8l28M/wDb1/6Sy0AeVV7rF8FdMv8ATdEbStWuppbue0t7u6cxqlq83VXgbEinsvXccdO3hVa9/wCJdd1CztbS/wBb1O6tbUhreGe7kdISBgFFJwuB6UAeu3nwh8OG8uRZazqZjs9Pv7q5tzErzJJbBSFBwFO4Mfl4IIxk5zU6fDPwnp+leIp71NZuv+JDZ6xZJtAubTzpCjI6ghWfjuMbWz1xXnOi/E7xZpl3c3T6xe39xLYTafHJfXUsrWySgBniO8FHG0EH1A4NYUfijX4tUudSi1zVE1G5Ty57pbuQSyrx8rPnLDgcE9qAPQ9T+EqWVlqt59ovjaWnh231qKdocJLLJszHu6YG5unPFdJc/B/wfZX11a3Os6+0ljf2Flc+Xbw4c3kasmwluNpbJJHsB3rxk+KPEB0saadc1U6cIvIFqbuTyhHkHZszjbkDjGOKli1vxNqE87w6nrN1NI8U0pWeV2Z4xiJ255KgAKT0xxihu25UYub5Yq7GeItBfSfGWraBFMJmsb6azErDbv8ALdl3Edvu5xzXb+F9NjR4YreFGjwxO4Zb0JPTJ/p+ArA0yz1YXVxeX9pdXd1dt5ss8u7zdxJLEseSTkk579c13/hlbbTtpu4ZpvmxtZASvr2wR1/Op549zX6rX/kf3MxvEmmGcPPbR7VjbEgVOD+GO2Mn8K4u90i6WJnjj3qQNyqeQfQjrkZFesawtpd3Qn00ywRsMOjAgOpHPyHoc9jWeumxIjrG7IGGOgP6EEY9sY9KzliKcZcrZ20cmxtak61Om2k7ef3b/ceQNkhU2s3OQM0eU4Yl13YH8R6V6Hqfgqaa1kuraAMATlR8p+o5wR9BXDS6fPFctHMjKy9dw2sM8j61tueY04uz3K83mLhY1YA+pGP0rR8J6k2g+KNG1kx/aG069hu/Izs8zy3D7c4OM4xnBqidsTr5Sb0HDLgnH51N5xZWEezByfQigR6Y3xR0az8Raz4g0Pwh9l1nVI7kSzXeoi5jVpnDOwjMS9t64z0f2rmfiF42/wCE5l0a4l06Cy1CxsxZ3E9u4CTopOwhAo2bQSOpyMdMCuQktuM7mY+hqXy2Yb84QYHzA5/T/wCtQAkMaq5BJZCeOp5pvlAnYi/MCflxjipg2ZMEPtI5VeATj0FOw2FGfKXPAbHHvigCqVURokrBQp7MPzp0sOxuSFZcjHsaekaRSZcEswJGzqPfAp4hWUbkYnAwGbnA+lAHrOqfCvR7TQLuebUNR+0afaWN9dz+SotpYrhlBWE9SyhuCc7ipGBSat8FLfSPEel6TPd3l5PqN7dNAluY0LafFGGWcsxwCSfyVsAnAPCQanqd1p8Ol3Oq3k2mRN+5s3ld4lPQYQnaOp9K7PxDZazqEMXiBdS1CO+0SBQtzBdEPDCqsSqEkbSMnAU9CRg8Ck5JbmlOjOp8K269F6s1dQ+HGheHdP8AEsto/wDadtP4V/tO0kukBe3k+0KhKnAzwDhsDg9Kw/ib8LNG8HeH7t4danuNasTAZY2QGK4SQDLR4GUAJGCxO4dPSvOdQ8Va/fyztd67q9wJojbv597JIXhLbvLYk8rnnHTPOKiuvEmuXWkR6VdazqU2lx42Wcl07QrjphCdox9KZmzJooooAKKKKACiiigAr1X9lz/ku3hn/t6/9JZa8qr1X9lz/ku3hn/t6/8ASWWgDyqiiigAooooAK1NDtFmmMsxIjj5GDgk9sYqhbQPcSiNBzjJPoK6KBylp5G0AKflYHGB656HOfagC/dSlGQpIBIv8a8ZHv69qr3F4rxmMqNw4wtU7hmMiyFldCDu9ue4/wD11WiDkkqxVhyNo4oA09On+w3aXUWC6D5Q7YAyCPywaW91y+vMNJO6qTyivtH6D+eapxqsrEsyrtIzlMjnqM0QwoXLgooHb0+hqXCLfM1qdEMVWhTdGM2ovW19DoNJ8eaxpsZigaKaBhh0mXerj0OOv161vWWsaVr7ra6pbpD0xIxOSe65zn6Z/UVwM0cUZ+UnBPzADp/ShZhtCzoHXGAyjb/9aqOc9Nuvhvpl9C8+laskMsYx5Uq5QnHHzHAH5V53qejz6fI1vLKr7WOPLbbn6fzrf8M6tdadOEFyRbNgEFQwI9M4OOnrXomo6bpXibQ1NtdR/awuBG0iHB749KAPEU+c4JC4PVsfrk00pLEdzNt3H7w7/wBK3NV0DUbGWVmhligRsBlPyZ9cjjBrGuYGGJCV9ztxk/TpQBC6MAzIxA9+P0NN2DzBujJOME78gn8BWisMkqlgGXau5wEHA9eAOKZBZySTFoGxEg+eQ4RR9Scj+eaTaW5cac5tKKvcpmNCMD7hO5gWPX8O31q/Bp7GIST7LeDGPMY9f90dzUivbWePso+1TH/lo4win2Xv+P5VUMk9zckzSGR2G3JIOP8A63tU3cttDbkp0vjfM+y2+b/y+8uxXcNo8aWUHzsQDcSY3n3AGcfh+dex+CRHBoKXE1urhs75VG/zWzjAGOT6nHb8D4tAhjuM7dgxgk9SM9cZ4r3fwjqCNpVrMhjiuGTykAAzgkZAH1A59s+1UopGdStKpo9l06f1+J4b8R9DXStakntYTDZ3DnbH5ewRt3AGTgHqBx3GMCuRr3/4mab5tubY6fKkOAHkZvmY8EHI6Yz0I49MYz4Nd272tw8MuNy9wcg+4pmRDRRRQAUUUUAFFFFABXqv7Ln/ACXbwz/29f8ApLLXlVeq/suf8l28M/8Ab1/6Sy0AeVUUUUAFKoLMAoJJ4AHekrU0i2ViZpAOD8nXr+HQ+lAGlpdotrBmXG5uThtrD6fT0p8swjLDkg8lh0H+H4VHM6TBhhiVHDDGfxHeqE0m0YO185wwoAfPIWbaMSY644zULkSkBeCPz+lMkdoxkEA/XBp2Q5ySFPpxQBPF5hYNG5Uj8/8A69OjMeThc/3l6A0yFvL3ZTcCMZUU7c0ZAj3HIxkqR+dAEyTE7RE7bR2C8gf1p8ZAJcl8n/ZJH4jGarMWOHkIYDqAckflVqJ5ypO2ORSDyDk4oAcLjLtJKw38ADb/AFrqPDeo6iL0PpwczAcbE/kMkE/WuctY0mwiK7HqWIUBf1rR0+GM3gNu5BjXjZznOeMgg/rQB6PD8Qtb02D7PcaOJ2ByGcNgHp24GfbisVvFNprlysWo6Dp8UshJWe3iZGJ98dfqfeuj0C1i1kxpJEQWTkiAsxPrg4B+pqzrPwtsokJg1e+W5dS6W7aawUn22k8UMcbXXNsc5YafBEs32SIurH5j9849Ca4HxA0kWpPEiF7ZGxEoTCrwDx6dea7xfA+v6OytZJ57/wAS+UyjGf8Aa6D8sVv3OqeKVsjYv4egkeQbT5aqwxg8kKc4x3JNc9KhySc27tnsY/OHiqEcNTpqEI7Wvf59++254vD+7TGdjdznP4elRqAJC4JYnI54+vbIrr5vDOqTSs81rHEx+YJxhfwz0/GsmXRZRkiKVmQgscbcd+Of5V0HjGQDImNmTzyF44rtfCWsS6XcJPFvDOMbkcDYMYPzdh096wZNJcFWZSpYZJPyA/hj/wCtU1lp0twwO7cBwdiF/bAHr9etAHoes3V5relAPNuVjkYHygZ/h6E+nPb17+P69p/39rI0sZJyM/N6jnn/ADxXs0elvbWkTCF2ZFJVOTyDyWbGM/7I5+lcB4njmF55cUHbcflUdT1x/U/pQB5nRWnrGnyWreawOHJ3dwD9azKACiiigAooooAK9V/Zc/5Lt4Z/7ev/AEllryqvVf2XP+S7eGf+3r/0lloA8qoopygsQAMk0AS2sPnSgNkRj7zeldGYjF91FwQccYBH+NY9piPmJyTjkVoR3WIjHjcvXHTPuP8ACgAuZA7/ACg7gOucn/H9KzJWKOB1z71PuLKdzBl/UfgKi3EgZOcfyoAUqHJOD745xT1KqDk7WPXI/pUIwWHIxUr5UDaOCOhOR+FACRovlgMzMT0wM4H0p6MRny8KMYLDP+RTF2tlihyOvNOBxhYyM4zkjB/WgCYbXAyY/XcxGR+YqxahYVDI7M/oAD+lUpGdCMtz78U83DsMgDcvtyaANy3lYDcxjLMMnAA/UCpRO7RqSItmcAK+MfXP+NZCs4xhMd8r2q9HMJlALome23cT7GgD0/wR4m/s1oAssStgFtrkkAdRx/kV7HFrdveWCXECTuSobdHGSSPqRXy3DdGI+WEfOMFtzjn6KQMV23hTXLp7EW0sjNCPlGx2ZQP1wfbigD3K4nuVtfOJCpkCRZoQgB78so3dsYFFrqWn3C7bqYyIpBXzIdq/UAcfn+Vcn4dvLWC5EjXdo7svyiSUgg9+CST19q1Xu47mfP2VXTqXWLcCfYDJ/Ek96AOgvZ9Gu7bZOGngUbiuzagPTJ2gD881imy0cxusFrCkUhOZZSE2E9hkYJA6fz5psOnK935zyxBc7ipTDDt8ozzz7Vk6s9xHfolvP9niUcTzgBcZ67T6Y4wo7fWgDZ/sDQLuJ7e28lQAu4xWwywIxjOOpAxnrWNf2GnaaAlnBCJAQoSU7hH2+Y8gH8c9qdczNJpvlpO6xE5llUANJ69fXp/9ask3kF6Y0iTzYYPliiTATjPBGAPy5+tAEeqX63Mp2sH2AR4RcICfVuu0emcH071yms6bblnNze75CA7nAweP4Rnk/wCP4V1s8Dm1ZpYSshyAiLvxz24x79iK861W1njvGhjhcD5gX9T7k/qP1NAHMX0MMzShNpic9znPvn0zn8a4eaIwyFW/A+tenx/OhUfvJM7QT91fp61g+INFM6KYW3yKMoFHGO46/rQBxVFOdGjdkkUq6khlYYIPoabQAUUUUAFeq/suf8l28M/9vX/pLLXlVeq/suf8l28M/wDb1/6Sy0AeVVZt4zjccZI4Heo4E3Nk9B6jg+1XGwx4yue3vQAkZZTwcD9DU6RMXI7ckqDk/UVWDlZMDBDdc1ZiHmsVZiCOntQAx4wrfezmonOOQwPfBOM1PPuRism1mHIboarspwBn60APJyx2jGTnrmnnDOASQ3fA/pUSj5uCR71NJIMDGD2z3oA9M8O/CfUNc8OaVqttq2mx3OqQ3U9pZzeaHkW2YrJlgpRT0xuI6j3xm6H8PtV1b4fal4tge2Wzsmf/AEWQkTTIhQSSIMHKrvGTkdD+O/4Y+MUujeDNI8LSaP8AbNGt7W9tb+D7UY/tizvvUghCY2Qkj+LIY9KXQPjP/Y0WjaZbeGrR9Cs9PksJrSaYNNciXJlPnbBsDttJXafuigDyoQqxZlYYPsD/AI1G6AMAzbRnPIJH4DFTS7N2UYqmSArHPH16H9PwqJyAuxGHHqcH880ATZVyY0csMZyOg/4CRVmBnZF2gEqeoXiqCSHaFkHbhgc1asys7hDj1BIOPy/+vQBpRuY8NIBuBAQkED8q6DTZolhYSbNw4+fAJ9wC3H4Vzc0YhKq4dj7JwKltWKS4tpvnI5AZQSPQHkigD0fRtRmt4grPEygK2wMzFV98L/M4rutG1tC5KQwhSBvdYtxb2HI2148l/cxBYY5HfdyQpyR+Oeetbmg6law5RJnEh+95nHP16fmaAPYtL1neipb26Fv77uHYnpkkLwehrntZu83qvfyx7g21UwHOT6AY598d6xF1HasJnuA7424Qn09ASD9QBVlZmml83zpreNeCfMJ6+vtx36UAaUE8NnayfbRJtJPkrsDYH4nB7de3eq00810xubaFioxlh823gZOcYXjHr0qlceXHIjeahjHP7xizE4B6AY/WqXiHXporTKsCqLgRknaB9B+PBz2zQB0trqn2izeMTCA7QTIUJYp3xnpnnkkfQ1zV61g+VtHIY5B2rgt7lj/if51ybanfyI7SMEhGdzBsBcnk89T7AjHp6vtr5p2FvBEhK9CxOAPp0J57+lAC6strpYCytCWK5EaKTx7nqevtWfa3EjT5jVwzgnbgAe2T/wDqqPVP3cu5pYjtPEcKDHHTJ6DoPXHtWHcXey88y3m8xjwc52nnpxQBT8ZaQIGS9tYj5RG2dhzl8n5vYHIH19Sa5WvRtP1aGNWScLKzggiU5Ru2CDwBiuG1a0SzvZI4Wd4M/I7jBI/+t/kCgClRRRQAV6r+y5/yXbwz/wBvX/pLLXlVeq/suf8AJdvDP/b1/wCkstAHmqfIML0pyrtPsfapQADhhhf5U5YHcHaAV6jnrQA2JN2cqWAPOByKtJiAZykqD+8O3p/niktoyh3kk7SfmXPy/WtB0hlXCFVcgHaejf59RQBmuyyDBXaaquPm+RuB2oMTxOy4YDrg1HJ8/tQA8t6jmnq6dCmR+tMMh+VXYt74p6NtPBwffFADm2E5Dkd/m6fSh5ASADuHuKcT03eXjHBHUU2SMgA53A0ALvYvw2D6H+lIjoM5hPofmPNATjIVj6gjmm7tpyqkf73IoAkkyjDAOCPunkY/OrUBUKc7gPcYFVoXQKxCgHHrx+tMaYn7vBNAGissagIqhcn7wan28pQsokXDcbd/FZ8EzqCDzn2z+dWYZQjZdFYeuOfw9KAOgtrqOKAo7F3OfmWbG38BV+0mkt5BI83nS9VBB4+nI9a5/e7AFVKpjJG48inpKI1b5jk4+VyeP1waAOpsbyaO4cw280mThxITt9eh46Hv/wDXrfnupLi3XzgPOTlQWyqHsdo46d64EXNzONhKgY/jCk4PHbkVpW13yVKxOnYg9T9BQB0L6pdXERj8klhwSG+TIPXI+Y/n+FZbSQzziKRd5Ubh5bDaB16duvU1nSXMsYIKqWORhpd5P5f4UsQSKLzpwxZ+NpGEY9jg4BoAluLm0VwY45JXHBYsTjHqf60n/CQNFEMxxFlXA6ttH+f6cmqOpSuykvsGMARrzt9Kw3Yysc8bfyFAF2/1KWddy/Ow7scBfcdhWdOxEgJKk/7P+NU5VDviEl2H407y2K5JUHoTnNAFneqKn7wEjnd0x9Kq3Z+1jaMM46Maiky5GeQOQP606MlW3ce5oAzSMHB60lXdQSMFWiOT/FxxVKgAr1X9lz/ku3hn/t6/9JZa8qr1X9lz/ku3hn/t6/8ASWWgDh4sZCyL8wP5fj3rV06xSYMvmKpP3N33T9D2/H86yJ+FDHgE888f/WrU0BHkYiNw2OWjc4Yj+tAGxbadiQwzhoJwDsL9CPZx/XIqLWtDeHDKGVmONjLgk+o7HvyDXWafYrcW+xbpVb+7ODtB5yd3VcepAHT5qm+z3NjGfMUpGecAkoR1z3H4jP8AWgDyudnGI5hvx0zww4/P9KzZU+bAb8CP8ivRbxLG53LcW8fy9WQD+Y/D0P8AKub1PQYU/eWU5YN0jPLD8/6Z6UAc4rYJ4yD0B6Chhvx0BqRreaBiXUg+uOKaSeh6euKAHK2OCAR6ZpCQoyUVh9cGmqQScgYHdT1pQm3cVY8+2KABRtbKuVB7c4/Q09sLja+QfamcYAJOfQU8kH2H1H86AHuGblG3H2WmO+77zMePTFCg/wALrn3/AMaGHXJJb8xQAFQzHv8A7tWYmCJ8quP9w9aq8nufpmpGYqARke5z+vFAFyFxJ84R2I4zjdUm9W3blDEdAq4IP4VViLNnDoT264qSGVQpIKsR2Ckj+lABl0Ys3Q8AZ5H61s27STxhGyoUDgDHH0/+vWRDud9zMqZP8Cc1einJAhQMAOCzNt5oAvvdPBEIoohGQeTIBj86qXOo3G92dw8x4DM2cfQVUuFCuTK4JB4VR/jUJw2SpjXPUkkn/P4UAWjdnym83Zu7EjJH4dqrhlj/ANZ8wJ9MUpkj8raSCfyH5evvVWYbz9/2wvH696AJZrgMwACpngAVTfI+Uktj04pJ5o4hhVG4/wB3/E01HZQSDknqelACv91ScDPYVHvPbp6UbzTkOTkcAetAEczZhbj0qpVmYfIfbrVagAr1X9lz/ku3hn/t6/8ASWWvKq9V/Zc/5Lt4Z/7ev/SWWgDjJ0WSM7Qdo6rjp6+4/lSaXP5DHy8uvYdwfp/hU1xGuDscMMZG484/z/8ArqtEnzbgOh9aAOw0y7nRAy/vR94MuWHfHGM+vbHvXYw3yzIMx/MQSDG21j159D07153pl+sLYOwN2EmVz9HHSuhfUpCisY90fDbmGQp/31wR+VAEV9DDNONgkhmB52jax59uD0rCvopWYggAHPzMvIH1ArrvPguwVnZ4yRnccPn6n/62eKzJYIziNWD8ZAyG568Z56ei0AcjPbSQjDoxB4yOfxrLZFPADg56gZrr5jNZSbY5cKescibTj6Hg1mTTW9yG822hLcfdG0j86AMAoUzn9RgUZP8AdP07VeWGGTiTzYwDgFwcfrUM1qyn91hx6qaAKjnoUOCO/Wjbkk4A/Cnsrqfmz+BprMQc9KABhnqRx9KejlT8v+NIv7w8biPYGmSo2RkN9cf/AF6AFG4OSW5PbFS7XfGU5Htg1GMevzUL97GKALC7zz5WPqacigcqrA46ZyP61CXDEYfb7gk/zoZyXG5t47bsmgCzOxR8jAPc5xn/ABp1vKMEAhW9jgH8etUg2x8EcHrzgVejO4EIox06GgCG4LKw8v5vzIprKeFJJ/2V4AqcrIzYyR7YwB+tMC7QwU5I4JPAGfrk0ARiEgnLAscgYPT88VBNI0a9znpzirMgAXJfbu9Bgn8f8KiQLuztkYg9vrQBCVyBlevfH8qeYJHHXA9+KliieVzsRiO+D+mat+QcZLADtg5oAzxblOOv4cmkABcDOO2BWo6Ike0kbvfjH4VQmTJGwc+tAFW4+VCO561Uq7dFVjZNw3egqlQAV6r+y5/yXbwz/wBvX/pLLXlVeq/suf8AJdvDP/b1/wCkstAHmaXkypsYh09GGavWNxvlCxqrE/wOcZrIooA7G2ijmypDxEduGx74Na1lBdQMzWkzIoOSE+YfTb1/OuJtNXuoHTe/mov8LHnrnr1zXQ23iu2VVaWK4WT+Ly9p/XjP4igDrbIxy7hKqly3IQ7SSOeU6H3NIWsw7RsHWQjG9TjH1A/lWA/jPT2dN9vczAfxMiqw49QeefpUd74s0yVlKR3xUfwuq4/9CP8AKgDWnsr7btjlV4SMbHQMCMZ7DA/ECsCdFiZi9vErnjMZwB698ZqRvFlmir5K3Y4wQyr+HIbNUrzxHDeKRMLgHH8Kr/jQBEJR8wOQO2e/4VDJNgD5lb8dv4f5FVReWh3b45Gycg4xj9aWO8tF3fJNyOO/P0zQBLPJlPnST0GWDD+XFVfl5+TJ9802W5idyRvII6lR1/OmNPGQMKwP0oAnjcKOPvd+cU0gZzkn3zURuhtAUHj1ANJ56+jZ/KgCYMSc5wPrSF933ug7ZqL7SAeA2PrzSi4Xrl89qAJU+U5Xpx2p2VY5JCn1Jzmq/wBoUDoxPfNL9oTHRs/QUAWN/Iy3T1yak2ljuKP09M5/DNVUulU9X/75Bp/21B03H8P/AK9AF1JMICQVHT52wKC8Zb5MyH2UkD8aom6iLhiHPsVFOa+jOPlcgep/pQBoCTceeF9ABgUFYx8zASEj+M9PwGarDULULjZJu9di8fmTTI7s3MyRIs7M7BVSJcsxPAA9/pQDdtzcs1WRGDkDBydq5/QcfiakaLIIgjII5Lsef0/pWSdRitHkikhuBLGSpjkABVgeQR2PaqV1rF3cLsEhjj5wqccZ/wA9KATua9pBFJq9na3Rx586R4Xrhmxn2/Wq/jKBdL8QXljas/lR7MMxG45UMegHrWXo9yllq9jdShjHBOkrBepCsCce/FW/Fupw6x4gu762WRIZdm0SABhhFHOCe4rB8/t1/Lb8bo537T6wv5bP77r9DHorQ0TSp9ZvZLa1eNJI7a4uiZCQNkMLzMOAeSsZA98Zx1rPrc6Ar1X9lz/ku3hn/t6/9JZa8qr1X9lz/ku3hn/t6/8ASWWgDz/z9E/6B+pf+B6f/GaPP0T/AKB+pf8Agen/AMZrKorT2svL7l/kY+wj3f8A4E/8zV8/RP8AoH6l/wCB6f8Axmjz9E/6B+pf+B6f/GayqKPay8vuX+Qewj3f/gT/AMzV8/RP+gfqX/gen/xmjz9E/wCgfqX/AIHp/wDGayqKPay8vuX+Qewj3f8A4E/8zV8/RP8AoH6l/wCB6f8Axmjz9E/6B+pf+B6f/GayqKPay8vuX+Qewj3f/gT/AMzV8/RP+gfqX/gen/xmjz9E/wCgfqX/AIHp/wDGayqKPay8vuX+Qewj3f8A4E/8zV8/RP8AoH6l/wCB6f8Axmjz9E/6B+pf+B6f/GayqKPay8vuX+Qewj3f/gT/AMzV8/RP+gfqX/gen/xmjz9E/wCgfqX/AIHp/wDGayqKPay8vuX+Qewj3f8A4E/8zV8/RP8AoH6l/wCB6f8Axmjz9E/6B+pf+B6f/GayqKPay8vuX+Qewj3f/gT/AMzV8/RP+gfqX/gen/xmjz9E/wCgfqX/AIHp/wDGayqKPay8vuX+Qewj3f8A4E/8zV8/RP8AoH6l/wCB6f8Axmjz9E/6B+pf+B6f/GayqKPay8vuX+Qewj3f/gT/AMzV8/RP+gfqX/gen/xmlurexm0qW8sIrmDyZo4XSaZZd+9XIIIRcY8s+uc9sc5NdH4TtU1RJ9MlLJE9xazM6nnHmeSVHof3+c8/d6c8aU26suRpa36LsY1lGhD2ib0t1b667vsV5rDS7TNrf3l7HqETss6w2ySRqRj5QS6kkHIJ6E9OBk15dXmWJ7ewVbO1ZSm2NVEjIeqvIAGcHqQTtz0AAAFXULt7+/ubuYKstxK0rBRwCxJOPbmq1RKpZvk0RpCjdJ1dX57J+Rpxa9rEMSRQ6tfxxooVUW5cBQOgAzwKlOtrLEqXmlaXcMrEq/kmA844PlFARx3B6mseikq09r/qU8PSbvy2flo/vRtm40aCeS7t4bmWRtxitZEURQMQduWLMZApxwVG7HPcFkfiXWY2JGoTuGUq6yEOsoIIO9WyHODjLA8ADoBjHop+2mvh09NBfVqb+Nc3rr/X69T0H4e3VhdX2ozzxKuqnSNViCxRiKPb9gnIkAX5dwCshXABDqeoYmC5siJNLAsv9GayV4y2nxoj3H2XdGqygZlLP1U9Txhqz/ht/wAjFd/9gbVv/TfcVytXDEW3Xb8O/e5lUwnN8MrLXz3XTtbodhaW143ntJpka6qHgDQxWKSyLCfM3ubcjap4j7Lxt/vkt2H7OUUUP7RWixW7xPCk16qNFnYyi3mAK5JOMdOT9TXj9eq/suf8l28M/wDb1/6Sy1NSqpxSsXSoOnNyvv0t/wAP8l0uzq/+F5eB/wDoi/hv/vqD/wCRqP8AheXgf/oi/hv/AL6g/wDkavn+isTpPoD/AIXl4H/6Iv4b/wC+oP8A5Go/4Xl4H/6Iv4b/AO+oP/kavn+igD6A/wCF5eB/+iL+G/8AvqD/AORqP+F5eB/+iL+G/wDvqD/5Gr5/ooA+gP8AheXgf/oi/hv/AL6g/wDkaj/heXgf/oi/hv8A76g/+Rq+f6KAPoD/AIXl4H/6Iv4b/wC+oP8A5Go/4Xl4H/6Iv4b/AO+oP/kavn+igD6A/wCF5eB/+iL+G/8AvqD/AORq2vDnxT8G600pX4OeGoYo8AtiFsk9h/o2O3r3HrXzdp9nNfXSQW4BdupPAUepPYV3xMOk2otrJvLMZ+5LjLHGc7ue/OMfT2APaD8QPAozu+FPhrjOSIoMD6/uKzrr4rfD6BR/xafw6zE4x5dv/MQmvAtS1W41AlNzhHG4jv8ApUdrGkrrmdAcAkAc8Y7djQB7nP8AGDwRFkj4OeGmTsw8jn3/AOPeq6/GrwOS3/FmvDmB0P7j/wCR+K8taOxa1eKW5lMrKChIABIPJ56A8jH0rFe0dZniilWQLhiQc5zz2oA9ql+NvgVBhfg14bZu4/cf/I9Q/wDC8vA//RF/Df8A31B/8jV4/dWMltH9puYfLBGxY9uGcjkkjrxjmsOZNpDBdqnpzmgD3z/heXgf/oi/hv8A76g/+RqVPjl4GLrv+DHhwLnkgwEgfT7PXz9RQB9Ff8Lv+HX/AER/RP8Avzbf/Gamt/jv4BtnL23wm0iFzj5o0t1PBDDpF2IB+oBr5vopp22E0mrM+iv+F3/Dr/oj+if9+bb/AOM0f8Lv+HX/AER/RP8Avzbf/Ga+daKQz6K/4Xf8Ov8Aoj+if9+bb/4zR/wu/wCHX/RH9E/7823/AMZr51ooA+iv+F3/AA6/6I/on/fm2/8AjNH/AAu/4df9Ef0T/vzbf/Ga+daKAPpC2+O/gC1kMlr8JdIhkZHjLRpbqSjqVZciLoVYgjuCR3qH/hd/w6/6I/on/fm2/wDjNfOtFAH0V/wu/wCHX/RH9E/7823/AMZq3pf7QHgjSL+K+0r4WabY3sWfLuLYQRSJkEHDLECMgkfQ181UUAT30SwXtxChJWORkBPXAOK634XaPpur6nq/9s2zXVvZ6ZNeLEspj3MjJjkexI/GuW1b/kK3v/XZ/wD0I1p+EPE114Wvrm6s7e0uDcW7Wskd0jMhRipPAI/uj9awxMZypSjT3+42w8oRqJz2Ott/Dmi69pmla1oFnJZZ1aHT7ixu5jNExcrghxhscgEdeTjGOYNM8Af27rmr20V2bSW31Ca1WKCxmlhTa3BMgyEXsNxJwMmsm98eancT6WYbbT7K0065S7hsrSDy4TKpBDMM5PT17mrNt8RdRiD+bp+m3D/2i2qRGRH/AHUzNuOAHGRnpnOPyri9ni4p8j9Nb2+/f+tTs9phpNcy9dLX+7Ys6X8Nbq4s765vb4QJa3ctkwt7WS5O+M4Zm2DKr7n8qS68IaWfBGiX9tqKjVr2WWJYikhFw4cKEXjCkZ6nAOag0r4i32m3l5ew6bp32+4uJbkzjzVIZ2LEEBwGUEnAbOPeqCeM7v8AsGPTZ7SzneCd7i2umVhLA7tuYrggHnnkf0p8uLcrt6XXbaz/AFt+hPNhVGyWtvPuv+CXdZ8CCxs9Va01i2vr3SdpvrZInTy8nBKsRh8Hr0rovEfw5S88a+IY9LVrHR9PMC7YYJLl9zxIcKi5Y8kkntmuX1nx5ealY38K6fp1pPqO37bc28bCSfacjOWIGTycAZqZ/iLqdxquq3d7Z2FzDqflm4tWVxHujUKrKQ25TgetLkxj1vrZ9v7vy6St+JXPhNrafP8AvfPtcxPF/h648Ma7Npt06ysiq6yKCodWGQcHkH1B7isStLXdT/ta/NyLS2s12hFitwwUAf7xJJ9STVjw7YtLI12SAkBBGe57/wCeOvXivQpc3IuffqcFTl53ybG54atIrKylYhJbiaMlzsIMQ4wvP6/1xmqeqWRNuj/ad787uAW9vw9qj1G8+0SszM6IBjG7OR3xWY0wUYDsQTy2Tn8/yrQgguInhAMocgng9P6e9NE7xoqh+nPsKWYs5JOAehJb/E1CEbA7jvgigB3nPlcMRjjjt2qxZ3ckFwsiyOHHfJGR356iqqtsBwOT0Oegp8JAkUM7IvqBn9KANQanK/myyRbvMJYkDBb2z6CsqUgn1HOKuXKxqhCXIk24BG3H6/lVMqRg5XLdB3oAhpKllUZODk/zqKgAooooAKKKKACiiigAooooAKKKKACiiigBzszszOxZmOSSckmm0UUAFFFFABRRRQAUUU5VLsFQFmJwABkk0AS2Vu11cLGMgdWIBOB3OBXXTmytLPEAzKvybRkYAzxg8HJPqOtP0XSmtIGjZDKXG8vGCwJ9OB256/lzVbxIis/lSrFGQmd8bEhgOnagDm5nBkGWJwTnn/61ObPlIN3y49Ov681GQASDyR0Bzj8aC+SwBHl5ztx/SgBUCktg9ARn1/CmZ+bqeCcbeKeqNKCeSyjj3pojbBKkfQHNACfIQSVJP15NIoBwAMevPJq9a6Pf3Wm32oW9pcS2dl5f2qZEJSAOdqbz2yQQM9an0zQ9TvNOvtRsdOurrT7EA3NwkBaOEHoWI6dO9AFJMxxqwBIPIxgcZ71GxZgckYJzyecUA72JdQCOpxzxSZDAF24HGQSKAGlWAywIA4NQnqalOSdqjvjnj6U7GcqQeBjigCvRTmUqcMMU2gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACtzRNOYp9onDoGwIyp5PrVDSrNry5A2lkTBbAzkZ6fz/Kut0+3VCpkijOflO4BQBx07igDXtYLqztAba4UmQYYEhs9jkEfT/JrA8RTRySrcKnlsy7cxcDPfrwOR716JpVs7ofOnZQAAI5IuDjpg/wD1q5fxNpEs95LNbW8vCZJXkEf7vt6ZxjHSgDz+dW3OwPJ69jUTBR3HPQHnA/GrD25WQhmCnnLBf60i7UmZWUF+3pigCHcWb5yRjpk4/pTyqpDnO4dxjOP6VIDjoyqOmSaXjLfNIR1AjDc//W/GgD0X4X6hoX/Cu/H2ga/raaPLrJsBbTS2s0ynyZXkfiNWPTA7de/Ndx4A8beA/BugWXhe41K7v7G/kuhq11bwPHCyyZiXcjp5hCxqrDA4LHqeK+fnRI8bVDj0Pb6nNLsLvkocEZwQetAFjUYoIbu4iiuRdW8bsqTqmPOUHggHBAIwcHn1qIRAZyMjttAH58U+bcUIjVA/I25/+vTA5Conlk+vPP5CgBgBeQsfkKk8qcE01C2/cA5JJ5z19verAAXa6OpkHPAPApQz7gDn069frQAtlpN1q919nsIzJMc7QWAJwMkc/SsivWPhvJFZGeTyzJO6iAA5OASOwznp+nbrVP4t+DjprQa5YrI9tdgtcKIlVYW4Ab5eAGJP0I6/MBQB5nRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAU6NGkcIgJY9BTa6HRrLyofOcRmSRcAOcYU9/x57/1FAFyztjawRRhXTn/AFgYAE+p7fn9K17KJmkVZfkRTvKxkL0PUE/yrMJZCUZHgBI5RiB+f9fetC21GGDa/kqpUgZ2naT68dP88UAeo6Pc6fbaUifaW8kplQ6g49u2AOvPPoax9asBKzXVpMkqscmNRhlz3Az6ccVzkPiFXmUgRpuIVwT8pxjqD7dDxj0qzFr1rZzrCsPlxs2fLk2suT6HuMdOB9aAOb8TaG9q32hWHlzEkq6bSCeenT+X9a5eREKbCpDL1bOOfp2r2bVLPSb/AEiVracbnwzKH28np8rjHGM5B/CvK9QsSk7xjB2k7c/xY47GgDKjKsCijHOM/wCRT/LZk25iPPVhjH4HrUzIQNs8YRV6bcdfxNMdiSGVVcA43NlQB+dAD4vLVSrbUC8ht27P4Gq49VZQc9AecfhU+zc6sCWz1KjP6mn72ZPmVdo67WGfxPSgCKSVlEYOcg5Ij4yKdMBs3o+0HBIPLfrS29sHm35O49MDp+PeleFcnLuRnGVXgUAESo6tuBOACGbJB/OkRGeQDYRtO4Z9Ke1vGVzIzhvU9/8AGrUUWxIsBGTPIbjH5+woA9H+FSJIywbEhwxkeRzznjjPXAH0612/jibT5LCSxvR9ojlXyxHJkk/h29R3HB4xxxXw0u0trtgd0sko2h+GIPUAZGBnueegrtfEJe8tFS3j2zngMX3FcDkkj0zn6/XIAPmzxBpE+i6k9pcENgbkcdHU9Djt0P5fjWbXqfjzRzd26gn9/EDtchRuIBJHryfU15cysjFWBVgcEEYINADaKKKACiiigAooooAKKKKACiiigAoop8aGRgqj6nHSgC1pdus0+6VsRpycDOfzro50xlo0MgK52ZJX1JX3/wAKzrZktjCyRqAAQBKcg/0I960RPn95GQnrHnK/h6fSgAgvre3HyKzDGDGSf5YNMXVHLGWA+SoA+Vl3D/PvVa8nYjBQSNnKsrY/Wq0kz+XvV8+vOPwoAsNelpMMFVi2SVPy59amhuSzhd8uCMbV+X+XH41Ri4b8OCO351Mt1Az4k6L0yoI+ooA7fwXr5hEtrcSwmHkL5q/Jknn5hj36/hSeILJFcSw28SeZllKSF1x1PYf1rloYzIUNvsYZ6L0x710+g32nRu9rqMflR4AOEG5v/Hhn9f1oA5ySeXdsMYU+oYj9M1VkgViSA7N0Ytx+uea9Gl0TRVmEllN9rtz9zL4ZPYjqCKu6N4Y0C7u3e9aazjUbmkU7wxOBjGD+dYqvDn5Op6csoxKw31tJOn3TX5bnk9zE7xAghduRhTUUULBgJJHU9ck5Fe0ar4T8NXjmHS9VEUqnGTvkY/8AAFFc7rvw3vdn+hzQ3RB4BIhc/RX5rY8w4FVbzPkbcMfezj/Go1kdC21oyxyC23n/AD9K7dPhr4lmRTDpUfHHzTr/ACJFR3Xw58SQRlrqGK0AGSZJkBAHfbycfpQBxplUuD5gR+jOTn8qkQGYBEUhV67sAgfyrTOkWsE/kzTteXA4JiGR16Zz/TvWlY+HZrpXZUSGKPG3ksSx6DGOv50AP8IXb21xvjUs235VZtq8dWPt+XWvS7S5mvbeKJ1iiZQGKlcAL0B9Bz06juK5vTtAfTYYrjyZJZ9u4/KAEOO3fP61txafK8P22eZ4RyzjHtyD+PWgDnvGtvbeQhtVDYcmQlicn6n+RNeVa/ZouLiEEHpLxgZPfH+f516vfOsqmOJ5I1yeSck/lyT1OB/jXC6mvlq0gR1tyxXDEZYe49KAOHoqe6ga3k2tnaeQT3qCgAooooAKKKKACiiigAooooAK1LODy4wSPvjk5xx6c/yqrYqqyiSTO0H5frWmreZuMRIHcDnH4d6AJPKlicoH3KR3HT3/APr0rTOsTFAAfXbk1E7yIRvAx1DA4/z+NRCR9xLAcdeOR+VABNK5iDFFJ7nOKjV1kA3ZYY6Fc/5NPbayExnYuc//AFqjTO/5Qfy4/wD1UAPJFuoZWHGBgn+VSECRjlcAc896jdmK7Q4DDt1/D0pMHaA3mBh0JP8An9aALUTGI5I2huhVuPyzV2INIhYlinXq2Mf596oR2rKmXdUiPp/9erti32QmQXCgN3CnmgC/pVzIrh4bjynTglnyMemDxXVWOsyyTDMUDD0Dgn9f8K5dbmCd18wgMedyEjP61NaTqjsqp5qLkAuuf1J4qJU4yd2tTppYyvRpulCVovVro/kerWEEEkKyyWE/zDOYcMoHckYJH6121tDaR2NvHFaQujDIddsjN2yCCD+PavL/AANrX2C6U/Z1I+7lQpIP/AnHr2r1e0uNJngE8WoHTrx+uwoN5/2l3kN/P3FFpLbUOalV+Jcr7rb7t18r+SIY9HhvFJWK5tUHy7mL7s9zgt0/Cq+j+AfDD3cwuxd3zs+ZDNctHGD+A/zitFtVawTZJFbjPS6hTeGHqy5LL1/2h71lXOoagzpJDJb3Vu74DSvtXn0AwG69Of6U1JPQzqUJ01zPVd1t/XludJaeD9Ft1kfTrG3iQnAW0QIOOPvYBIqm2gafauQJolkYDYigFx2OMHgdPx9eBRC+t3cIFzK7RMuBHbLti7feY4OfoR/WsrWrWa2XyyRHG5yVVvMZjjoFx1/MVRkakWn2CQJFA6vN0xvyWx3znA9T3rC162NwPL2qYU+9K5IQY/uj29u1LFfGztTHDblLll4MpXzG/Becex6Vjz3B1GZTdyy3DDJEa5CKoyCTwBkZ7Yxg8+gBhalpNtNM8zXn2eFRgIo2scnnj0/n1rlNVWwlaSC3MkzxAqJGc4Z+eAo7Djp19+tdP4vsxJDGiICuMgNnaeM4AB+bp2J+tcnp1i8s8vl8AcAL3P8AdGOScduPegDltasmkgWJ9y46Z6bu3T6+lck6NG7I4wykgj3r1LVdJawtmaSRWnYEn5unt16dOa4LVLJ/KFwqNxw3Hb1oAyKKKKACiiigAooooAKfEu5wD07/AEptXYYlWHJbk+3FADjhRwPk9PSnI2M4GVIx3GfrSIfnxwR78irCEqT5YG08AigByOsp2evbOe3602cMqhgBkHG4HJ/P/Go4pAkgCock565q87JKhBHz4wQRyaAM5kMiDglj0I4psKCJ/usW+tB+QlR+ORWv4T8O6j4r8Q2ei6LGJ9Qut/lIzhAdqM55Jx0U0AZ0WRllQsvbPGKepDZ2kB8/dPP9K6TUvBHiDS9Y0fTri0hmbWCBp8trcxzxXBLBPldCV+8QDk8Vn+MfD2o+FPEE+ja/arBfQBSyh9wwyhgQVJB4PagDMZnXhjnHUdcfmaWGRixAfKducfzqLeM/NIwyPT/61OhkRZsgMc9Tv2mgC3G7REEqjt6FKla5eQ/Oi+mDVbeqKdrMD6AD/wCJpkM77wVQ7myDlj/KgDf02R7ciSNVWT+A7QNv/jvp712Oh69eIvkXF2zREc7ZmUL9cEfyrgLWZrdxIhdXPJOT0/Ktm11U7AI2kUE/dAGW/AEE0Aet+E7v7KxNo6FWGCwKkL+YrQaIm/kky5kkG5po12Jk+oI2/wAz7ivNYddvUCbGSBVPLYYMfwJ4/Guz8Na/JLEHe9A4ywMYDAcZxk4/LNJpPc0p1Z03eDt/XXuejeEIBqWsgzyGW0tLdppYxK6q54AGS2OTgYx61q6l4Z0a31PW2uIrpoxaC9t1ikLBVJA4GQODkAZI6k81582u3ZE0MLPHBMRvCI/zqOQWJwCM/l60Q67erJAtjPdia3jMccom4RDjKqVPAJGcZ9PamZvU6bTNF05dX0K0SSZp7+zF5JE9tG0Cq0DvgseCQQoHHvUtj4dhn8LnULmV4J1sjerENjRsgOAegHTpk++K88e41BL+O7l1S5tWgjEMcgkO5UwV2oeqjBxtHGD+ASXxDcxWDQf2nq7WpBRbWGchdrHJyucAfnQB2XjbS9P1HxzJpTRNDaFoBKYkJ4aNCTgc8ZzgYz+dSSfDbTIdQDpd3EdmlrNcoiOjeasbKDtYdPvjOQSPzrym7168kv1vTdyi5QhkmnuS8hKjAO7JJwBwB6VW1PxnrJvEu4tXuZr5BtW7kmYtH1+6SaAO51bwDo81zLez32qX1mb22tII7WJS+JlJJII6qwIyAQccYzkNf4YaDc6LbafK94dRHiCXTJr2PGx0EiqMqTgDa2RgZ3ZGcYNee/8ACyPEtvpt5ZR6tcmW6uEnkvmuJFuCVUqFDBh8pB6Edqx9P8Tapa2E1kmp3UVjI4kkhWZkV3BBDEA9cgHPXjtwaAOjHwTgGqWUF1eX1ql54ml0WMNDg+QsW8Sjd1JII9MCkHwq8KXmi293pur65517pd/e2i3FvEFD2bssnmYY4ViowBkjqSelZN94y1jV7ZFvNa1VHhkD21wtw5aGYAASKS27djIznOCRkV55JrmuWbLbLrGoKluksEapcyBVSQkyKozwrk5I/izzQBj0UUUAFFFFAFiCPgsRzjjPFOxntgHqDTlTack+3tTyMLkY7UANJZQcDPuakVtyAZPHp3poPHJHPpT1iZ8bFBJ7igBCVIwQeP4hU0r/ALlQwLDs1M4XllI7ZH9abKCykKTtPoaAERmGCuM12fwf8VWXgv4j6Tr+pQ3Mlla+d5kdsqtId0LoMBiB1YZ5HFcRuwMdqcAHBGSCR7UAe5W3xX8OPqvhvxBcabfR6to2mTW0Wm2sEaWAueQkiYYFFO5iwC5BC4zjNcZ8UPGmkeL9O8Ny2mnz2WsadamwuVdy0Twof3O12bezAFs7h368VwXVOhbB4J5psMfzHdnn2zQBIo43qhBzg4ORTmkVVBiCDH8TY/TjNIxSPGACehyDk0rsoUbgcnt2/wAKAJ1LvFuZ8nA5Q7TUflIV3MzfiT/hTB8zbQFQEcj/ADing7DuGMjvv/lQBYtVQSD55C2DjccitVJQ8KxmJGC4GXbIH4E5FYyP5wyWBOfuhv6VdiEioCp2jHOH/wAKANhLqQmOKJvJQcAJndW7BdSwIHt2fAwGLuynPrk/yrjoM5O8qYz94DBJq2gIGAY41zxt4Oe2aAO5iuYRbGS5kPnkAl52U/gOA2PSrVvPJCSouTtPTcynGD2B+7371ylnqE00ZEknlRg4OBycY/L61pi+EsKNF8uzgHblvTG5qANl5gXd4VlncDqCFH5g4/IVnQyPJcStNK7tnPTIU9sfw/jmqAaWUsJ7kxxqfmCZGR6E8Dn8apwyTSXRhhRvJ28Dfkgfhk4/SgB2sRq0mQpYggbcg8fjVaWaAWSu6l34GC2Bk9OfT3FGsHyIyjhIw3JGckHHft+QrnJpzLL+85VT26UAWndWwA5mbdu54Vc+n/1/TpVa+eOMYA+Y4GSeT+FRB3Yu+diKM4HaolbL72GR65wcUAS28koTCow988D6f5/xqLVLMyWomBzLGMNzxt6/nTWYK5G4kDgDP+c0kshYoCpHP98mgDFoq1fQeU+9AfLb2xg9xVWgAooooAvxks20jnswPWnKhJKNnP0zSsp8sMMEZwGU1JF8zKGwx4AHAYUAQ7CG2k/KOnrWzp+mNNFviKu23kKdrEf57cVB5PnHG75gc88H6Y//AF1pWFsBhopZIXUc+lAGbe2UioWyxYcEMvzD2qhGqqG3cgjGV5xXY3tyrxIt5EkpXgMDscfQ9+veuevYIJVLW02eeVYYI/Hof0oAyRtORnp3xT9uB6j+VDZBII6U0MDwcZoAViNuCo/lQuD0zk0ZOSuM8ZHGaOSfvUAOy3TIJ9qTBK8rkCmsA+Mnn8qbINgySfTPH86AJYwNx3AbcevP8qnWCJlypYd8kgj+lVomwuRsb1zzQJGDDbjIoAnQrGSVYIRxuxz/ADq3Ady73Z2B9BgH8qoNk4Lswb0pyf7KjPrv2n+dAF9piE2rlDnj5ePrWhaXYVQSXbC9WY4/lnt2rGkztGxORznd1/Gi3udmFO1VPJ5YfyoA1Zpo3cqEYAnPzMXB/Bu35VbklB2BJMLjnAGOPcVQjmER3r1xyAc/qRU0N02GUYGecr8zH/PvQBJJuZk+USEEEbvu/p/KrAu5woKTkLwMJwBx2x/9aqbS7cllIz6/4dBWddTy+YQ65HoWI/SgC5dz7juYZcnJdgSM/wBaoTz78L8zKDkELgfgKXczBidxI7KOB+P+NRiZY5PmHzd8nP60AEjcDCkHp8xqCQljncSf0FOuDuYndgH161DITsAGMDqxoAeBsKkZ6Zo81lBI4P8AeHX86i3EYVVY+560772Tzt9zQAs7Bbcj724Y+n41n1dnlLRbQAFFUqACiiigDQDeWASxU+uOtTQsGJ+QAg5yOoqJWODgjnt6084VQcbT9cEf/WoAu2s2ZFDxs6jrt+96f54rttNt47uOKSyu0SUABkk6egA+voK4fTEWWTKuBIOdp+v5/l612elXVvJ+7vkBfG0Sq+xx25PQjt0/OgB2qaUzJjyhBL6p0b8uDXNXttLa5bZnsPl4Pfgjiu8SFYYP+PiRrYjIdlJ2jHfHSqGo2ayRlopY33c5JGD+PT9aAPO5SLhiFCI+eQTiq8yhNo539/mzWprFpJFcOzqcjk9CR9e/51m5TGVH5ZBFAEaAY77qVgexal2kglRn2PJp0bEjaZMfnQBECOmOnpQrfOVAUe/U0rsSckbse9IT0OB9M5oAlBXJLJnHXNIxOGAG1T2zimAZ+bg89BRjP3l6dMnGKAJ49ykFdnuRk0edGrbpNzHphf8A69QEZ4GfzzUvEcfzKeegJNACxSEvuVFVT0JyBUkk8hT5flXPXJpVnRYwAQSexSotysTuyeeBnigCWNXkVVC4XqCM4oO8kmV3IHZQcVEr5yADjphR/Opi7EhVQY9WI/kaAGzSlgBE59ODyarldzfKAv6fnU5kcP8AK4J6fKM/5/CmBSWZmBK+rcHNAEhkPyouSAOdo4HvUDjvhsc8ntUrKWHTYfT/AOtQ6HaNx5HQAZzQBAxGzhFJ9SOlIgJUdvcnpTkBY/MCR2AHWpShC7ioTPTJyxNAFcsGYqGyadtBGME1PDETwpxkctjp+NRuqgkDJA7+tAEUp+Ru4xjjtVKtF8vA/wDCig//AKqzqACiiigC0kqt1Az796tRNtX94Nyf3e4+lZdPSRk6UAa8CIsgcu2zsR1FdZo6B9jROsh7jbhj9QOv5d6420u13jey88HPB/w9etdJp0FvKCDI0bAZ44wfcdPyPPpQB1USm3iLiMhTn5oGO3P+71/LNZ19EcNJEpYEktJG3ceuMjv3GaX/AE62XdFcCUKMY/iA7ZB5qN9XDNi5gRJRxuVtjH8Dj+ZoAybyVyGGR5eeh5x+BrCnRRIz7WXHO5fmroNQnEk2BsyD0fKsOOmf/r1iXg2PwShHGHHH4EUAVAIyGYH5fQ8UFtgwmcejDIH41HllbO4qe5zxQMliTyc9sZoASdtoBKL+ApFJChgvB7dalkJWMbsE9s4yKgDDHzYxQA/ryBz6EChnAH3AD9RTBj7wOD78UrE7Bll/E0ALg4yV/rUsSoMFmAHcE4qFTtGdqN7nJ/lRFLh2+UfTnAoAnn2qV28Z9F/rSpEcAkLj1bmhVWX7zkD2XpUqyIi4IlKr3yBQBA4yTkrtB6DgUqMqgjcMemCR/SlmWNRkqc+7ZzSHORltoPZTjH1FAE3U8q+B7YWo5CxbCsQP9kf1pUEIUFXcsewXp+OKltY2duJMMOuSCfyoAYqhUHlgsxI5POPr2FSCzkCl3KxJ3J6/h/kU8hQ+GViBxknP60+2Rnc4GF7MTtA+hoAZDaeYSIUZu+T3GfT/ABpHtnEmxFyeQT2HOMen4VrQ2xlJCOp9Tj5R/jUN5eW1lGAZRLJgg4P3eP07en1oAykjdnwxLf7IFRyIpnSOEM8khCqEXduJPRe5NQz6m7AiIEZJJZjnPvjp/On+GmLeJtJLEk/a4eSf9sVM5csXLsROXLFy7Fe9EtvM0E1vJBKv3llUhxnnoenBqnXTfEj/AJHTUf8Atn/6LWuZqaM/aU4zfVJk0Kjq0o1H1Sf3hRRRWhqav/COa3/0BtS/8BX/AMKP+Ec1v/oDal/4Cv8A4VlUVpen2f3/APAMeWt/Mvuf/wAkav8Awjmt/wDQG1L/AMBX/wAKki0LxBF/qtL1VP8Adt5B/Ssaii9Ps/v/AOAHLW/mX3P/AOSN/wDszxQQB9i1rA6DypeP0pG0rxMybGsNZKddphlx/KsGii9Ps/v/AOAHLW/mX3P/AOSNs6N4ixj+zdXx6eRJ/hSHRPEJHOmat/4Dyf4Vi0UXp9n9/wDwA5a38y+5/wDyRrjQNeHTSdU/8BpP8KX+wNe/6BOqf+A0n+FY9FF6fZ/f/wAAOWt/Mvuf/wAka50DXjwdJ1T/AMBpP8KT/hH9d/6BGp/+A0n+FZNFF6fZ/f8A8AOWt/Mvuf8A8ka3/CPa7/0CNT/8BpP8KUaBrw6aTqn/AIDSf4VkUUXp9n9//ADlrfzL7n/8ka//AAj+ug5Gkan/AOA0n+FKuha+pyulaqD7W8n+FY9FF6fZ/f8A8AOWt/Mvuf8A8kbLaH4gb72l6qfrbyf4UDQvECnK6VqoPtbyf4VjUUXp9n9//ADlrfzL7n/8kbTaH4hYfNpmrH628n+FNGg6+Omlap/4Dyf4Vj0UXp9n9/8AwA5a38y+5/8AyRtHRPEJAzpmrHH/AE7yf4VWvtP1aygV7+0vreEttDTRui554yR14NZ1aujf8g7Xf+vJf/SiGqioS0SfXr/wCZOrCzbTV107u3dmegmEbTIJNisFLjOATnAz6nB/I1pw23lRpNqOpta71DiFFaSdlP3WC8KAevzMpxyAQRmxqWo32k3CWWm3lzZxRwxeZFBK0eJTGpk3YPLbywOeRjbwAAMKWR5pXlmdpJHJZnY5LE8kk9zRJRg7bv8AAISqVVzbJ6rv+Kt+Ztrdae6/LqWs2qn/AJYhFmC/8D3pn1+6MdOcZMI0ZJ4mksNTsJgGH7uWX7PIAc4JEmFyMYIVmwT3HNY9FLni94/1+X4D9lNfDN/Oz/4P4mgNHvm1aPTUg8y9k27EjdXDBlDAhgSMbSDnOMVbtbbSYrqEnWrmJg4AlitCdjA8v98Hb0II+Y4OVXjOf/aN99g+xfbLn7F/zw81vL65+7nHXn61Uo5qa2V/X/gW+/8ABC5Ks1aUren56p/d07s7zwDo8ur/ABM8Li4lg1u2uNUtkuWbc6socFkkEoBIKK3BGGAIGcEDmYtFkltrJkurY3N7jyLX5/MfMhjHO3YOVPVhxW58Iry4g+JHhi3hlZYLnV7FZkHRwtwjDPuCOv19TWbB4h8nT9LiWK5M2nOJIgbn9wziVn3NFtznDFchhxV01Re+mn69Pl3M6ixEElT118trPf52Vl0/CqujiR2MWoWUlsiF5bhTJtjAKr8yld/V0AIUg59mxn3UP2edo/MjlAwQ8TZVgRkEd+h6HBHQgHIrSi1GwgMsUFhOLSeIxzBrkGVhuVxhtgUAFF/gPVueRtq6zqD6pqEl1Lu3MqoN772IVQoLN3bCjJ4ycnA6Uqip8vu7/P8AX5fiVSdbntNafLy7dd/LYo0UUVgdQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVq+Gv8AkIzf9eV3/wCk8lFFaUf4kfVGOJ/gz9H+QeK/+Rp1n/r9m/8AQzWVRRRW/iS9WGG/gw9F+QUUUVmbBRRRQB1Xwp/5Kj4O/wCwzZ/+j0rlaKKACiiigD//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Systolic and diastolic views from a transesophageal echocardiogram (TEE) showing a \"flap\" of atrial septal tissue covering the patent foramen ovale (PFO). In early systole, the flap opens and the foramen ovale becomes patent, allowing right-to-left shunting of blood. In diastole, the flap closes, preventing left-to-right shunting.",
"    <div class=\"footnotes\">",
"     LA: left atrium; RA: right atrium.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_48_13057=[""].join("\n");
var outline_f12_48_13057=null;
var title_f12_48_13058="Role of band 3 protein";
var content_f12_48_13058=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F61578&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F61578&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Model for role of cytoplasmic domain of band 3 protein in regulation of membrane extensional rigidity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 313px; height: 499px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHzATkDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKoa/qcWi6DqWq3CPJDY20ly6JjcyopYgZ74FAF+iuB8JfFDSfEEF/NLaXmnRWdtDdySTbJFMcoynMbNhv9k4b261rDx/4WOmHUG1q2jtBcfZGeUMhWXaWCFWAIJAJGRzQB1FFcuPH3hc6Ra6musW7Wd1KYIWUMzPIOqhAN2R344pfCvis+IvAdt4ktdNnLXELypZRurSMVYrtDHAycd8daAOnorlPAfjFPFn9qRtp1xYXWnTiCeOSRJULEZG2RCVbjrg8V1dABRRRQAUUUUAFFFFABRRRQAUUjsqIWdgqgZJJwBQrB1DKQVIyCDkEUALRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUV578cfG8vgbwRJe2DxrqlxKsFoHUMA3VmI7gKD+JFAHoVYGpiz8Y+Fdb07Tr1TFdQ3GntcohdUcoUYjoH2k9jjIIzkGvPfAnjVvi/a/YzKulWttGp1K1ilxPdMeqoeqwHuR8xzt4HLeuWltBZ2sVtaQxwW8ShI4o1CqijoABwBQB5PpfwcmsdPv4o/EZtrufTItLjm0+yFqAsbq3mSKHJkdtu0tkEqzDjPFrSPhMbCaGVtYhLJrVvrBSGx8tMxRMnlgeYcZ3Z3ZOPQ9a9TooA82j+Gc9pqkWqabriwajDq19qUTvZiRFS6ADxFd4yQFGHyPpW94W8K3Xhr4fWvhzT9W23drEyR3/2YHBLls+WSQeuMZ/KurooA434feC5PClxrN1c6kt7c6nKkkiwWq2sEexSo2RKSASDyc84FdlRRQAUUUUAFFFFABRRRQAUUUUAee/GeDU9V0TT/D+kabcXw1S7RbvYSiLbx/vHDS4IQttCgnrk49KT4IJq9h4Rk0PXrG5tbnSLh7WJpVO2aHO5GR8AOADtyP7or0OigAooooAKKKKACsvxB4g0jw7ZC713UrTT7cnaHuZQgY+gz1PsK1K+UPj5eXNz8WNRhuC/k2lpbxQA9ArKXYj6sxyfYegrHEVvY03O17Hp5PlzzPFwwqly819bX2Te2nY9zb4veAFOD4q03pu4cnjOPSug8N+LNA8TLL/YGr2V+Yv9YkEoZk9yvUD3xXxbVPVFBihYM6OJo0DI5U4dgjDII4KswI9Ca86Gac0knH8T7DFcBOjRlUhXu0r2cbbed3+R9lal8TfBWmXdxbXvibTI57fHmp5wbYT2OM8+1QW3xY8CXFxFBF4p00ySkBAZNoOenJGB+NfJAAAAAwBwAKOlT/a39z8f+AbLw+XXEf8Akv8A9sfdqMrorowZWGQQcgj1pa8i/ZhubmX4eXVrcSF4rLUpoLcYA2RFUkCj2BkbHoOO1eu168ZcyTXU/O61J0akqct4tr7goooqjIKKKB39qACo7iaK2gkmuJEihjUu8jsFVQOpJPQVJmvHP2oLmWPwbo1qrssF1qirMgbAkVYZpFB9QHRG+qionLki5Pob4Wg8TXhQjvJpfe7HaS/EnwhFcPC2uW7OvUojup+jBSD+BqxZePfC15IUh1yzDA7f3rGIE+xbGa+OKRlDqVYAqRgg9CK8j+1n/L+J+ivw+hbSu7/4f+CfbWp+ItF0qcwalq+n2k4UP5U9wiPtPQ7Sc44rxT4m6Np3xL8aWp1Dxbo+neGtOiCRbbyJ5Z3bDOyjOEHCrlufl6HNeGWqOsWZbia6lbl5533yP2G5u+AAPoAO1S1dXNHGbio7GGB4FjXw8KtSs05JOyW19e59efDbw/4N0PT5I/BX9nzBT5c9zBMs8rHrh3BJ99vA9AK7Kvkz4FXdzZ/FbR1tpdkV6k1rcp2kQRPKv4hoxj0DN619Z16GHre3pqdrHxucZa8sxcsK5c1ra901cKKKQkAZJGK3PMFopAQSQCCQcH2paACiiigAooooAKKKKACiiigAooooAKKKKACvGvjFd3Vt8T/BENvqF7bRXGn6x5kcFw0asUtdysQOMg8g+oHpXstcl4s1LwpZ+JtEg8RQWz6vPBdtYPLamRljSLM4DYO3KdR3HHNAHzTNqE7fDtZrjxJrIlbwdDNIBeuxLNqeC/1/gz/d4rQ8Wati38Y3h1jVBAt3oO7ZqDIyqYMkqewYnOe+M9q9eh8UfC1tGim+z6ZHp50hbhQ+n7VWx+0bFBG3hfO/h9ecd6dqniL4W2jawL+003EM1il7nTSyu7pm2z8nzYXof4fagDyLwpqE8/i3wnDJqWppFN4u1mGVBfOeAkWxDz2yMfU/3q8t8O3JvdOjuZJbuaaRR5j3U5mYsCV+8QOMAYHavrzRtf8AhxcavZWemw6auof2td21sBYlWF6iq1wVO3htrLl++QMmvnLxtqfhrVfFN1c+CIreLQjFGsIt7fyI8gHdhMAj5s9hnrXDmP8AAfy/M+o4N/5G1P0l/wCksxKqap/x7xf9fEH/AKNSrdVdR4hix/z8Q/8Ao1a+fpfGvU/YMb/u1T/C/wAi1RRRUHSaXhEWa6P8RXl89Lg6VKjyJOygxkWxA2AYyCDz3Bxiur1B9NM1q0010Gl1fw6+43bMXZbFtmcjvjk9ScHPAx0XwL1zwlZeEPF0HiM2bSxXElxdRyweYxtfItwSRg5XcDx7dK9DuvFPw2inVbiKw3i4sI8tYE4lkiZrUn5eoQHB/h6cV9ZR/hx9Efz5mf8Avlb/ABS/NnluhmzTxKpt/tLMnjDxCjZmZcMbJifrxjB4PX1OeY0F9OPhe1NrDceYPh5qRybosNpuJQwPHXO7tjtjgY+hNN8T+ApLySC0hs47k6te2zAWJUm8jiLXLZ29Smcv/FnGT0rP0zxR8MXsoriyttPjhGhTXaKNOK7dOWRhIMbOELq3yd+uOa1OE8Ejmsbnw94ity18kEn/AAiylvtBygNuCCMd+Bn35GMV3GgGyi8W6t55lZh8Qi6FLhm2yeXKOQPUA8H6dsV6O3i34ZpbalLJHpqwRfYPtROnHaRKoNqT8nzADp1247VqWXiPwRNqlzbQLZrew6wbST/QyCb/AGs2c7eWwH+b680AfPPhKfSZ/DGiI/nsLfRPEHkObiTcFJkLHgANkE9uMg8kA1n+PLnQhfaNa6dbTpff2bpjB5Z5HxALKTau08KRle2eSeMmvoXRvGXw3mtbF9OFgkM1reTW+NPZR5MWftGPk4HByP4vevO/2gdR8L6hb6D/AGLHaHVjJDcySxW2x/sj2s/lZfA+XkYXt6CscR/Cn6P8j0cn/wCRhh/8cf8A0pHj9FFFfKH9AENkQbZcDAGRj0wcVNUFk5kgLFSpLvwT/tGp61r/AMSXqzhyz/cqP+GP5Ik05bV/EOhrqETy25u8lUlMTBhFJtIYEEYbB684xXqFxJpw8YxwwXF25/4WF50g81seft4T029ePqOnFcd8NbrT7L4jeHLjV2QWaXE27zF3KSbWcDI78kY98V9IReJfBMmom3jgtDdprJtDiy5F8Mkvnb97r8/6172XfwF8z8m4z/5Gs/SP5Hzv4bls/wCzbNmNzKo8P+IWZmu2ORliw68tyefoeSM07Vfsl1o0wlEnlnwRoibRK6kp9riyeM+3I/qa9zs/G/w/NjBLbWECwS2F9dqq6eBiCLm4BGOM85X+LvUcvxD8AWlvJM1ksdvHpFnfNILBQotZZFSFOnZnX5eg/A13Hyonwe8g+NPie0KFZP7cAdmcsTiMevQZLY//AFV6nXO+Ftb0XVdV8Q22jQiO7sLzyL9hAI9820fNn+LjAyfSuioAKKKKACiiigAooooAKKKKACiiigAooooAK8l+KumXt78T/Atxb6Pf31pb2mrJNLBHlIzJbBVDN0UtgqN2MkjGeRXrVFAHydDoWuxfD6G2Hg/XXu18JJAyG2KsZF1IMYtu0ncVzJjrt5xmtbxRpOqzx+NPL8Ha7PHLLocsEawZMpES+ZjjBKY2tgkA9dtfTdFAHzN4Z0PWbfxV4ekm8Ma8Ibfxfqty8zQ7QsbouyQ5xiNs9c4O04JOBXkGnaZcaPaQWd5peoaXOsYLwX67Zcksd2MAgHtkA49ep++K8B+Pfw/1u+8QjxH4fsZ9UjmgSG5tYWXzImTOHVWI3AggEA5BUcEE45MbTlUouMVqe/wxjKODzKnWrytHVX9Uzw+quokiGIgZ/fw/+jFrXn0DxXBE8kngvxMEUZJFiTjv0Brc8EfDXxL48sYLyzhXSdMkVbiO9vdriXHzKqIjEnJABJxgZ6nivFpYOtzq8T9NxvEmWfV6nLWTdnot9jlqKu/2F4jfUdRsbXw1qt/Np9wbW5ksIxcQpKACVEinBIDDjgjPIB4qzB4S8Y3Ewii8Ga+JGbavmQLGufdmYAD36VP1KvtynQuJsqa5vbr8f8jV+Hmm399o/jqO08O6pfrLYTrHcwkCN3MVuBCg25L9SeTwBgV2t7oeuypsHgzUWRbzQypMiltq2jLI3oPKY7T2yeo5x618JPCM3g3wgljeyJJqFxM11dGM5RXYBQqnuFVVXPcgnAzgdpX0dKLjCMX0R+LY+tGviqtWG0pNr0bbPBdO0PWINUd38KX+xfE+sXKMsijMclq6pKenDlio7e/QHnNI8K+IotGtLdPCOo26v4JvtPMRlUhJ2mkZYzk/eYFTg8/OPQ4+naK0OQ+bH8LeIDoniRj4LvzNPBoXlQC7j/eCGNRIi+hRiw56+3fqbHSNbTxLd+b4Yu/IHjBbpJhOir5BSQm4HqAWAI/2sdcivaqKAPm7TPCfiQaNoaTeEL1W/sfWIJ4Xu4ybeV1YRqD338Accb+4Ga5f4iaHqlhLpt1qGg3Wn239nadapPLMki+alrJui45yvzDOP4D6ivrmuH+MHhC58ZeEvsenTJFf2s63duJOEkYKylGPYMrsM4ODg84rOrFzpyiuqZ15fXjh8VSrT2jKLfommfJNFdhD8L/HbjEvhi4icLkg3dsRn0BEnP6VRXwN4pfX/wCw10V01UxLOsM1xFGrRk4LB92GC/xBdxHpXzn1Kve3KftP+s2VcvN7dfj+VrnLWYKxMGxnzJOnT75qeut8WfDXW/B2sadpc9xDqq6lMIbK7TbE9xM2WZGiz8mPXJUjGSCcUTfDfxjF/wAy9eP/ALhQ/wDs1XWwlb2krR6nPlmf5asHSUqyTUUmm7NNK2xj+EfOPi/RRbaLJrcrTyKLSOURsc28oLBm4G0Hdz6V7ZbaTrkPiKW7XwlMm/xiWMkc6jdalSPtZ9Rg8r+HWqHwW+GWu6Z4qj17xHbrp8VmrfZbcyq8kruhUu20kKArOMZJJOeMc++V7OBpyp0VGW5+acUY2jjcxnVoO8dFfvZHzhpvhvxEPs3meDLqJo9L1qAj7QvBkz5aA5xlyByf72RxTb7wrr66OYrTwXdyufCmn2xiN4ihp47pGMPIwCq7mJx/DjuK+kaK6z544fwDpt7ZeK/HFxd6XLZQ3moJJBM8qsLlRGBvAXp07/0NdxRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5D8T9Il8Pajod34cvrrwzo1/ePba1d2AHlRLKvyytEQURi+AZ+CpbJ3Zr16orq3hu7aa3uoY5reZDHJFIoZXUjBVgeCCOMGgDwvQoLvwHJLdWFsJNT0UC31+wgzv1ayJ3JqUa5+ecZJYnqRKueFr3HT7211KygvNPuIrm0nQPFNC4dHU9CCOCK8fl0SbRdbtPD1hcPDrumxvd+F766clLu2/5aadK55ZV/ujkJ5bjlDU/hHWo9BvodU0+G4h8J63d/Z7vTnT59C1IthgwH3Inb7wPAdlYcSUAew0UUUAFFFFABRRWZ4h1/SfDlgb7XtRtdPtAdvmXEgQE+gz1PsOaANOioLG7t7+yt7yymjntbiNZYpY2yrowyGB7gg5qegArN1/RrDXLH7PqVpFcqjCWIOSpSReVZXHzIQf4hzWlRQB86WFr9o06HXvH08viGNrd9F8RC6iSKXQJCc74lQcICVDOPmI2SBsAivWPAGp6jBLc+GfEc4udV09Fkgvsgf2jatwk4HZgfkcc/MA2cOKj8daPfWl/F4q8N2xudTt4/IvtPAGNTtMnMXPAkQkuh9cqeGNcDbafZSrpNl4b1eJLeffqHgnUnVmFtIFPn2LnqYyM4VhnazL1iFAHutFYHgvxGviTSTNLbNZalbSG21CxdgzWtwoBZCRww5BVhwykHvW/QAUUUUAFFFI7rGjPIwVFGWZjgAepoAWiue0fxp4d1rXrnRtJ1a3u9Rt4vOkiiyRsyBkPja2CQDgnGRnrXQ0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAYfjHw5B4n0j7JLNLa3MUi3FpeQ4821nX7siZ79QR3BIPBry6+aSW412fVtNtlv1jW08VaQhbyb2zPC6hbcFmKpnrzhXQncimvba5Lx5olzOLXxBoUbHxDpOZIURgn2yE/wCstXJBG1wOM9HCnjBoAoeB9dnsr628Na1fLqBkthcaRrG8Mup24HdhwZlGC2CdykOO+O8rwpo9HfSLWzivGsfB2ozfbNE1QYjk0DUASTAwPCJndtBxgl4zwVrobT4pvc+HPDhtbbTrjxBrL3FvEpvBFZ7oC6yTeYQzeUdhZcKSQQPegD1SuR1rx/o9i1xb6YLnX9TgIV7DR4/tMqHIHzkfLH1Gd5FcNq91Lq15Zw6xqWq+J750ydF8MIYNNOQRmackZXPZ5QDx8nanPdTaXod5p+p32neGrWNgsWieDojcXy7v4WYJkMx7rGvrvoA3L7xXq8V5bQa9qWj+GpbpQYdKt86hqUhPYAfKD1+6kg/2q57SIP7L0+fWry1OkJFL8mv+Nrj7TdvnIOyAMPK5AAUMmRj5TWt4V0jX5JYJ9A0Ox8K6bLDia91RftWsXA6jfgkKep/eO5HGVHSuq8PeBtM0mf7Xd3F/reo+Z5ovNWn+0SI3byxgJHjtsVaAMz4RLeWml6lpssc8mlWt0W06+lt/s/2iKUeawWM8hUd2VTgDaFAHFd7RRQAUUVHcTxW1vLPcSJFBEpeSRzhVUDJJPYAUASV5Z430K00aa4E/mQeGdZulluLmN9raPf5HlXUZ7K7hQ3YNgnh3rlNX8c654sMk1nd3Gj6FMB9mhtz5dzLH2kkkHKbuoVMEDGTnIGRGdSt7a5httb1R0uEaOWK/unvoZFIIKvHMWG05527SfUV0Rw05K585X4pwFCs6LbdtLpafn+SOxF3qen+Ir7UWiUeMNIt0XVbWIFU1zTQTsuY16LIp3kAZIIaM5DKa9b0u/tdV021v9OnS4s7mNZoZU6OjDII/A189+ENZutVZNAmRLPxf4aC3Hh+483K3tsVINqzN13KjIcnIwGyShJ6b4eeKNLsfHS6PoFwG0rWY57+fSXYCbQbtDmdJFP3EZiRtzgODtG1s1g007M9+lVhWgqlN3T1R7PWT4k8RaV4bsftes3aW8ZIVEALySseAqIoLO3soJry20+IE/iyy0rVh4ig8OaLezSxw6dZwfbNSuwrtHyQGEeSAcKjEf3+eIoYZdIg1LUdO02DwXby/63xH4gmF5qM+Ou2JmY/Tc/f7nakaHcS+JteuZxLb6Lb6RoYTe2p61cCJu/S3Hzen32Q1xUYm8XWvmJbXfjaAXOTc6if7M0qLBIykWC0yrznIkBxw1TWVr/a+r2Gp6H4av/Et0ACNf8STm2gi7hoYCuc/7kSD/arrI/Akurwyf8J5q82vl3Di0jU2llGByFESNlx7yM2fQUAcfPcyXPxK8Nro+qR6ndaTIIW0vSrDy7Ozt5V2ytLcZIyFwyoCMsijbzke0VDZ2tvY2sVrZQRW9tEoSOKJAiIB2AHAFTUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHL6n40sLfVbjSdMtr3WdYgXMlrYRbhGSMhZJWxFGT6MwOO3Sub1D4j61oeLjxT4RTSdOOMO+t2rTe/7ssoP0ViTWta/DLw9Y2slrpLavplo5Ym3sdWuYYwWOSQqyYHXtVfTfAuo+H454/DOuW8SMAYzqWnLdSq2SSWlV0d85/iJPvQBseDvHnhjxlaRz+HdYtbstn9zu2TLjrujbDD8sHtkV01eGeJrLX20Sd/iTf61FFFOoS50eytJ4UOfkkjPlmeM5xyQMHHNazfEDVPCmnwf2xY+ItcgjkH2i7fQ5IJI4v77FAY2K9+EyM9+CAeu0VQ0LWNP1/SbbUtGu4ruxuEDxyxnggjPI6g88g4I71foA4PxV8L9G8Q6u+pPc6haTO8c7wW82LaWeNgUmlhIKSONoX5gcqMehGT4o+Hmqa9bapZbfCdnb3EsV0lzDpJM8k0bq6mQF9pBIIJ5yrEd69Spk0scETyzyJHEg3M7nAUepJ6UAcZD4S1XVFsH8Ua5II7cfPpujA2dm5xjDHJkdf8AZ3hT3Wtgf8I14NsnCjSdEtnLSsqiO3DkDLNgY3H1PJrkdY+KCf2xd6fo+ka7eW8CsjX9npM90jSdMR7QFZR3YtjI4BBzXB+DRNqPiS+u/D+seNdQ11H2X09/o9qghYdYi0yr5Y5z5aHj0oA9G0b4nWXiK5WLw3aJdK7ERG6vIrZ51H8ccRJkK+hZVz9Oak1LxtrMDi0PhS6027aJpRd6rcRpp6BeoaeEyFT6BlXODyKtXHhe/wDEWhJF4rXRH1E52yR2AmMI7YZzy2MZIUDPQVPo3gWy07T2tJ9U17UUZmLG71KU5B/g2qQoTHG0DGKAMqTxrrGm2rXOo2Gj6nE0XmwwaDqDXN1OBjPlwtGu/GezVpHxdqA0k6ldeHZtKtMBs6tewWzBSM5YBmCn2YipNP8Ah14U0uYzaNo8OlTsnltLpzvauy5zgmMgkZA61ST4dWkOr3GopqV7eSSlSkWrkagluV/55GT50zk5w1AEPhf4seF9cmuLaa/g068gdUKXM6eXKG+60UwJSQHkcHORggVY+NZnb4T+Jls2YNJaFHZOcRMQJD9NhY/SszxdaeLVhuYrvzdR0Z+Fi0OzthL5eOVkiuiyvzx8hyf7orj9L1OPw9byaDG3jaaLVt6raazozSxgFDujhMIXy1x/CNwXqF9QUrtOxk0VmaKupW9pbWl5p2rtMkLP+9tJTcLGrbQZkxuDEDO4Aq3XIJ2jTsVuNRYJptle3kh42xW7cH0ZiAqf8CIr141oSV7n41iMoxlCq6Tpt+ibTLfhPS4tc8eW+mXscklhcaVdmXY5RkZZbYo6sOVdWwQRyK9FsPAt54btUsfCs+mSaSrmVbLVrZpmSVmLM4mDbiSTn5gx9CBgVxmkeItH+GfjOaz8Zxz2l9qFtF5F6hMtusQLfLwMq28kMQCDtQ8ACvaNL1Ky1ayjvNMu4Lu1kGVlgcOp/EV5teSlNtH6hkWFqYXAU6VVWkr/AItv9Tz3SvBXjC31W/n/AOEo0zTLPULv7bdR6VpSrKzbFQoskrOACEUlipOc4xXQaZ4X8LeDDfa2Y4oLh/3l1ql/O0sp7ZMshJUc9AQOelO8SeK3s76307RbG51K9lDNJLBC0sNqoHBkIwNxOMJkE8nIHXznU7+WfxPpLa5B43u9dcSLYWkENrbW7Y5ZxEXbbjgeY5OOOayPWOm1L4vaKL+Oz0XZdMWAlur1pLK0iz0/etGdxPH3QRz1FQ3h8eateXD3N4lhosyD7LP4beG6ZRxlnadAWzz/AKtf8a2LHSvGV+8c95ra6VaGMqbBoIbuUk9C0u1VBHdQGH+0akX4b6JNqh1TU2vL3UmiWJpvtD26kDpiOIqo/LNAHP6Kb6TTJV07xRe6xLCxW4uoSY7y1IHHmWsuUb3G1CR0Brd8MeNFlWGPV7mxmtZnWG01a1fENzJ0MboeYJcgjYxIJ4Bz8ov2/wAPPCMCzbfD2nO8xBlkmhEskmOm52yx/E1bPgzwuyKjeHNGKA5CmxiIBznONvXIzQBvUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACOiyIySKGRhhlYZBHoa8913wjq+jiGfwJql9YWMYbz9Hg8l1lz0MBnDLERk/Lwrcfd6n0OigDxXT7jWI/ElzfaH4q0vU9bs2EOpaPf2v8AZ9zcxgEqr4O3cob5JBHg9NxWvVfDuu2mvWbzWglikhcxT2867ZYJB1VgCR+IJBHIJBzVDxL4fa6uH1bSfKj1hYPJZZVDRXkQJYQyg9sk4YcqWJ5GVPlfhC40rSEl8Yad4dl8H3Msz2+pWiyCayuSjFWicrgW8iOCAzLGuSQdwbNAHuN9dwWNnNdXkqw28KGSSRuiqOSa8r8Uao+sM+ra7qmk6N4QiRfstpqUHnS3MuQVmeIMMdtkZ3Huyg4ArXfiPQfiqhiha61Tw/bN9oTT7TdGbwoflknkbaIUVlbajsrMV3cgAHpPhzpa6no+m6ndaRbaPYQMz6dpFtgxRDLKtwxAG92X5lOMANnqc0AZ3h/SvFXiDW7e91HxDq8fhhIiTbTWkdlLeOcjG1QJI4wOfmIY56Acn0TRtKsNF06Gw0m0htLOLOyKJdqjJyT7knJJ6knJq7RQAUUUUAFFFFABVDXtItNc0q40/UELQTKV3KdrxnHDo3VWHUMOQeav0UAeIeJtB8VeCk0zVofFUmoQ2+oWttDZXIYRzK7CMmeeR3MRwxyyAAnjacjHqXhDW7nWrK7N/ZR2d7Z3LWsyQz+fEzAK26OTau5cMOqgghgRkVs3NvDdW8kF1DHNBINrxyKGVh6EHg189f8ACFX3hD/hJNE0l9bihSRb7Sbi2l+0i3idjkrbqVkxG4w2wvkMpKHPIB2P7Rvgefxf4NiuNKtmuNX06XzIY0GWkRsB0H/jrf8AAa838A6LJ4IivNE/tO10nWNTCxz6xcysbZYwAZIYAMK06k4yTjIO05BFenWPxDh1jSItH+3QN4jSIx6mtjuZ49uFcwJw+9ycoCBt5LfdwaOi+FrfWYY/Ddn4bt9E8OWdqguLh5EmvvN3ZSEONwRlA3s25iNygYPIAMjwno2rSz2vh/wL8QL06LYxYvZo9ItxEVLHHlShBukJDgsN2CrbiGGD7Homg6foyt9jiYzuP3tzM7SzSnjlpGJY9PXFc74W1Cfw5d2vhXXygIXZpl+qhI7xFH3GA4WYDqOjD5h3A7agAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvJvi3ro8J+K/C8umyiK51q6NvqMLwGaGa0RPnlkUH5Sm5PnHO0nOQuK9Zrxay1ufxVomseJLLBttReSxtbkp5ck0O9o4rW3zyNzDc8vYsQM7MqAR2lrb2njvSfBmqWzaN4evkuZoNAjhDW1xPG/m70nUDdERuYxHaQQAV2sor22vENP8P6poXhg+FZb+41ifRoopFQL/AKVH8+6K8tSeWCZZDESc+WVB52t6f8P/ABFF4s8GaRrcEscou4AztECF8wEq+AeQNysOeaAOgooooAKKKKACiiigAooooAK4j4wyW+neBtS1xrp9P1HTIWlsr6JQZIpmICqAeGV22qynhgfXBHb15940vn1DxfZ6JYQLe3dlAmoG2mGLZGaQrHNM2OkfluyoPmZtp4xkAHIa7dX0+gweNIopNF1aS28i91K3sissEeFLx3cDjcu3b8sgJ2naSAhOfY9GsbPTtNht9NRVtsbwynd5hbkuW/iLEkljySc149pGjahDrV14lTXtSurbWpfsa/bVH2W5dVKxtLEBhIZDuRcAEARnJ3muw+FmsiWXWPD0sU9rcaTIhWzuSTJbxyAkRhsAPGpDBHGQU2dwRQB12vaPZa9pcthqUXmQSYPBKsjA5V1YcqwPII5Bqj4UTW7WK4sNeZboWzBbbUAQDdRnOC6D7si4w3Y5BHcDeqG9jmls547WYQXDxsscpTeEYjhtuRnB5xkZoA5Dw98R9H1vxNrejQrPDJpaPI08oAjmRHKO6EHkKwwTTLv4neGjpOrXej6jb6ncafZNfNbROVLxr3BIx14OM4PWue0z4NxaS+jz6d4gvVurS2mtrlp1MqXCyqd+F3DZl2L9Tz69atXPwp8/SrGy/tnabbQJND3/AGXO7ft/e438Y2/d9+tAHWWnjPQ5hbJJfwxXMzwQmIknZNMu5IiQMbiOgplz498LWqxtca5ZRLI8kaF3wHZGCuB6kEgcVwms/DC80nwJ4i0vQLmXUTdPDeWVsQscsF4pTdKJnfoSu4g8jkAnPPTeG/h9Fot14TuIrsD+xLCa1eLy8+fJLtLybs8fMGOMHO6gC4vxA0O2sTc6zfWlgpup7aMed5nmGI4bGB97/Z/Dmui0bVLHWtMt9R0q5jurK4XdFNGchhnH8wRj2ri9F+HH9ma1o+of2r5v9n6jf3/l/Z9vmfalK7M7jjbnrzn0FdB4A8N/8Ij4Us9FF19r+zvK3neX5e7fK8mNuTjG/HXtQB0NFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBxnxZ12LRPCqpLJNG2pXUWnJ5ClpWMjYZYwOS5QOF9CQegrB0PRn1D4h6VcaosYu9DtXljtLd/3GmJKojigwDhpCgkZnx2AAAxV/wAbaqs/jvRdDtIIbvVbaE6lb28uCqOxMSzv3CRqZSccklQMGp/hPpMdnba7qcdxLdnVNSkl+1Syb2nCARb/AEALIxUDgKVAoAg+KOkIdU8N+IUuHsrnTp5LUXqkYtluE2CR1JAdRIIgVPGGPTrTPhbrk1z4g8X6FfWMdhqGnXUc9xDESYy8wYmSM/3JCnmgHkGQg8iuo8d6IPEngzW9HKhje2kkKA9NxU7f1xXm/hjW47Hxp4SFxMxn1iwNtDJMpZ7qBVMiqzjgywOGRs9RMG65oA9looooAKKKKACiiigAooooAK8LtrkePvCV1PbyXZsPEN29sSn7trtmZk2hsBvJgiUk4++yv2zu9X8calHpXhe+uZrmK0QhIPtErbVi8x1j3/hvzjvjFcv4c0NJvE3h66NiLO30jTZEsrM8NaROVSPcP77qjFuPl2BRn5iQDrfEWjw6j4U1DSFt0khltHgSEnaPu4UZ7YOOe1ecW/iNrDVfCepXIea11KaOws9QYbpGWUkNaXJxxIkgXax+9tcHDZLev15Dq2mR6Lpniu2YyGyGoNfzhVMjWjSv50V5Go5wkv3h0xEWHQhgD16iqOg3x1PQ9Ov2EYa6t45yI23KCyg/Ke454NXqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8w8SxQXPj/Uo7d0i1G6sI7K5vYmxJYWCbpZW3fwM5lCqfVd38Fdd8PNOGk+BtCsVjMSw2kYWMkkoMZC5PXGcfhXEeP7TS7q48V2JjkWS8t/tOrtA+2SS0t4VKR7hyN7SbfdfMr1O0z9lh3LtbYuVxjHHSgCWvBbIw+GI9GsbuMGK11iW406cjHlzi6aK5g5PBeKVpUXuN/8AdFe9V4V4wRNOXX49WBntbrVX1a1LLjybq1MUnlA+skKZA/2X9aAPdaKKKACiiigAooooAKKKKAON+JxtH0zTItTUPYC+juJ48BmkEIMqIq5+ZmkSNdvfNL4Hspota1y91AA6tdrbm9IOVikCuywLjjaiOgz3JLdWqP4iy2cF5oN1fWn2n+zppdRiXu0qRGJEH+0zzqB74PapfhrpMuj22tw3ZaS+m1A3V3OZNwlnkhiZyo/hVchAPRBQB2Fee+KYBp/je61q2hee9Glx+bbYLC7s45ZPPQA8bl81HHcn5ejV6FXB/ECCePxNoesWSyy3mlWd7cRW8ZI+0DMG+L0yybsf7QBoA0fhjc283g+2gsWD2djJLY27r0aGJykZH/AAldXXJfDKCytdBuoNJKNp326ee3KAgFJm88Yz/wBdcfhiutoAKKKjuZTBbSyiN5SiFtiDLNgZwB6mgCSivI/CfxeXVY7y91FdKtrS1t5bi4s47iQ3tsE/vRsih/faeM10Z+KHh6K2v5rv7daNaJDL5U9sUkmSU4jaNe4Y8dsd8UAdzRXC23xQ0C6sIprVL+a7lu3sUsI4N1w0qrvYBQcYCkHdnGO9VrT4oWsuua1Z3WjaraWul2IvpbiWBgwUIzsGTHy4CEDk7jxQB6HRXBN8R7CS60mWFbmDT7uG7nP2qyljklSGFJd8WcDbh+uCGxweK0PCnj7SPE2qCwsYdQguHs11CH7XatEJoGIG9CeoywGffjIoA62iiigAooooAKKKKACiiigAooooAKKKKACiiigDx34iaJBff8JrZQ3d1b3Gs7ZLuWJtrRW9pbRv8p7BmdEOeMO1etafM1zYW07gK0sSuQOxIBrzPxnpCXviTxXYRXUouNa0/T9PK4OYI5pbhJnTPGTFHnp1jGa7nwTJJJ4S0oT/AOtjgWF/m3ZZPkJz3+7QBt14n4ijlkXXLe8eQtd6z/alpiUBozbXEEMka56boQpA/wBp817ZXhOlQHVJNIV55Y5JfEkWtK/UtBcCcmHn+HdCQR7D0oA92ooooAKKKKACiiigAooooA4f4iw2v9r+GL68WV4tNnuL4xoeH8u3kIBHfDbGHuoqx8ONNl0qPXYLp5pLqfUWvZ2kbcBJNHG7Kvoqk7QPQUnxJ0v+0ofDzfaZLf7NrNrK2wf61N21oz/skNz9BUXw4WaabWdVnz/xOJVv1BbOEJaKLA7fuoYj9SaAO2rgfH0M8XizQdZhacrotne3jQowCzKTCjqR3IRnI98V31ef68yL8SbW/kkkaK0gh06SHGVKXbuCT9XigH4GgDU+GulW+jaJe2lm5e3GpXUkfzBgqNKWVVwegUqB9K6yuU+FenvpfgDR7aa4NzKIi7zFcFyzE5P5gfhWh4l8QRaMsFvFE15q12StnYxnDzMOpJ/hQZyzngD1OAQB/iTX7bQreEyJJcXty3lWlnCMy3EmM7VHYerHAUckil0a11N9IlTXrpHvLgszC2GxbdWGBGjdTt/vHknJ44AreG9BlsriXVNZuEvtduV2yTqu2OFM5EMK/wAKD82PJ7AdBQB5n4h+FkN9p2pyLql/qWtS6fNY2c+qTKVgEi4PKICfTLbjirFt8K9Jm0i5g1u6v9QvruG3jkupJhvg8nlFhwoCqGyeQSe+a9EooA4ZPhtp621sF1TVlvrW4a5t79GhSaFmTYwULGE2leCCpzTpfhxYSzX8smra076hpzabeFp0Y3CFXUO2U++A5xjA6cV29FAHJal4C0vUItGjmnvVXSrCfT4NjqN0c0SxMWyvLBVBGMDPY9Kn0PwZp2jarpl/azXbzafpCaLEJGUq0KsrBmwo+fKDkYHXiumooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOD8Z2Ulj468O+JIWHlRQ3VrdRn+PEMksTfVdso/7aGm/B+0Oj6LcaGfMYWxjulZ33Z+0IJXA9hIZce2K1PihoNz4h8FajaabcPa6nGhns50UMUlUHAweDuG5D7Ma5rwnrccnxOvJIiF03WLC1jtgMnbNFF5pX0yY5s/8AbOgDt/F91d2nhu+fTf8Aj/dRBbHGdssjBEY+wZgfwrzb4ceHx/wkWhlr0zp4esbqwcH70ssdzJDHI3/ABKfq+a674la0+mjw1ZW9s9zcanrVpBsQ8xxrIJHlP+yoUA+7Cm/DLShajxFqfmCT+09XupIwvRI1ldQB65YO+f8AboA7WiiigAooooAKKKKACiiigDA8e6S2t+ENTs4ZfJufK862lxny5oyHjY+oDqpI7jIrnPDbZ8VWF/axBLOWwg0xSjHY4EJuEZRnsGYfjXoRGRg9K8bvJLjwxe2lk93JNBo+tG8UBNrDT/sZXaf7wjDsM9xGKAPZK8U1B77U/wDhLvIupYtR12OKfT2KbhAsN15EZVT1P3JD7vXsmoXlvp1hc3t7KsNrbRNNLI3REUEsT7AA1498OvE1n4p8U6Bbae0QltdGkbULdoJI3spVlhPkFX5zuZSGOQfLbH3vlAOA+P8A4/vdC8d6LpXhi8ktx4diXLKchpGUfKw6MAgUYP8AeYV7T8H5JtW8PDxFq9jeQa9fnFzJdx7CVHKrEP4YQD8o+pOSSSnhP4WaDomr3Gt3yHVvEFxM1xJe3Sj5XY5Plp0QZPHUj1rv6ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8R8S2GueAZ7uXT9Gudd0Vb6LUtNkhlWP8As1xlJIZOreT5bPhwGwGII4Br26igDxvWru78XXNimiXdrNr908AMlmTNBo9osqySv5hADSOUQY4LYAAwpNetaVYQ6XptrY2u7ybeNY1LHLEAYyT3J6k9zVqigAooooAKKKKACiiigAooooAK4D4haRqEet6d4j060k1Oztree21PS4gDNdQOhCmLJALqSeCRuViBzgHv6KAPGvFV3qusfD6Hw6by30v7RGbe8jkZpdRltNuFjjiKgefIuEbccAlsZ4x2/wAN/Db6Jo5vNUi/4qHUVjm1Gd2WSRnVFRULqqg7VUDgYzuI6knrqKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuV8XeN9O8La94e0zUo5t2tSvDFMuNkTKUHz5PAJkUZren1Syg1S206S4UX1yrPFCASxVerHHQdsnAyQOprnPG3gWz8X6xpFzqku6ysobqGW12H98JlRchwQVKlM9D+GKAK3hT4m6B4jF68EkltBBqCabFLPgC5lfOzZgnhscZxU2s/Ejw3pOqWdhcXheW4u5LJmiXcsEsahmD85H3lHAPJFYEnwlSK21CPS9X+wvJqdtqdiVtQ62jQKFRCpb5xge1OtPhhe2ssV4niNW1SPWptY+0PYDYxliWNkKBx/dyCD36UAdb/wmvh0axJpbanGl9GZAY3RlBMYJcKxGGKgHIBPQ1myfE/wj/Z+pXVrq8N59gtDeSRW/LtGOPlzgMckL14JGcVz1z8JZ7nxQ2r3HiEzYuLidBLaF5QssbIIzIZPuru4AUdMe4ux/C9PsVhay6qzJbeH5tBYrb7S4kABlHzHGMfd569aAN+fxpYN8P7nxbpyPdWcVo10IidjHaMlCecEdO4+tJpnj/wAO32kXF+uoxqlqkTXKBWZojJgIMAZYEnAIBB7VG3hK6uPhrN4VvtUjlleyNiLxLXYAu3ap8veckDGfm5Pp0rnJPhdfXFpqDXXiZ/7TuYLa1juLe08mNIITkRsgky4bncd4/AcUAdM/xD8Jx6fFeya3bJbSySRIzBgS6AFk2kZDAEcEZ5HrUes/EXw3p2gQ6ompQXMd1BJPZxxEs1xsByAACQMjBJGAetYHhL4VnQNY0y/OrRzGz1G81AxRWflI3n26w7AN52hduc85zjjrVa2+Ek9hptnBpviFYbiKwu9NnlksRIssE8zS4VfMGxlLYzk5x0oA7m08QSXngqy1+z02e4ku7SG6Syidd58xVO3cxC8buSccA1W8A+LovF+nXlzHYz2UtpdPZzRysrjeoBO10JVhz1BqW20C9sPAtjoOl6otveWdnBapfNbCQHywqkmInGGCkYzxu655qp8O/BzeELPUI5dQF7NfXJuX8q3W3hjJAG2OJSQo49eaAOtooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAZLIkMTyyuqRopZmY4CgdSa+dfC/x/udT8QajpcsNnGLy7KaVd3J8uKBC2B52OSMc8YJJwSAcj2D4padreteDbzSPDYjW81DFs88smxIYm++x7nKgrgAn5vauU+HXwO8N+FPLutRQazqi8ia4T91Gf9iPkficn0xQB33hvw/BoqTTPK95ql0Q13fzAeZOw6Dj7qDoqDgD3yTtUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHlf7Q97NZeHfDZhvDZxy69bRTyG5e3QxFJNwd0IYJxyRyMZ6ir/AMB767vfA0gvp7i6a3vriCO6llaVJ4w2VeJ2+Zo8HAJ54Nei0UAFFFcn4o8Q6npni/wxpen2drPaakLtrmWWXY0XlRBk2jvljg8HA/OgDrKK8ntfHPjKXw4L46PoT3Z0Y3gjS+O03X2jyxH/ALuzknP3vlz3rUv/ABR4vibX/smi6PKbMWK2ivfbfNaUKZ9x7Bd2FOBnGeegAPRK81+I/ijWbPX7fSNEnjsoFt/tF1cmISSksxVEj3ZUY2MWLK3VQMZJFiw8YeIrm+sojounvDca7c6ezx3wzHaxA7ZSP75wTt9MdN3HEate6xqeqfa/EmmQ6ZfyWqK1rDdC4RVEku07hxkjr+FeVnWIqYbBzqUnZ6fi7HoZXRhXxMYVFda/kWU8R+JFZM+I70kEtgwW3Psf3XSpX+IHiHRXW8uGGr2Y+WW1aNIpSWICsjqFAwTyGByM4wRzk1neITt0zII/18PUZ/5apXxODzfGvEQTqN6pa+bPqsTluF9jO0EtGdXB4l8VOhe+1pI53JJjtLaNYkz0C71Zjj1J564HSh/EPiYW7CDxDN5xzsea1gZQe2VVFyPYEH3qkeh6fhRxnA5P8qyeeY9vm9o/wsSsswqVuRHpvw98SyeJtCee7t/s+oWk7Wl2ighDKoB3JnnYwZWGeQGxzjNdPXhvgbxPrWhjx00HhuS+0yzaS+jvFulQSTra23+jbMEgkc7unsa6W3+JWqXMAeHwq6lpNNRPMv0UOLqLzJMEjrF0I/i6jFfpOFqOrQhUlu0n96PjK8FTqygujaPTaK4Ww8b6jdXzQP4daJP7butKWQ3i8xQxs4nxtH3yu0J1Gc59cnSfiZrGoafY3LeDpoDcaPdao6PfoPKaJ2VIclRy+FO44xu6HBxuZHqFFeYyfEfXk0/VJh4MY3NnbWEyQHVIx573O3cgbbgeXk/MfvY6AHNaZ8a6ydburGPwuWgh1iDTftB1BFDQujM1xtK/w4UbOp3cHjFAHd1y3xJ8Vf8ACH+Fp9TjgFxclhDBG2Qpds8t7AAk+uMcZqnZ+KPEss+kR3HhDyPtn2wzn+04m+zJEP3TcD5/NJAwPu5yc1wHxr1fxBfeFbKHU/Dq6ZZPHBcy3Jv0m23DI+62CgZO3rv6HHA5qKjcYNrsdOCpxq4mnTls5Jfezzqf4q+Op7iSX/hJJoA7FhFb2lsEQZ6LviZsfVifen2fxW8b211DK/iGe5RHDNDcWtsUkGeVbZErc+zA1w9FfOfX8R/N+R+z/wCqmU2t7FffL/M9R8T/ABx8Q6wIx4dSPQ4kJWQsi3ErOpIblxtC56fLkgA5Gdow1+K3jwZz4jckjH/HlbYHv/q64S1YMs2M8Tyg/USMDU1XUx1fmdpWOfB8LZU6EHKlzNpatvXT1se9/B34rarq+vWnh7xLtvJrsOLe9jjEbb1RnKyKuFxtVsMAOQBg5yPc6+LvAF9qmneO9CudB0yPVNRWaQR2klwIA4MEob5yCBgZPTtX1De6/wCJotQmhg8NQSWyapb2izHUowWtXH7y424yCp42dT1HTn18DVlVpc09z854pwFHAY90sOrRsnb/AIc7CiuKs/EniS41C1jPh20S2kub+KST+0kLLHDxCwXHJkbIIH3Op9Kzbnxf4yh08Tf8IpYGYaQb11/taPat15u0Q56Ebfm3dM/Lnuew+dPR6K5/w/qmr32t6xa6lp1raWlqtv8AZ5IroSvI7x7pAygArtJABP3hzXQUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFct4o8NXWseKPD+qW96tvFpsd4kke0ky+dEEXH0Iz+Arqa4nxlLr0fjXwwNJnnTTTb37XkaIpWRxEvk7s88MSQB1oA5uD4Z63b+HIdOGsWks8WjDTvOeN13S/aBKXIU/d2jHrmrviD4earqFnq8Vnq8VtLe/YQkmHPliAAPwD1bHHP1rnLO/wDHa+DIZri5u2uh4ejleQbd/wBqa5OT93qI++OMVo6vceOon8SvaX0oSI6abNGhBxlF8/BC5bc2f/rUAWdJ+G+tWGpadOdYtzDb+I7vWZUVXBeKVSqx9eoyc9ufbnhLDQtU8MXz6Nrt+uoXtvaxOZ03bSrSTEAbueK7DS4fHo1bTZbq8vpLQeJ7vzlAXBsCo8sN/sqQ3v8Apjz/AMKya9dxi68YS3E2svbxrKbiIxuAss235SBjgjt714nENv7Pnfy/NHq5L/vkfn+TOgrK8TkrpBIIH7+Ac8f8tkrVrF8Yyxw6DJLOUWJZ4C7O21QPOTJJ7Cvz7Bf7zT/xL80fZYr+BP0f5HT9zSDOeoAPQYoz6dzxS8/rXKITwd4Z1LXdO8cf2XqLWb3c81liR2aPebS2CPsHAwd3PXmt27+GerSaclrHqlodj6cwMiPx9njKSEYPVicj0rmPDt54msNF8dnQ45UZpria3kSEP++W0tduOpznPBHP8tx9Y8dRyMkK3k8izaYGC2w+40DG46jH3sZx0PpX65gVbDU/8K/I+AxX8efq/wAzprHwbqcOorPJqUCxLrl1qYRIyd0MsLIqHP8AEGbOenFYmm/C/UbbTbSCbVYWmtdButKiYbyBLMzHzOTyACBg56Va8Pav4xvNQuPP3/ZYfEN9bt5lpsH2NYm8nb3I37fm79KzLTVfHklpp8N1LKbiTw9eTTPBaYAugzCE8jhsbcL3Oa6jAfcfC3VpNH1C2/te2kuLmw0y0DujgFrUqXZsHo23jHrzXS23g/UItWvbma/jmgn1mPUkRiwKRqpGz8DjHbiuYu9U8fWVrriGZ7ia2ttMNsyWY+eVsC4/h78nvjtiug0u68Wy6xqazC4jsl1xI4DJChBtAG3bcDO0kAZPIoASx8E6xZXGkvDrUarateNOfLOZPORQmOf4WXPNch8a9JvLDwZYvf6hJcBPs1ssSsQnmJDLvfB9cDHeuy0L/hNLm306TULxYkzdC6LWqo+Co8htvYqc9OvcVxvxq/tf/hELSPU7ySXy0tjKv2UIry+XKHbeBjOcfKOnpWVb+HL0Z25Yr4yj/ij+aPAaKKK+TP6EIbYELLu5PnSn/wAfapqitySJSf8AntL2xxvapaup8TOfCfwIei/I6b4WxPP8TvDMURIZ55x1IH/HrP1I7V9GX3hLV5b+5uLe7s187VYb3595JhVGBQ8dctxXzp8LTdj4leHjpyxtc+ZOEEn3c/ZZsE/jivoa8ufGjavcw24Mdr/a8KQuY0wbTY5k5weMheTzzXvZb/A+Z+Scbf8AI0f+FDtO8H61Bq1veT6nATDdajKNm4ny7jHljkdVIyR09Ky1+HOrS6Z9mvNQs5Jjo7ac05VizSNM0hbp93BHvmrGmXHjGV7RpLi6eMSao0pe2RPlVttsuMZOCeMcnHOaz11LxyvhgTNJcfbV0LzCPsgLNd+cRnGOuzHH416B8id1oHh6TS/Eeu6m10Zk1FbZVjIx5flR7D+fWuhrnPDv9tN4i11tTZjp2LZbNTt4bysy4wM43EdffFdHQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVkar4c0rVtZ0vVdQtPOv8ASxMLSXzHXyhMmyTgEA5XjkHHbFa9FAHFj4X+D10oaamkbbMWD6YEFxLkW7S+ayZ3Z5cBs9e2ccVNe/DnwtejVhcaazDVRai8/wBJlHm/ZseT0bjbgdMZ75rrqKAOUs/h94cs7qC4t7OVJYNSm1dP9JkIFzKu13wWxgg/d6e3Jz5prnhzT/CeuDR9HglhsktI5Y/NmaVmLSSljliT19+9e7Vl63oGl635J1SzjneDd5UmSrx7sbgrAggHAyAecDPSuDM8G8bhpUE7N/o7nZgcUsLXVVq9jxInHrWD44a1Hh2Vb8xi2eeBHEn3SDMgwfavVPGPw6tVsDqPh6S/hv7MNMLYXDyR3S4+aMq2eSM7SMYOO2a8rs9ZsLFdXvdy3h1nSprjR57qIyJa3CQN8qBhhPMjJODgkqw/ixXyNHIamGxlKNWWj1TXda29T6Orm8K+FqSpx1Wln2elzqWGSMNgjnA6H2NKcZ9c0eBPBmma5f3Om313qYtdKsLVIIre8kgPzNICzlCCxxEo54HPrXc2vwr8NwXkdxu1iUociOXVrloz9V34P41nhuG6mJpRrRqKz20ZNfOYUKjpyi7o5H4beDbLxDH4p1aa81qAX8s+mAQ3TRxFBHCjSxrjG8PGyhuRwevbsn+GmlOOdS14fvbKbI1F+tqmxB9GHL92POQcY7KytLawtIrWxt4ba1hUJHDCgREUdAFHAHsKmr7yjSVGnGmuiS+4+VqTdSbm+rucjbeAtOt7xrlb7WDI2o3GpYN62PMmjKMmP7gByo7HvVC0+F2jWtpaW6ahrjLbadcaYpa/Ylo5ixZ27FwWOD244+UY72itSDgpPhZoclhf2jXmt+Xe21payH+0H3KltjYVPYnaNx789Mmr/wDwgGknVp9Ra51UzzanFqpH219oljVlVQM/cwxyvQ8A8ACuuooA4uw+G+h2KacsMmqEWDXbRb76Qkm5GJNxzk8Hj0PPXmuE+NXhHTtC8Hx6jYi9Z4YrXTP3ty7okKBljO0nG4syjd1y3uc+31DeWtve20lveQRXFvIMPFKgdWHoQeDUzjzxce5thqzw9aFZfZaf3O58L0V9QT/A7wTNdPP9l1FC7bti6jPtB9gWPHtWXqPwY0bTdVh1XSbCfUoIUw+lT30kYdw2Q6PnrjIKP8jDH3ec+N/ZU/5kfpf/ABEDD2/gv70fNllLHNC0kLiSNpJMMpyD856HuKnr3LxJZ+HPHXijSoPCmiwmeCCW4uJJPMs47qOE+W1rFgbWkD7Qz4IQADJBwOh8N/DTwJ4i0uDUbSyvIwWZJbeS5cPBKp2vFIM8MrAg/TgkYNE8rm5NxkrE4XjvDQoxjVpS5kkna1vldniXw00KDxJ490fTbtLhrVmkkmNvO0LqqxP825SGA3bRwe+O9fT914G0e5uJp5Wvy8upxaswF5IB58YAXAzjZx93p09BiTwl4H8PeEpJ5dC08QTzjbJM8ryuR/dBcnaOhwMDIzXS16WFoOhT5G7nxWf5rHNcW8RCPKrJJehy9r4F0W2vo7uMXvnR3N3dKTeS433IxLkbsEY6D+HqMHmqDfC/wybOO18i98iPTG0kKL2b/j3Zw5H3uu4deuOOmAO3orpPFMfSfDmnaVrOqapZJMt3qSwJcF5mdSIUKJgEkDg8469TWxRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV87fFnwfFFqGqaEQkel65FJd2G1dot51KmReMdJGWUeu5x0WvomuG+Mel/bfBc9/DGXvNHcajDjGcID5qjP96IyL9SO4FcWYYZ4ii4x+Jax8mtjqwdf2NVOXwvR+j3OD+EWrt/wmGnXFzE0Musae9pOinKx3MDF/Lz7ZuOf9mvda+Zg9voRGoaZFmewv4tXkVJMfIz4mYZ4+aMTcDrk45NfTAIYAggg8giuLIsRGthuWOnK2vk9V+Dt8jpzWi6Ve76r/gP8haKKK9o8wKKKKACiiigAooooAKKKKAPJ9X0UeHVtfD/ANoSw06a6/4pnUVXLabdkFlt5CfvI7bgo/iUmM87SXWeuzaHqOp67d2IgeAJD4ntIMkQuANl/EM/NEU3bv4ioGRujKn0nWtLtNa0q603UoRNaXKGORDxx6g9QQcEEcggEcivOZH8QWF0yMHvdd0OM70wp/t3TWJ6DIxOmAPTfn+GXgA9QhljnhSWF0kikUMjocqwPIII6in15l4J1O28OXNjYWt1HN4L1c7tCuMY+ySsSWs3J9W3eWDgjDRnlVFem0AFFFFABRRVbUL+z021e51G6t7S2T70s8gjRfqScUAWaK5zR/Gug6zeQW+l3kl157Mkc0dtL5LsqliBLt2E4BPXnBro6ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKR0WRGSRQyMMMrDII9DS0UAfNcNg/h29g0eaLfHBPLpecD/AFKbjCz+uUVRj1kr174O6i974Es7a4MhudMd9NkMgwxETbUY+paPy2z33Vwvxagng8XXiLZ+clzZx39sxYASTxNtKe2NsBzj+I+lXfg3qqp4p1G1Xzlttas4tUgWQj5ZECxyLjsdhg4yfutXzWX/AOzZjVoNWUr/AOa/BtfI9zGfv8HTq9V/wz/FL7z2OiiivpTwwooooAKKKZPNFbxNLPIkUS8s7sFA+pNAD6KgtL21vFY2lzDOq8ExSBsflU9ABRRXKfE/XZdA8Iz3FsG+03E0NnGy5BQyyKhcHsVUsw9wKaV3Yzq1FShKb6K/3Gf4i+JWm6ZfCz021n1iZXMc0lrJGIYGBIIZy3JBBBChiCMHBrldf8aQ675CS2V1o+pWv7+x1aKQTRwS9Nkqrh2jbgMu0qR1wQCOShijghSKFFSNBtVVGAB6U6vQWEhbVn5zU4xxjqc0IxUe1nt5u+52cl1BfW9xqcNvJ/Y9+wtPEGnQzAmwmJBW+iIOABkOXXBKlJOqnPYeCtYvVuZ/DfiOZZNesE3rcbdgv7fIC3Cr2PIVwPuv7MteU+D5by217UjpkDXkyWyzz2DYK31nuKzRKvAMi/IybjyZXUkBuJ9IudUt9Y0uTWb3SNI0/TmuH0mx1+5a21EQupTE0nzK8a54RTyFQs2VrgnHkk4n32AxaxmGhiErcyPV38baI8tzDpty+rXNuSskOmRtclWHVSUyqn2JFZjeJ/ENzpl3eS6NaeGbSMZS7167Q4H95oo2wB7GRa8/+Gt5ff8ACFvpLa1euuml7GO38OaT5UkkaEqkxlkUqS6gNuG3r1PJrqIPC95FYySaJ4Zgl1CUZN14r1F7p88clVMv5ArUnYVdL1P+19Ju7iXxLr3jDDlGt9AthZQg+iSqVb8TMalVW0rQDc31h4e8HqNxSbWrgahcAerfOuWPp5jdvpXQw+Fdc1HT2h8S+Krze/WPRYxYxoP7qt80ntnePpUSJ4K8Fu0EduhvkHmPshlvrs55BZsPJz1GT9KAOZha+1Wx0jUdF1jxB4qvEv4JopvKSwskjDgSnG1Ay+WZAPvnJGOea9frj9G8f6XrNtcXNra6mLW3BaWRrf5o8dmjUmQH2K102l6jZ6tp8F9ptzFc2k6745YmyrCgC1RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5RqVp4wvrORfFGgT6wyPI4ttK1ZLW1kX+FcEq78Y4ckZ7VieJ/wCy30a3/tiXSvAlrJCpQvp7G+gk6cT8KpB7gN9a9ypssaTRPHKiyRuCrKwyGHoRQB5laar4g0HTI7mDVr3xXaRRD9y+iSpcTjBIMcqAISePvLg9yM5rtfD3ifSfEBlj066Bu4QDPZyqY7iDIzh42wy9e4xVHWvCrSI83h/Ur3Sb/crr5c7NbtgglWhYlAGAwSoBGcjpXE660F39m03XtU8ReHfEjI0trJHEl0WETBmaKVIjvXBGVO04PK0Aa3xrtNumaPrC782N6kEm09YrgiLBHf8AeGE/8BrznwrdNY69pUkM5dtL1pbeTcuMx3A2hM9gi3KH/tmK9D0vxFYeK9NuPCesarYXl3fWrwxXcA8g3DbW3fuGO+OVQA+OndTwQPFW1W91SbUrPSNP1KfVP7PeG/t7aEt9gugdsYctgA7jIM9wgPQZrwMyw9VYulXoxv3+T6+sXJHr4KtB4apRqO3b5/8ABSZ9a0VV0prt9Ls21JEjvjChuERtyrJtG4A9xnPNct488dWnhmaOwhlsH1eWMT+XeXa28UEG7aZpGOTtzwFUFmPA7ke+eQdLrWrWGh6bNqGr3cVpZwjLyytgD29z7Dk15qPisl+9/II7zQtLT5LW+vtGu5mn45k2qoVF54yxJ6kDpXJ6Zc6ZqvjB7tfiL4h1LxHqgcWttpWmrAgiTJ8uEzxsqKB1YuN3UknmvQ/BvhPXz5154v8AEWrTmY/udNW6VVt07B5IlQyP3JGAOgz1IByF5Po8miw3eo+I/DvjC7iY+ZJdO8Er+qqsRcK/OAojGPSti00a28V6RpeqDwxrNsbeNhDpWrlJbZsg8tDJJx7NhWA7dq9N0vTrPSrRbXTbaK2t1JbZEoUEnqx9STySeSetW6APILHwrrN2/l6l4S0jw9K8IH9p+GpYxcqSfmVWYIU47jfTdXuY/wC2INJ/sWO0kt/kXU/FNxJIZcDBaLaWD8dzIn0r2GigDyM67Jor38+keONP1NpAqJYCymvYIJVXlVaJ3kQHjIJbHYVU8ReJ7P4heAr20aGbTte0+aG7W0uleBbiSJw4WJ3Rd6vtZRwDkjIHGfSNY8K2GoRT/ZZLvSbieQSyXOlzG2kkfGNzleHOP7wNcf4x8J+IbexgmsfFGvalptuh+36c8NpNNdRgE5jLQ4Lg4+Uj5ugKnq07O5FSCqQcH1Vjz1HWRFdGDKwyCDkEUtRaNYeGDrOiaQmv6rbS3rSJBvjjSWZnbflgoeFhnIOAjgkcnJr1Kx+FemR3sNxqGpalfRxci2dkjic4Iy4RQzdehbbwOK71jI21R+dT4NxSqWjOPL31/K36mP8ABbSJZtX1XxJIX+xyQR2Nl8+VkAYvLIBjGCxRcjr5Z9q9UvLK1vVRby2huFQ7lEsYcKfUZ70+3hitoI4LeNIoY1CJGihVVR0AA6CquuatY6FpNzqWq3EdvZ267nkdgB6ADPUkkADuSAK4Zy55OTPvsFhY4TDwoR2irF1mCqWYgKBkknAAri9b8bI7fY/DCSX1w6bxfx2c11ZQ4YAhmhB3N1woPbkisLW9VsNdgfWdW8T/AGHw7ZwtI1pp4W4BBXlrlgrqSvI2AYB5JY4xYsdF1jXxbvZ654m0vRt/zm4MEM00YXCiNFizGpODltrYHAGciTqMTxNbyS31lL4h+IenxyEbodM1LTjb28pGCWEXmLIxHuzYBqzY2sV1dwfYvC10Lox+edY8Nzizt5WyQFO9k35CjIIcc9a9I0vQdP0wRGCFpZ4gQtzcyNPP833v3jktz6ZxWpQB5raaZ4s1OS4bXNOtvJicSWVwboW+oKwPAZoQ0eB07BgcEes8OheMLbZfW8ukDWjMqzzea6RXduHztljCY83aSPMXHP8As8V6HRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVDWtJtdYsxb3YkG1hJFLE5SSJx0ZGHIP8+QcgkVfooA8w1SLWV8XPpviO20O/0yba2lX8m+2u2k+Y+UJFUqsq7cgjbuByOQwHH+KfEvjKxn1Oyv7Ww0lb+IafBc6ohaScFiF2vFJ5bMokbAwGbjKrXuer6ba6vpd1p9/H5lrcxtFIucHBGOD1B9CORXkk/h66s9Ej8GXGrx3GoKTJZ2+rTeYuooh3I8MhO+OVDtyPmCkZ27SDWVaM5Qapys++5pSlCMk5q6DT/ibq1rpFzo10LfWvGpmW3sYLKHy2mRo9wnkjL4VVIfcQwXhRlc8WbVtbt70WWh2GkR+NL3y7jUrrUpDczwQklRJJ5YCLjGEiV8enAY1xPhPUbw+MNbtAt9aeIZ9KtUk0K22x3LSiWTO64K/u41DhiwxlWDDsD7j8P/C8XhDwxbaYkz3Nxlprq5kYs88znLuWPJ5OBnJwBWWCnUnQg63xW19epeJjCNWSp/D09C1oegxabcy31xPLfatPGkc97PgMyr0VVGFRcknaoHJycnmtmiiuowCiiigAooooAKKKKAOW8WeGzeadt0OC0trh7yG4udo8lrmNXDOnmKNyswyN34ZAJNcD4G+KGmWVtfrqlvrdpYtqkkEDXyfLaKAqGPczbmCsrE4B27sdq9nrzPxx4as4tVuLvUbjyNBvmSS4E6JNaR3HCHzonBGyQFcuCpVlyWG6gD0G91G0stMl1C4nQWccfmmQHIK44xjrntjrkYrzie+uNe8OrrXiXQFhWSQGz0vW2CIhBYxkQqrs8x/ukA5GFA6nAtBr2lzWmh+Il0Sw8PaerXGmagJXmtmjU5jCo3JliAXYrEjGSNxRa7DwJ4WkbVm8Sa3JqN1ciPytPGpS+ZJHGeWmKABYpH3EbVUbVUA8lhQBZ8J6Hq2qabZ3njdbSOULui0eyQpaQfNuUup5eQcZydqkfKM/Me4oooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArxr4lXv2z4j6DdWlpDcQaNFcwG5kw0f2mQwkwYzknykbJA+XcOcjFeq6/qsGiaPc6jdLI0cKjEca7nkYkKqKO7MxCgepFfP2p28ej3HhWx1m6l1XxLJeXC3NxaufsVnIYnklixnmVi6sxOWPU7RtWuTHVJ0sNUqU3qk2vkjowsIzrQhPZtI6HQr+3g1vRPHGkXW/w8bA22oW1+mb/TreRi6u0rEu8KyKPvE7RuIJGQPcAcjI6V83eBLzSU06y8O36zWjrJqLWOpACQWqR3LK8c5727GQfK3y84JBww9m+GEuojwfaWGveWdY0wmwuzESUZkxtdSQCQ0ZjcZAPzc1rh68cRBVIba/g7EVqUqM+SW/8AnqdXRRRWxkFFFFABRRRQAUUUUAFcf8UGurzwxcaDpKQyanrMbWiCbPlxxHAmlcjoFRj9WKjvXYV5b4pv4brWNXv9SUXOiQRHT4NPQbX1CdGLS72bAWFDhSc7SVO4kABgDl7OfTtWh1Dwhot7HJrejRokP2iAjTtUbCtG7ADasvmJ99CDuUkbhlR7XoeqQ6xpkN5AskYfKvFKpV4nU4ZGB6FSCD9K4vV/Dh03QJtVvreK/vjuk1SCNAFuLdsZhTpjylVCh4OY+xcmoPh7Ncaf4n1JZtU/tPR9d23WmXRjKOJI12yxSjAxIEEeCQCQjZG4HIB6VRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHC/FBLy/k8P6Tpt4tnJNem6urhh/qbWFGMkgPQMGaLaTwGIPauPuLa31LQ9U1K106ay0/SryCx01J02ySIXjMtwQTnMpkHzN8zKgJ5Y1u+MUKePbvUNVjD+HbLSoA0SEtLd3TTS7LdU/iB+Ulf4m8sHIBrc0Pw8NV+HwsNdl3XGqK11eTWc7DEsjeZmOQc4U4CnsFHasq9P2tKVNdU195pSn7OcZ9mmeLLqDeD7WfUEtvtqQap80BCkzRXMqiSMAkDkTMBnjIGa9M+GMH9k+MNesra6abQr+3gvNIWQkvEsZeOeA55BicxrtPKgqp5FaUPwn8JJDLHNZ3d0JW8yQ3V/PMHYAAMVZypIwuMjgqD2Fcb4Qv7y+1PwLr96sdr9ommstTtjIC0V4YZBHID6SqoJA6t5R5Oa4sswdTB0nCpJNt309F+p047ExxM1KCskrfiz26iiivSOIKKKKACiiigAooooAranexadp11e3LbYbaJpXP+yoyf5V5B4O0O7ibRPD2uhbzU7mJbvWGXmOzijw8NoOvLSNvY5y2GJ4Zcdz8UF1ibw9bW3h2ON7+41C2jzKoZETzAzOw7qoXJHcA1U8AzW1zr+sxWCebZ6YFtUvml3SXc7MxuXP/A0Vc+sbAYAFAHaXttHeWdxazgmKeNo3AODtYYP868UW4up5dP11HEF/pOprH4gtnyEnjika3+3JgfeCq2cdVLKeUU17jXmniPT76fWdb020toYLh0F7o105VklmZCLi2cZ4VwmSD13sw5QYAPS6Kx/B1yl54T0a4jEih7OIlZSC6nYMqxHG4HIPuDWxQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHmPi2TUIdc1e+SwN01pJHDo1ojgm6v5YVHmHOAojTPU4AMjelei6ZZpp+m2llEcx28SQqcY4UAD+VeR+NdTl0+68Z388V44s5k0+wSGPe8k91DCHkQDnKR7QPbf617KKACvCprWW0njutGjAFh4gj0u+t5yArQG+DwXK4zgxlzGCeq7x2Fe614z4ivRDcXV3o1mk8seuHRbyKaIMrieRHjmI77JmAB9370AezUUUUAFFFFABRRRQAUUUUAcV8RRqVzfaBpujl4J72aaM3obizXym3SY7tt3KvTDMD2qb4dIJYNRvbeyey02WVINNRiPntI0ASQYJIDsZGG7nBBPWsr4nyXM/iDwzotj5yTa0LmyadR8kMOI3mYns5iR1U+rZ7VtfDvVF1fT9UuIlkS3TUZoIEZdqiKPaiFB/cZVDDHXdmgDqq4XxjBFeeJodJZ5baTUrLzIr2MDNpPbyq0LcnnLSkY77dp4au6riPHcL3Wv6Tp7Ryx22p2l3Zm+QAfZZ/wB1JC2cg5zGxUDqR9KAL3w0mvLjwokmpWi2V2bu7ElupyI2FxICAe4JBI9iK6muS+GFzPf+GWvruQG4ubqcyxhCohlVzHIgz1AkR+feutoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDzPxRfeRqfi2fyZbx9JtvPisYmZGmluIUijw46N+7lUEcjzDXo9rIJrWGVQQroGAJzwRnr3rjNV2y/EWGwkkVRNDb3xUkLuSBps/XEjwE+ma0Phnq1trHgvTprO0ubKOJPs/2a5bdJHs+UZbvlQrA9wwoA6ivFk1e2SayvLe2mf+0fEU+jtEeEeRb5riKZsc8IshB9GHavYNTvYNN067vrtiltaxPPKwGcIoLE4+gNeO+C7+O+1vwVp8CuTc2Ft4gxs4iAt5oJCfQ5eFevUmgD2uiiigAooooAKKKKACiiigDh/iRPJFe6FbpLHA2pSTabFO+R5U0sZ2kEchtqSYx3xWl4Hu7a7GuCxsLiztrbUns0MjEpN5MccZeMdkBQpgd0Y9Sab8QbmHTtO0/VLuFJbawv4ppC20eWDuj3gtgDBcc+maTwtcwWWp/8I8yTLfW2nQTyuT+7dmaTfjB+8GO5vXzF60AdTXDeNWbUdXudGsoblNSOlvdW14H/AHUU6SBoV293LIW/3UYV3Nea6t4g0601jxNq1zK8MGhXdks8zD5dpQqxHqAJ3B9wRQB1vgjULbV/C9lqllB9nt78Ndqm4t/rGLk/iST+NbtZvhmxXTPD2m2SLsWC3SPbt24wo7dq0qACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA4b4ova2Fvp+rXlxFZLF59kb2RWIt/tERRWyOQDIIh+Iq74SvYR4o8VaPENrWEtq5BGMq9ugDD2/dkfVTW7r+l22t6Le6bexRy291E0TLIuRyOD+BwfqK888Iast14pn11WjIvLw6NfoshzbzxQx7VZccESLMuP+moPegDtPGkRuNIhtcApcXttFID3TzkLD8VBH41yfwthiuNf165SNf8AiWTT6RG68gBbqeQqD7K0WfoKb8S9Ysk17SXv717XSfD91DqF/KmGHmyExwxEZz0d3PXAVeCWFdZ4Ds2tPDNu8tuLa4vJJb+aPbhlkmkaUhv9ob8H6UAdBRRRQAUUUUAFFFFABRRRQBm+JtNj1nw7qemzRRzJd20kOyQZU7lIGfxrhNG1O3ufFOg6pb3cFz/a9zPb7oSWMZSzQvE5HAYPA5wf516bXmHiPTLuz1y+i0IR2s0Pna5aW0Mmw3c2Iw67BjdkiTcfWYZ60Aen15jdWLXesLo1xsk/tTT7S5mWRQGcx3ZeXK46bZCPyzXb6vqFpJoaMJ5PL1EJBbvARvYyjCsnPOAS3sFJ7Vn+GNL0c3NvqGmZlNnYR6XBK3O2JQGIDd8/Jn3T2oA6eiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuB8bfDpNbnu73R9SutKvLxomvI4pGWC88s/KZApDKwAADoyngZyBiu+ooA4K28ArcSaRDqgsY9J0u4+3RWFmj4nuv4ZZXclm25Jx3YgknAFd7RRQAUUUUAFFFFABRRRQAUUUUAFc54y8KxeJI7OaG9udL1axcvZ6ja7fNh3AB1wwIZGAAZSMHA9BXR0UAcBb+EdWtImsrOTTooCZljvzJM9xbLLnc0KOSqNycYbA44IGK7HQ9Ks9D0ey0vTIRBZWkSwxRjsoGOfU9ye55q9RQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Conformation of the cytoplasmic domain of normal band 3 (panel A) offers little resistance to the extension of spectrin tetramers during membrane deformation. In contrast, the conformationally altered cytoplasmic domain of mutated band 3 (panel B), by getting entangled in the spectrin network, sterically hinders the extension of spectrin tetramers. For reasons of clarity, not all of the individual components of the skeletal network have been delineated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Republished with permission of the University of Michigan Press, from Mohandas, N, Winardi, R, Knowles, D, et al. J Clin Invest 1992; 89:686; permission conveyed through Copyright Clearance Center, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_48_13058=[""].join("\n");
var outline_f12_48_13058=null;
var title_f12_48_13059="Annular lichen planus - penis";
var content_f12_48_13059=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Annular lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Violaceous annular plaques and papules are present on the penis and scrotum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Kosman Sadek Zikry, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_48_13059=[""].join("\n");
var outline_f12_48_13059=null;
var title_f12_48_13060="Potassium and hypertension";
var content_f12_48_13060=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Potassium and hypertension",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/48/13060/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/48/13060/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/48/13060/contributors\">",
"     David B Mount, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/48/13060/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/48/13060/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/48/13060/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/48/13060/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/48/13060/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H9649826\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A low dietary intake of potassium may increase the blood pressure, and potassium supplementation tends to lower the blood pressure. The data demonstrating these associations, as well as the potential mechanisms, will be reviewed here. The approach to patients who present with concurrent hypertension and hypokalemia, and the clinical features of primary aldosteronism are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5338?source=see_link\">",
"     \"Approach to the patient with hypertension and hypokalemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=see_link\">",
"     \"Clinical features of primary aldosteronism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     POTASSIUM INTAKE AND BLOOD PRESSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low dietary potassium intake (below 40",
"    <span class=\"nowrap\">",
"     meq/day)",
"    </span>",
"    has been associated with an increased risk or exacerbation of hypertension and an increased risk of stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13060/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Short-term potassium restriction in healthy humans and patients with essential hypertension induces sodium chloride retention and an increase in blood pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?12/48/13060/abstract/3-5\">",
"       3-5",
"      </a>",
"      ]. The ratio of sodium to potassium intake may also influence blood pressure. In the Dallas Heart Study, for example, each three unit higher urinary sodium-to-potassium ratio was associated with a",
"      <span class=\"nowrap\">",
"       1.6/1.0",
"      </span>",
"      mmHg higher blood pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?12/48/13060/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In two population-based studies, individuals on a low potassium diet had a 40 to 50 percent increase in the risk of stroke, independent of other risk factors such as the systemic blood pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?12/48/13060/abstract/2\">",
"       2",
"      </a>",
"      ]. A similar effect has been demonstrated in stroke-prone hypertensive rats, in which the incidence of both stroke and renal vascular disease can be diminished by a high potassium diet [",
"      <a class=\"abstract\" href=\"UTD.htm?12/48/13060/abstract/7\">",
"       7",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, potassium supplementation appears to modestly lower the blood pressure in some normotensive and hypertensive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13060/abstract/8-12\">",
"     8-12",
"    </a>",
"    ]. The magnitude of benefit was illustrated in two meta-analyses of randomized trials.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a meta-analysis of 32 trials, potassium supplementation was associated with a fall in blood pressure of",
"      <span class=\"nowrap\">",
"       3.1/2.0",
"      </span>",
"      mmHg overall and",
"      <span class=\"nowrap\">",
"       4.4/2.5",
"      </span>",
"      mmHg in patients with hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?12/48/13060/abstract/9\">",
"       9",
"      </a>",
"      ]. The effect was increased in trials in which patients also had an increase in salt intake.",
"     </li>",
"     <li>",
"      A later meta-analysis employed stricter inclusion criteria and accepted only five trials with a total of 425 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?12/48/13060/abstract/11\">",
"       11",
"      </a>",
"      ]. The magnitude of reduction in blood pressure was similar to or higher than in the meta-analysis of 32 trials but was not statistically significant. A probable explanation is that the number of patients was too low to detect a benefit of this magnitude.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A similar effect was noted in a randomized, crossover trial in which 16 hypertensive patients with diuretic-induced hypokalemia (serum potassium below 3.5",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    (60",
"    <span class=\"nowrap\">",
"     meq/day)",
"    </span>",
"    or placebo tablets [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13060/abstract/12\">",
"     12",
"    </a>",
"    ]. Potassium chloride was associated with rise in serum potassium of 0.6",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and a significant reduction in mean blood pressure (average 5.5 mmHg). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=see_link&amp;anchor=H27627359#H27627359\">",
"     \"Causes of hypokalemia\", section on 'Diuretics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effects of potassium supplementation on blood pressure appear to be greater in blacks than in whites [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13060/abstract/9\">",
"     9",
"    </a>",
"    ]. Urinary potassium excretion in blacks is consistently less than in whites, even after potassium supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13060/abstract/13,14\">",
"     13,14",
"    </a>",
"    ], possibly due to greater colonic excretion in blacks. Another hypothesis links the reduced urinary potassium excretion with the increased predisposition to hypertension observed in blacks by invoking a relative increase in the activity of the Na-K-2Cl cotransporter in the luminal membrane in the thick ascending limb and macula densa [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13060/abstract/13\">",
"     13",
"    </a>",
"    ]. This hypothesis explains the decreased plasma renin activity, decreased urinary potassium excretion, and increased salt sensitivity often seen in blacks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9649910\">",
"    <span class=\"h2\">",
"     Clinical application",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the above observations, some, including the JNC-7 hypertension guidelines, have suggested that hypertensive patients should be encouraged to maintain a high potassium intake from fresh fruits and vegetables (assuming that renal function is relatively normal) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13060/abstract/15\">",
"     15",
"    </a>",
"    ]. Although there is a paucity of dose response trials, hypertensive patients should ideally consume at least 120 meq (4.7 g) of dietary",
"    <span class=\"nowrap\">",
"     potassium/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13060/abstract/16\">",
"     16",
"    </a>",
"    ]. Dietary counseling, performed by either the physician or a dietician, is the usual approach to increasing a patient&rsquo;s potassium intake.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     Potassium chloride",
"    </a>",
"    supplements are also used, particularly if the serum potassium is low.",
"   </p>",
"   <p>",
"    Few Americans achieve the recommended level of potassium intake. In a report from the National Health and Nutrition Examination Survey (NHANES) III, the average daily potassium intake in adults was 74 to 82 meq (2.9 to 3.2 g) in men and 54 to 59 meq (2.1 to 2.3 g) in women [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13060/abstract/16\">",
"     16",
"    </a>",
"    ]. Only 10 percent of men and less than 1 percent of women had a daily potassium intake of 120 meq (4.7 g) or more. &nbsp;",
"   </p>",
"   <p>",
"    We would",
"    <strong>",
"     not",
"    </strong>",
"    recommend potassium supplementation or a high potassium diet to attain these goals in patients at risk for hyperkalemia due, for example, to therapy with angiotensin inhibitors, potassium sparing diuretics, or underlying chronic kidney disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms by which potassium intake might be related to hypertension and vascular disease are not well defined. The reduction in blood pressure with potassium supplements may be related to decreased vascular responsiveness to vasopressors, particularly norepinephrine [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13060/abstract/17\">",
"     17",
"    </a>",
"    ]. In addition, sodium and chloride intake may be important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Relation to sodium excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between potassium and blood pressure appears to be due in part to changes in sodium excretion, as noted above [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13060/abstract/6\">",
"     6",
"    </a>",
"    ]. Sodium excretion is diminished by hypokalemia or a low potassium diet and increased with potassium supplements, apparently through changes in sodium reabsorption in the proximal tubule",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    loop of Henle [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13060/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Potassium intake and blood pressure'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/6/6245?source=see_link&amp;anchor=H6#H6\">",
"     \"Hypokalemia-induced renal dysfunction\", section on 'Increased sodium reabsorption'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The observation that potassium supplementation has little if any antihypertensive effect in sodium-restricted patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13060/abstract/19\">",
"     19",
"    </a>",
"    ] is compatible with a central role for changes in sodium balance. The vasculoprotective effect of potassium supplementation in animals is also most prominent on a high salt intake.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Role of chloride intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chloride is an important determinant of the rise in blood pressure in salt-sensitive forms of hypertension. In comparison, dietary potassium (eg, from fruits and vegetables) is primarily associated with organic anions such as citrate, not chloride. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24120?source=see_link\">",
"     \"Salt intake, salt restriction, and essential hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most of the above trials that evaluated the effect of potassium supplementation on blood pressure used",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    . The efficacy of dietary potassium was evaluated a trial of 47 patients with well-controlled hypertension; increasing dietary potassium intake from natural foods was associated with a significantly greater reduction in the number of antihypertensive pills taken per day compared with no change in diet (24 versus 60 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13060/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relative efficacy of potassium citrate and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    supplements was directly evaluated in a randomized crossover trial of 14 patients with hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13060/abstract/10\">",
"     10",
"    </a>",
"    ]. Both preparations produced a similar reduction in blood pressure. Potassium chloride and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/35/7731?source=see_link\">",
"     potassium bicarbonate",
"    </a>",
"    had similar effects on office blood pressure in another randomized crossover trial of 42 patients with mild hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13060/abstract/21\">",
"     21",
"    </a>",
"    ]. Thus, the available evidence does",
"    <strong>",
"     not",
"    </strong>",
"    support the accompanying anion being important in the effect of potassium on blood pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maintenance of adequate potassium intake or the administration of potassium supplements appears to lower the blood pressure, particularly in blacks and in patients who are not sodium restricted. Furthermore, a higher potassium intake may reduce the risk of stroke. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Potassium intake and blood pressure'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Relation to sodium excretion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mechanism by which potassium reduces blood pressure is not clear. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some experts suggest that hypertensive patients consume at least 120 meq (4.7 g) of dietary",
"      <span class=\"nowrap\">",
"       potassium/day",
"      </span>",
"      provided they do not have a predisposition to hyperkalemia. This level of potassium intake can be achieved with either dietary counseling or potassium supplementation. (See",
"      <a class=\"local\" href=\"#H9649910\">",
"       'Clinical application'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13060/abstract/1\">",
"      Coca SG, Perazella MA, Buller GK. The cardiovascular implications of hypokalemia. Am J Kidney Dis 2005; 45:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13060/abstract/2\">",
"      Green DM, Ropper AH, Kronmal RA, et al. Serum potassium level and dietary potassium intake as risk factors for stroke. Neurology 2002; 59:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13060/abstract/3\">",
"      Krishna GG, Miller E, Kapoor S. Increased blood pressure during potassium depletion in normotensive men. N Engl J Med 1989; 320:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13060/abstract/4\">",
"      Coruzzi P, Brambilla L, Brambilla V, et al. Potassium depletion and salt sensitivity in essential hypertension. J Clin Endocrinol Metab 2001; 86:2857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13060/abstract/5\">",
"      Krishna GG. Effect of potassium intake on blood pressure. J Am Soc Nephrol 1990; 1:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13060/abstract/6\">",
"      Hedayati SS, Minhajuddin AT, Ijaz A, et al. Association of urinary sodium/potassium ratio with blood pressure: sex and racial differences. Clin J Am Soc Nephrol 2012; 7:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13060/abstract/7\">",
"      Ellis D, Banner B, Janosky JE, Feig PU. Potassium supplementation attenuates experimental hypertensive renal injury. J Am Soc Nephrol 1992; 2:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13060/abstract/8\">",
"      Geleijnse JM, Kok FJ, Grobbee DE. Blood pressure response to changes in sodium and potassium intake: a metaregression analysis of randomised trials. J Hum Hypertens 2003; 17:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13060/abstract/9\">",
"      Whelton PK, He J, Cutler JA, et al. Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. JAMA 1997; 277:1624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13060/abstract/10\">",
"      He FJ, Markandu ND, Coltart R, et al. Effect of short-term supplementation of potassium chloride and potassium citrate on blood pressure in hypertensives. Hypertension 2005; 45:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13060/abstract/11\">",
"      Dickinson HO, Nicolson DJ, Campbell F, et al. Potassium supplementation for the management of primary hypertension in adults. Cochrane Database Syst Rev 2006; :CD004641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13060/abstract/12\">",
"      Kaplan NM, Carnegie A, Raskin P, et al. Potassium supplementation in hypertensive patients with diuretic-induced hypokalemia. N Engl J Med 1985; 312:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13060/abstract/13\">",
"      Aviv A, Hollenberg NK, Weder A. Urinary potassium excretion and sodium sensitivity in blacks. Hypertension 2004; 43:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13060/abstract/14\">",
"      Turban S, Miller ER 3rd, Ange B, Appel LJ. Racial differences in urinary potassium excretion. J Am Soc Nephrol 2008; 19:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13060/abstract/15\">",
"      Adrogu&eacute; HJ, Madias NE. Sodium and potassium in the pathogenesis of hypertension. N Engl J Med 2007; 356:1966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13060/abstract/16\">",
"      Appel LJ, Giles TD, Black HR, et al. ASH position paper: dietary approaches to lower blood pressure. J Am Soc Hypertens 2010; 4:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13060/abstract/17\">",
"      Bianchetti MG, Weidmann P, Beretta-Piccoli C, Ferrier C. Potassium and norepinephrine- or angiotensin-mediated pressor control in pre-hypertension. Kidney Int 1987; 31:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13060/abstract/18\">",
"      Gallen IW, Rosa RM, Esparaz DY, et al. On the mechanism of the effects of potassium restriction on blood pressure and renal sodium retention. Am J Kidney Dis 1998; 31:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13060/abstract/19\">",
"      Whelton PK, He J. Potassium in preventing and treating high blood pressure. Semin Nephrol 1999; 19:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13060/abstract/20\">",
"      Siani A, Strazzullo P, Giacco A, et al. Increasing the dietary potassium intake reduces the need for antihypertensive medication. Ann Intern Med 1991; 115:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13060/abstract/21\">",
"      He FJ, Marciniak M, Carney C, et al. Effects of potassium chloride and potassium bicarbonate on endothelial function, cardiovascular risk factors, and bone turnover in mild hypertensives. Hypertension 2010; 55:681.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3876 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-1201EFFE29-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_48_13060=[""].join("\n");
var outline_f12_48_13060=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9649826\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      POTASSIUM INTAKE AND BLOOD PRESSURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9649910\">",
"      Clinical application",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Relation to sodium excretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Role of chloride intake",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5338?source=related_link\">",
"      Approach to the patient with hypertension and hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=related_link\">",
"      Causes of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=related_link\">",
"      Clinical features of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/6/6245?source=related_link\">",
"      Hypokalemia-induced renal dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24120?source=related_link\">",
"      Salt intake, salt restriction, and essential hypertension",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_48_13061="String sign on MR angiography";
var content_f12_48_13061=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F65212&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F65212&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 602px\">",
"   <div class=\"ttl\">",
"    String sign on MR angiography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 582px; height: 312px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left internal carotid artery dissection in a 43-year-old man. A hemorrhagic crescent on axial T1 cervical MRI (A) and the string sign on follow-up neck MR angiography (B) are consistent with dissection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pary LF, Rodnitzky RL. Traumatic internal carotid artery dissection associated with taekwondo. Neurology 2003; 60:1392. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_48_13061=[""].join("\n");
var outline_f12_48_13061=null;
var title_f12_48_13062="CML blood smear";
var content_f12_48_13062=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F56954&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F56954&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic myeloid leukemia blood smear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 282px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Characteristic peripheral blood smear of chronic myeloid leukemia shows basophilia and granulocytosis with neutrophils and immature granulocytes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: McClatchey, KD, MD, DDS. Clinical Laboratory Medicine, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2002. Copyright &copy;2002 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_48_13062=[""].join("\n");
var outline_f12_48_13062=null;
var title_f12_48_13063="Idiopathic guttate hypomelanosis - thigh";
var content_f12_48_13063=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F61761%7EDERM%2F67346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F61761%7EDERM%2F67346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Idiopathic guttate hypomelanosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple small, hypopigmented macules are present on the thigh.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Idiopathic guttate hypomelanosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple small, hypopigmented macules are present on the arm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_48_13063=[""].join("\n");
var outline_f12_48_13063=null;
var title_f12_48_13064="Zolpidem: Drug information";
var content_f12_48_13064=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Zolpidem: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?20/44/21189?source=see_link\">",
"    see \"Zolpidem: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/38/26215?source=see_link\">",
"    see \"Zolpidem: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F15898498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Recommending Lower Initial Zolpidem Doses to Reduce Risk of Morning Somnolence",
"     </span>",
"     <span class=\"collapsible-date\">",
"      January 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The U.S. Food and Drug Administration (FDA) is requiring manufacturers of zolpidem products (Ambien&reg;, Ambien CR&reg;, Edluar&trade;, and Zolpimist&reg;) to change labeling to recommend lower starting doses of zolpidem in women. Blood levels in women may remain high enough the morning after use to impair activities that require alertness, including driving. Women appear to be more sensitive to this effect because they eliminate zolpidem more slowly than men, although the FDA is also recommending that the lower doses be considered for men. The recommendation is focused on zolpidem products approved for use immediately before bedtime. The FDA is recommending that the doses for immediate-release products be lowered from 10 mg to 5 mg and from 12.5 mg to 6.25 mg for extended-release products in women.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Patients already prescribed zolpidem should contact their healthcare provider prior to adjusting their dose.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Additional information can be found at",
"       <a href=\"file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm334798.htm\" target=\"_blank\">",
"        file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm334798.htm",
"       </a>",
"       .",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F236158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ambien CR&reg;;",
"     </li>",
"     <li>",
"      Ambien&reg;;",
"     </li>",
"     <li>",
"      Edluar&trade;;",
"     </li>",
"     <li>",
"      Intermezzo&reg;;",
"     </li>",
"     <li>",
"      Zolpimist&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13452765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Sublinox&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F236195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Hypnotic, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F236162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Insomnia:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     The lowest effective dose should be used; higher doses may be more likely to impair next morning activities.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release tablet, spray: 5 mg (females) or 5-10 mg (males) immediately before bedtime; maximum dose: 10 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release tablet: 6.25 mg (females) or 6.25-12.5 mg (males) immediately before bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sublingual tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Edluar&trade;: 5 mg (females) or 5-10 mg (males) immediately before bedtime; maximum dose: 10 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Sublinox&trade; (Canadian availability; not available in U.S.): 10 mg immediately before bedtime; maximum dose: 10 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Intermezzo&reg;:",
"     <b>",
"      Note:",
"     </b>",
"     Take only if &ge;4 hours left before waking",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Females: 1.75 mg once per night as needed (maximum: 1.75 mg/night)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Males: 3.5 mg once per night as needed (maximum: 3.5 mg/night)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Dosage adjustment with concomitant CNS depressants:",
"     </i>",
"     Females and males: 1.75 mg once per night as needed; dose adjustment of concomitant CNS depressant(s) may be necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F236163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release tablet, spray: 5 mg immediately before bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sublingual tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     U.S. labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Edluar&trade;: 5 mg immediately before bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Intermezzo&reg;: Females and males: 1.75 mg once per night as needed (maximum: 1.75 mg/night).",
"     <b>",
"      Note:",
"     </b>",
"     Take only if &ge;4 hours left before waking.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Canadian labeling (Sublinox&trade;): Not recommended; tablet cannot not be split for a reduced dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release tablet: 6.25 mg immediately before bedtime",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F236164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; however, some zolpidem labeling recommends monitoring patients with renal impairment closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Not dialyzable",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F236165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     U.S. labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release tablet, spray: 5 mg immediately before bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release tablet: 6.25 mg immediately before bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sublingual tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Edluar&trade;: 5 mg immediately before bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Intermezzo&reg;: Females and males: 1.75 mg once per night as needed.",
"     <b>",
"      Note:",
"     </b>",
"     Take only if &ge;4 hours left before waking.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Canadian labeling: Sublingual tablet: Sublinox&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild-to-moderate impairment: Use is not recommended; tablet cannot be split for reduced dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe impairment: Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F236134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as tartrate [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zolpimist&reg;: 5 mg/actuation (8.2 g) [contains benzoic acid, propylene glycol; cherry flavor; 60 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as tartrate: 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ambien&reg;: 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, sublingual, as tartrate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Edluar&trade;: 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intermezzo&reg;: 1.75 mg, 3.5 mg [spearmint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as tartrate: 6.25 mg, 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ambien CR&reg;: 6.25 mg, 12.5 mg",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F13456321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, sublingual, as tartrate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Sublinox&trade;: 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F236119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes oral spray, sublingual tablet",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F236197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ambien&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085906.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085906.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ambien CR&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085908.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085908.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Edluar&trade;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM135937.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM135937.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Intermezzo&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM281854.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM281854.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Zolpidem:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089833.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089833.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Zolpimist&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM143465.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM143465.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F236139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ingest immediately before bedtime due to rapid onset of action. Regardless of dosage form, do not administer with or immediately after a meal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ambien CR&reg; tablets should be swallowed whole; do not divide, crush, or chew.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edluar&trade;, Intermezzo&reg;, or Sublinox&trade; (Canadian availability; not available in U.S.) sublingual tablets should be placed under the tongue and allowed to disintegrate; do not swallow or administer with water.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpimist&reg; oral spray should be sprayed directly into the mouth over the tongue. Prior to initial use, pump should be primed by spraying 5 times. If pump is not used for at least 14 days, re-prime pump with 1 spray.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F236138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ambien&reg;, Edluar&trade;, Zolpimist&reg;: Short-term treatment of insomnia (with difficulty of sleep onset)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ambien CR&reg;: Treatment of insomnia (with difficulty of sleep onset and/or sleep maintenance)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intermezzo&reg;:  \"As needed\" treatment of middle-of-the-night insomnia with &ge;4 hours of sleep time remaining.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sublinox&trade; (Canadian availability; not available in U.S.): Short-term treatment of insomnia (with difficulty of sleep onset, frequent awakenings, and/or early awakenings)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F236204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ambien&reg; may be confused with Abilify&reg;, Ativan&reg;, Ambi 10&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Sublinox&trade; may be confused with Suboxone&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zolpidem may be confused with lorazepam, zaleplon",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ambien [U.S., Argentina, Israel] may be confused with Amyben brand name for amiodarone [Great Britain]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F236193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Actual frequency may be dosage form, dose, and/or age dependent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Central nervous system: Headache (3% to 19%), somnolence (6% to 15%), dizziness (1% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Blood pressure increased, chest discomfort/pain, palpitation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Abnormal dreams, anxiety, apathy, amnesia, ataxia, attention disturbance, body temperature increased, burning sensation, confusion, depersonalization, depression, disinhibition, disorientation, drowsiness, drugged feeling, euphoria, fatigue, fever, hallucinations, hypoesthesia, insomnia, lethargy, lightheadedness, memory disorder, mood swings, sleep disorder, stress",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash, urticaria, wrinkling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Menorrhagia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal discomfort, abdominal pain, abdominal tenderness, appetite disorder, constipation, diarrhea, dyspepsia, flatulence, gastroenteritis, gastroesophageal reflux, hiccup, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection, vulvovaginal dryness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, balance disorder, involuntary muscle contractions, myalgia, neck pain, paresthesia, psychomotor retardation, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Asthenopia, blurred vision, depth perception altered, diplopia, red eye, visual disturbance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Labyrinthitis, tinnitus, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Dysuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis, sinusitis, throat irritation, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergy, binge eating, flu-like syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Agitation, anaphylaxis, anemia, angioedema, cerebrovascular disorder, cognition decreased, complex sleep-related behavior (sleep-driving, cooking or eating food, making phone calls), concentrating difficulty, cystitis, diaphoresis, dysphagia, dyspnea, edema, emotional lability, falling, hepatic function abnormalities, hyperglycemia, hyper-/hypotension, illusion, leukopenia, lymphadenopathy, migraine, orthostatic hypotension, paresthesia of the tongue (sublingual tablets), pruritus, renal failure (acute), scleritis, somnambulism (sleepwalking), speech disorder, stupor, sublingual erythema (sublingual tablets), syncope, tachycardia, thrombosis, urinary incontinence, vaginitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F236142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to zolpidem or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Significant obstructive sleep apnea syndrome and acute and/or severe impairment of respiratory function; myasthenia gravis; severe hepatic impairment; personal or family history of sleepwalking",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F236123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abnormal thinking/behavioral changes: Hypnotics/sedatives have been associated with abnormal thinking and behavior changes including decreased inhibition, aggression, bizarre behavior, agitation, hallucinations, and depersonalization. These changes may occur unpredictably and may indicate previously unrecognized psychiatric disorders; evaluate appropriately.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression impairing physical and mental capabilities; patients must be cautioned about performing tasks which require mental alertness (operating machinery or driving). Zolpidem should only be administered when the patient is able to stay in bed a full night (7-8 hours) before being active again.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Postmarketing studies have indicated that the use of hypnotic/sedative agents for sleep has been associated with hypersensitivity reactions including anaphylaxis as well as angioedema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sleep-related activities: An increased risk for hazardous sleep-related activities such as sleep-driving; cooking and eating food, and making phone calls while asleep have also been noted; amnesia may also occur.  Discontinue treatment in patients who report any sleep-related episodes. Canadian labeling recommends avoiding use in patients with disorders (eg, restless legs syndrome, periodic limb movement disorder, sleep apnea) that may disrupt sleep and cause frequent awakenings, potentially increasing the risk of complex sleep-related behaviors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use with caution in patients with depression; worsening of depression, including suicide or suicidal ideation has been reported with the use of hypnotics. Intentional overdose may be an issue in this population. The minimum dose that will effectively treat the individual patient should be used. Prescriptions should be written for the smallest quantity consistent with good patient care.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug dependence.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dose adjustment recommended. Canadian labeling contraindicates use in severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis. Canadian labeling contraindicates use in myasthenia gravis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with respiratory compromise, COPD, or sleep apnea. Canadian labeling contraindicates use in significant obstructive sleep apnea syndrome and acute and/or severe impairment of respiratory function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depressants/psychoactive medications: Use with caution in patients receiving other CNS depressants or psychoactive medication; effects with other sedative drugs or ethanol may be potentiated, including risk of sleep-related behaviors. Concomitant use with alcohol is not recommended per Canadian labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; dose adjustment recommended. Closely monitor elderly or debilitated patients for impaired cognitive and/or motor performance, confusion, and potential for falling. Avoid chronic use (&gt;90 days) in older adults; adverse events, including delirium, falls, fractures, have been observed with nonbenzodiazepine hypnotic use in the elderly similar to events observed with benzodiazepines. Data suggests improvements in sleep duration and latency are minimal (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Females: Intermezzo&reg;: Dosage adjustment is recommended for females; pharmacokinetic studies involving sublingual zolpidem (Intermezzo&reg;) showed a significant increase in maximum concentration and exposure in females compared to males at the same dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: When studied for the unapproved use of insomnia associated with ADHD in children, a higher incidence (~7%) of hallucinations was reported. In addition, sleep latency did not decrease compared to placebo. Zolpidem is",
"     <b>",
"      not",
"     </b>",
"     FDA- or Health Canada-approved for use in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Symptomatic treatment of insomnia should be initiated only after careful evaluation of potential causes of sleep disturbance. Failure of sleep disturbance to resolve after 7-10 days may indicate psychiatric and/or medical illness.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rapid onset: Because of the rapid onset of action, administer immediately prior to bedtime or after the patient has gone to bed and is having difficulty falling asleep.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Abrupt discontinuance may lead to withdrawal symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F236189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F236128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May increase the serum concentration of Zolpidem. Management: Consider using a lower starting dose of zolpidem in patients receiving systemic azole antifungals. Monitor patients closely for increased magnitude and/or duration of zolpidem effects when using this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Zolpidem may enhance the CNS depressant effect of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Zolpidem.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the CNS depressant effect of Zolpidem. Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Zolpidem.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flumazenil: May diminish the sedative effect of Hypnotics (Nonbenzodiazepine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FluvoxaMINE: May enhance the CNS depressant effect of Zolpidem. FluvoxaMINE may increase the serum concentration of Zolpidem.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Zolpidem.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: Hypnotics (Nonbenzodiazepine) may enhance the CNS depressant effect of Sodium Oxybate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May decrease the serum concentration of Zolpidem.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F236154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May enhance the adverse/toxic effects of zolpidem. Management: Avoid use of ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Maximum plasma concentration and bioavailability are decreased with food; time to peak plasma concentration is increased; half-life remains unchanged. Grapefruit juice may decrease the metabolism of zolpidem. Management: Avoid grapefruit juice.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease the levels/effects of zolpidem. Some herbal medications should be avoided due to the risk of increased CNS depression. Management: Avoid concomitant use of St John's wort. Avoid valerian, kava kava, and gotu kola.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F236129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F1615032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. Adverse effects were noted in animal reproduction studies at doses 20-100 times the maximum recommended human dose. Severe neonatal respiratory depression has been reported when zolpidem was used at the end of pregnancy, especially when used concurrently with other CNS depressants. Studies of prenatal exposure to zolpidem have not been conducted in children. Children born of mothers taking sedative/hypnotics may be at risk for withdrawal; neonatal flaccidity has been reported in infants following maternal use of sedative/hypnotics during pregnancy. Use during pregnancy only if the benefits justify the risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F236167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F1615035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For faster sleep onset, do not administer with (or immediately after) a meal.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F236145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Zolpimist Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/ACT (7.7 mL): $79.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sublingual",
"     </b>",
"     (Edluar Sublingual)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (30): $235.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (30): $235.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sublingual",
"     </b>",
"     (Intermezzo Sublingual)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.75 mg (30): $248.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3.5 mg (30): $248.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (Ambien CR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6.25 mg (100): $971.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5 mg (100): $971.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (Zolpidem Tartrate ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6.25 mg (100): $611.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5 mg (100): $611.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ambien Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $919.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $919.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Zolpidem Tartrate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $462.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $462.54",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F236131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Daytime alertness; respiratory rate; behavior profile",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F236146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adormix (CN);",
"     </li>",
"     <li>",
"      Ambien (BB, BM, BS, BZ, GY, JM, PR, SR, TT);",
"     </li>",
"     <li>",
"      Ambien CR (AR, IL);",
"     </li>",
"     <li>",
"      Ambulax-2 (IN);",
"     </li>",
"     <li>",
"      Conyx (KP);",
"     </li>",
"     <li>",
"      Dormeben (CO);",
"     </li>",
"     <li>",
"      Dormizol (AU);",
"     </li>",
"     <li>",
"      Flazinil (EC);",
"     </li>",
"     <li>",
"      Fulsadem (AR);",
"     </li>",
"     <li>",
"      Hypnogen (EE);",
"     </li>",
"     <li>",
"      Ivadal (AT);",
"     </li>",
"     <li>",
"      Lioram (BR);",
"     </li>",
"     <li>",
"      Niotal (IT);",
"     </li>",
"     <li>",
"      Nitrest (IN);",
"     </li>",
"     <li>",
"      Nocte (CR, GT, NI, PA, SV);",
"     </li>",
"     <li>",
"      Nocte Sublingual (AR);",
"     </li>",
"     <li>",
"      Nuo Bin (CL);",
"     </li>",
"     <li>",
"      Sanval (RU);",
"     </li>",
"     <li>",
"      Sobrium (MY);",
"     </li>",
"     <li>",
"      Somidem (AU, MY);",
"     </li>",
"     <li>",
"      Somit (AR, PY, UY);",
"     </li>",
"     <li>",
"      Somnil (CO);",
"     </li>",
"     <li>",
"      Somno (PE);",
"     </li>",
"     <li>",
"      Stilnix (IL);",
"     </li>",
"     <li>",
"      Stilnoct (BE, DK, FI, GB, IE, LU, NL, NO, SE);",
"     </li>",
"     <li>",
"      Stilnox (AU, BF, BG, BJ, BR, CH, CI, CL, CN, CO, CR, CZ, DE, DO, EE, ES, ET, FR, GH, GM, GN, GR, GT, HK, HN, HU, IT, KE, KP, LR, MA, ML, MR, MU, MW, MX, MY, NE, NG, NI, PA, PE, PH, PK, PL, PT, PY, SC, SD, SL, SN, SV, TH, TN, TW, TZ, UG, VE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Stilnox CR (AU, CO, HK, KP, MY, SG);",
"     </li>",
"     <li>",
"      Stilpidem (HK);",
"     </li>",
"     <li>",
"      Vicknox (HK);",
"     </li>",
"     <li>",
"      Ziohex (PH);",
"     </li>",
"     <li>",
"      Zodorm (IL);",
"     </li>",
"     <li>",
"      Zoldem (AT, DE);",
"     </li>",
"     <li>",
"      Zoldox (TW);",
"     </li>",
"     <li>",
"      Zolmia (ID);",
"     </li>",
"     <li>",
"      Zolnox (PY, UY);",
"     </li>",
"     <li>",
"      Zolpibell (AU);",
"     </li>",
"     <li>",
"      Zolpicin (TW);",
"     </li>",
"     <li>",
"      Zolpid (KP);",
"     </li>",
"     <li>",
"      Zolpinox (DE);",
"     </li>",
"     <li>",
"      Zolpitop (BE);",
"     </li>",
"     <li>",
"      Zolsana (BG);",
"     </li>",
"     <li>",
"      Zopidem (TW);",
"     </li>",
"     <li>",
"      Zorimin (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F236122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Zolpidem, an imidazopyridine hypnotic that is structurally dissimilar to benzodiazepines, enhances the activity of the inhibitory neurotransmitter, &gamma;-aminobutyric acid (GABA), via selective agonism at the benzodiazepine-1 (BZ",
"     <sub>",
"      1",
"     </sub>",
"     ) receptor; the result is increased chloride conductance, neuronal hyperpolarization, inhibition of the action potential, and a decrease in neuronal excitability leading to sedative and hypnotic effects. Because of its selectivity for the BZ",
"     <sub>",
"      1",
"     </sub>",
"     receptor site over the BZ",
"     <sub>",
"      2",
"     </sub>",
"     receptor site, zolpidem exhibits minimal anxiolytic, myorelaxant, and anticonvulsant properties (effects largely attributed to agonism at the BZ",
"     <sub>",
"      2",
"     </sub>",
"     receptor site).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F236141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Immediate release: 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Immediate release: 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sublingual tablet: Intermezzo&reg;: C",
"     <sub>",
"      max",
"     </sub>",
"     and AUC is increased by ~45% in females compared to male subjects",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.54 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~93%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic methylation and hydroxylation via CYP3A4 (~60%), CYP2C9 (~22%), CYP1A2 (~14%), CYP2D6 (~3%), and CYP2C19 (~3%) to three inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release, Extended release: ~2.5 hours (range: 1.4-4.5 hours); Cirrhosis: Up to 9.9 hours; Elderly: Prolonged up to 32%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Spray: ~3 hours (range: 1.7-8.4)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sublingual tablet (Edluar&trade;, Intermezzo&reg;): ~3 hours (range: 1.4-6.7 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release: 1.6 hours; 2.2 hours with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release: 1.5 hours; 4 hours with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Spray: ~0.9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sublingual tablet: Edluar&trade;: ~1.4 hours, ~1.8 hours with food; Intermezzo&reg;: 0.6-1.3 hours, ~3 hours with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (48% to 67%, primarily as metabolites); feces (29% to 42%, primarily as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/48/13064/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/48/13064/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Durand A, Th&eacute;not JP, Bianchetti G, et al, &ldquo;Comparative Pharmacokinetic Profile of Two Imidazopyridine Drugs: Zolpidem and Alpidem,&rdquo;",
"      <i>",
"       Drug Metab Rev",
"      </i>",
"      , 1992, 24(2):239-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/48/13064/abstract-text/1576937/pubmed\" id=\"1576937\" target=\"_blank\">",
"        1576937",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holm KJ and Goa KL, &ldquo;Zolpidem: An Update of Its Pharmacology, Therapeutic Efficacy and Tolerability in the Treatment of Insomnia,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2000, 59(4):865-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/48/13064/abstract-text/10804040/pubmed\" id=\"10804040\" target=\"_blank\">",
"        10804040",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lange CL, &ldquo;Medication-Associated Somnambulism,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2005, 44(3):211-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/48/13064/abstract-text/15725964/pubmed\" id=\"15725964\" target=\"_blank\">",
"        15725964",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Langtry HD and Benfield P, &ldquo;Zolpidem: A Review of Its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Potential,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1990, 40(2):291-313.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/48/13064/abstract-text/2226217/pubmed\" id=\"2226217\" target=\"_blank\">",
"        2226217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Salva P and Costa J, &ldquo;Clinical Pharmacokinetics and Pharmacodynamics of Zolpidem. Therapeutic Implications,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1995, 29(3):142-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/48/13064/abstract-text/8521677/pubmed\" id=\"8521677\" target=\"_blank\">",
"        8521677",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sanger DJ, &ldquo;The Pharmacology and Mechanisms of Action of New Generation, Non-Benzodiazepine Hypnotic Agents,&rdquo;",
"      <i>",
"       CNS Drugs",
"      </i>",
"      , 2004, 18 (Suppl 1):9-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/48/13064/abstract-text/15291009/pubmed\" id=\"15291009\" target=\"_blank\">",
"        15291009",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Taylor JR, Vazquez CM, and Campbell KM, &ldquo;Pharmacologic Management of Chronic Insomnia,&rdquo;",
"      <i>",
"       South Med J",
"      </i>",
"      , 2006, 99(12):1373-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/48/13064/abstract-text/17233194/pubmed\" id=\"17233194\" target=\"_blank\">",
"        17233194",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10057 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-41.78.124.10-D68EE5DB58-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_48_13064=[""].join("\n");
var outline_f12_48_13064=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15898498\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236158\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13452765\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236195\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236162\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236163\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236164\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236165\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236134\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13456321\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236119\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236197\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874935\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236139\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236138\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236204\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236193\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236142\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236123\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236189\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236128\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236154\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236129\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615032\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236167\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615035\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236145\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236131\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236146\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236122\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236141\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10057\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10057|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/44/21189?source=related_link\">",
"      Zolpidem: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/38/26215?source=related_link\">",
"      Zolpidem: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_48_13065="Treatment of recurrent and resistant dermatomyositis and polymyositis in adults";
var content_f12_48_13065=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of recurrent and resistant dermatomyositis and polymyositis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/48/13065/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/48/13065/contributors\">",
"     Marc L Miller, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/48/13065/contributors\">",
"     Stacy A Rudnicki, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/48/13065/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/48/13065/contributors\">",
"     Ira N Targoff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/48/13065/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/48/13065/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/48/13065/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/48/13065/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dermatomyositis (DM) and polymyositis (PM) are two classic forms of inflammatory myopathy. Most patients respond to initial therapy, and some achieve sustained disease control either off all therapy or with low-dose maintenance therapy. There are two additional patterns of response:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recurrent disease &mdash; After achieving disease control with treatment, some patients experience disease recurrences (flares) during or after the period of medication tapering.",
"     </li>",
"     <li>",
"      Resistant disease &mdash; In other patients, the disease does not respond entirely to conventional initial approaches to remission induction, and alternative methods must be considered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Approaches to the treatment of recurrent and resistant disease in adults with DM and PM will be reviewed here. The initial therapy of and clinical manifestations of these disorders in adults, the management of the cutaneous manifestations of dermatomyositis, and issues related to DM and PM in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=see_link\">",
"     \"Initial treatment of dermatomyositis and polymyositis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15513?source=see_link\">",
"     \"Initial management of cutaneous dermatomyositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29368?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/24/38281?source=see_link\">",
"     \"Management of refractory cutaneous dermatomyositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/5/2138?source=see_link\">",
"     \"Treatment and prognosis of juvenile dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RECURRENT DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete discontinuation of treatment is unsuccessful in the majority of patients. For patients who experience disease flares after the achievement of disease control, a variety of clinical scenarios may occur. The following discussion, based primarily on the authors' experience, assumes that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    is tapered before attempts to discontinue either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Flare at more than 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      &mdash; Disease flares at such doses of prednisone require one of two actions:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Addition of a glucocorticoid-sparing drug if neither",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      nor",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      has been used",
"     </li>",
"     <li>",
"      Treatment of the flare as a case of resistant disease if the patient is already taking either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Resistant disease'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With either action, a higher dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , generally in the range of 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, will be required to reestablish disease control.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Flare at 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or less &mdash; If a disease flare occurs at a prednisone dose of 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      or less, there are two options that are not mutually exclusive:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Increase in",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      to the lowest dose required to reestablish disease control. This dose is based upon the severity of the patient's clinical findings. If the disease flare is detected early, the dose required may be significantly lower than 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day. The usual minimum dose is 20",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"     <li>",
"      Increase in",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      to a higher dose, if the dose of the patient's glucocorticoid-sparing drug has not already been maximized",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once disease control is restored, we suggest slower tapering than that which was used during the initial course. Some patients are maintained on low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (eg, 5",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for one year or more.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Flare off",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      but on a glucocorticoid-sparing drug &mdash; There are two options in such patients that are not mutually exclusive:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      is reinstituted at the lowest dose required to reestablish disease control. The dose selected is based upon the severity of the patient's clinical findings and may be significantly lower than 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      if the disease flare is detected early. The usual minimum dose is 20",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"     <li>",
"      The glucocorticoid-sparing drug can be changed from",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      or vice versa.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the patient has been treated previously with both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , the flare should be regarded as a manifestation of resistant disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Flare off all immunosuppressive medications &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      should be reinstituted with the daily dose varying with the severity of the relapse. The minimum starting dose of prednisone is 20",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      In addition, a glucocorticoid-sparing drug should be resumed or started.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RESISTANT DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple options exist for treating patients who do not respond adequately to glucocorticoids plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . Evidence of clinically significant benefit is greatest with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    and intravenous immune globulin (IVIG). We suggest using rituximab first in this setting and then trying IVIG if rituximab fails.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    targets CD20-positive cells (ie, B-cell precursors), leading in most patients to the depletion of B cells in the serum within several weeks of administration. It is a promising agent for the treatment of both DM and PM. A variety of dosing regimens have been employed in the limited number of patients reported in several small case series or case reports in both DM and PM [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13065/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. In rheumatic disease, the trend with the use of rituximab is to employ two 1 gram doses one week apart.",
"   </p>",
"   <p>",
"    Some data indicate that patients who suffer disease flares can be retreated effectively with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , but a larger clinical experience with this agent is required before definitive conclusions can be drawn. Controlled trials involving larger numbers of patients will be required before the full impact of this treatment can be accurately assessed.",
"   </p>",
"   <p>",
"    Observations with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thirteen patients with refractory inflammatory myopathies were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (1 gram every other week for two treatments) and were followed for a mean of 27 months [",
"      <a class=\"abstract\" href=\"UTD.htm?12/48/13065/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      CK fell significantly.",
"     </li>",
"     <li>",
"      Strength as measured by handheld dynamometry improved by 21.5 percent at 24 months.",
"     </li>",
"     <li>",
"      There was an insignificant increase in manual muscle strength testing at 24 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Six patients with DM were treated with 375",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      once weekly times four doses [",
"      <a class=\"abstract\" href=\"UTD.htm?12/48/13065/abstract/1\">",
"       1",
"      </a>",
"      ]. The principal results were:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      All six patients showed major clinical improvement, with the gain over baseline strength ranging from 36 to 113 percent.",
"     </li>",
"     <li>",
"      Improvement in muscle strength was evident as early as four weeks after the initial",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      infusion. Maximal improvement was evident as early as 36 weeks after treatment.",
"     </li>",
"     <li>",
"      Extramuscular signs of disease, including rash, alopecia, and reductions in forced vital capacity, improved within 12 weeks.",
"     </li>",
"     <li>",
"      Two of the three patients with reductions in forced vital capacity (FVC) had antisynthetase antibodies (specifically anti-Jo-1). Although the antibody status of these patients did not change during therapy, lung function improved in both cases.",
"     </li>",
"     <li>",
"      Four patients suffered disease flares within the one-year follow-up period after their B cell levels returned to normal. These disease flares occurred between 24 and 36 weeks after treatment.",
"     </li>",
"     <li>",
"      One patient did not flare during 52 weeks of follow-up, despite the return of normal B cell numbers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A case report described the response to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      treatment (1 g each week times two) in a patient with the antisynthetase syndrome and antibodies directed against both anti-Jo-1 and anti-Ro [",
"      <a class=\"abstract\" href=\"UTD.htm?12/48/13065/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"       \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The primary findings at six months were:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The daily",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      dose had been decreased from 30",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      to 7.5",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"     <li>",
"      The serum CK had normalized, from a value above 8000",
"      <span class=\"nowrap\">",
"       units/L",
"      </span>",
"      at the initiation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      therapy.",
"     </li>",
"     <li>",
"      Muscle inflammation manifested as edema on magnetic resonance imaging had resolved completely.",
"     </li>",
"     <li>",
"      Interstitial inflammatory infiltrates in the lungs, evident on computed tomography scan of the chest, had disappeared.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In this patient, the anti-Jo-1 and -Ro antibodies remained high during the clinical response, a finding that has been noted in other responders [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13065/abstract/4\">",
"     4",
"    </a>",
"    ]. Disease flare at eight months correlated with return of the patient's B cells. A second course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    restored disease remission.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In another report of treatment-resistant disease, two patients with PM and one with DM received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      1 g on days 0 and 14 [",
"      <a class=\"abstract\" href=\"UTD.htm?12/48/13065/abstract/3\">",
"       3",
"      </a>",
"      ]. The major results were:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      All three patients achieved disease remissions and had reductions in serum CK that began within one month.",
"     </li>",
"     <li>",
"      Maximal improvement in the three patients occurred at 5 to 10 months.",
"     </li>",
"     <li>",
"      Two patients experienced disease flares. In the DM patient, a disease flare occurred despite the absence of B cells only two weeks before the CK increase.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The apparent success of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in the two PM patients in this series suggests that B cells may be more important in the pathophysiology of PM than previously recognized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Intravenous immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;For DM, intravenous immune globulin (IVIG) is a reasonable second-line therapy for patients with refractory disease. The 2012 American Academy of Neurology guidelines support the use of IVIG for refractory DM but found evidence insufficient to support or refute its use in PM [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13065/abstract/6\">",
"     6",
"    </a>",
"    ]. The expense of this treatment is an important consideration in its long-term use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=see_link\">",
"     \"General principles in the use of immune globulin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two studies, one in DM and one in PM, have provided evidence that IVIG is an effective short-term therapy for resistant myositis. The mechanism of action is not known.",
"   </p>",
"   <p>",
"    The efficacy of IVIG was illustrated in a double-blind, placebo-controlled trial of 15 patients with DM who had resistant disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13065/abstract/7\">",
"     7",
"    </a>",
"    ]. The patients were continued on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (mean dose 25",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and were then randomly assigned to a monthly infusion of either IVIG (2",
"    <span class=\"nowrap\">",
"     g/kg)",
"    </span>",
"    or placebo for three months. Crossover to the other treatment arm was permitted for treatment failures.",
"   </p>",
"   <p>",
"    The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The eight patients assigned to IVIG all had significant improvement in scores of muscle strength and neuromuscular symptoms; the seven patients assigned to placebo had no benefit.",
"     </li>",
"     <li>",
"      Including patients crossed over to the other treatment arm, 12 patients received IVIG. Nine had major improvement in their symptoms, two had mild improvement, and one had no change.",
"     </li>",
"     <li>",
"      Including patients crossed over to the other treatment arm, 11 patients received placebo. Three had mild improvement, three had no change, and five deteriorated.",
"     </li>",
"     <li>",
"      Among responders, improvement became noticeable about 15 days after the first IVIG infusion. Maximal improvement generally occurred between the second and third infusions. The time course of improvement in skin manifestations and serum muscle enzyme elevation mirrored improvement in clinical muscle strength.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An open study of IVIG included 35 patients with PM, all of whom had disease that required ongoing glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13065/abstract/8\">",
"     8",
"    </a>",
"    ]. None could be weaned from glucocorticoids despite trials of one or more additional therapies, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    , plasmapheresis, lymphapheresis, and total body irradiation.",
"   </p>",
"   <p>",
"    Each patient was treated with IVIG (1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day for two days per month for four to six months). No changes had been made in the treatment regimen in the two months before IVIG, and existing therapies were not increased during IVIG.",
"   </p>",
"   <p>",
"    The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All 33 patients with initially elevated serum CK levels showed biochemical improvement, but not all patients with decreases in serum CK levels had improvements in muscle strength.",
"     </li>",
"     <li>",
"      Improvement in muscle strength occurred in 25 of 35 patients and returned to near-normal in 10 of the 25 responders.",
"     </li>",
"     <li>",
"      Among the 11 patients with esophageal dysfunction, dysphagia resolved completely during therapy in eight patients and improved significantly in another.",
"     </li>",
"     <li>",
"      After the initial course of IVIG, 12 of the 25 responders had complete clinical responses (absence of myositis activity) while receiving not more than 6",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      . The mean follow-up period for these patients was 39 months. Five patients discontinued all other medical treatments for myositis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Six of the 25 IVIG responders remained dependent on IVIG infusions but did not require additional medication. After six infusions, the dose of IVIG was reduced to 1",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      each month.",
"     </li>",
"     <li>",
"      Seven of the 25 responders relapsed at an average time interval of 17 months after discontinuation of IVIG. Four of these patients responded to repeat IVIG treatment; three were prescribed other therapies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Summary: Rituximab versus IVIG",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reasons for favoring",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    over IVIG, the only treatment tested in a randomized trial, are the following:",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       Rituximab",
"      </a>",
"      appears to be effective in connective tissue disorders resembling DM and PM, such as systemic lupus erythematosus and rheumatoid arthritis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21130?source=see_link\">",
"       \"Rituximab and other B cell targeted therapies for rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If effective,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      may be more likely to lead to a prolonged period of disease control. Many patients who respond to IVIG require continued treatments on a monthly basis.",
"     </li>",
"     <li>",
"      Although expensive,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      is cheaper than IVIG. However, given the absence of a controlled trial, insurance companies may balk at covering rituximab for PM and DM.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Calcineurin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The calcineurin inhibitors, which include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , achieve their effects by interfering with T cell function. Data on the use of calcineurin inhibitors in DM and PM are limited to retrospective case series and anecdotal reports.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efficacy for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    has been suggested for both primary therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13065/abstract/9,10\">",
"     9,10",
"    </a>",
"    ] and resistant disease, including interstitial lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13065/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24697?source=see_link\">",
"     \"Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one report, six patients previously resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    IVIG underwent treatment with a mean daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    dose of 3.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13065/abstract/11\">",
"     11",
"    </a>",
"    ]. Over the median six month course of treatment with cyclosporine, the mean daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    dose was reduced by 75 percent. All six patients demonstrated improved strength in the shoulder girdle; four had stronger hip flexor muscles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Tacrolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    has been used in a limited number of patients with inflammatory myopathy. The optimal dose for this indication is not certain.",
"   </p>",
"   <p>",
"    It has been suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    may be particularly effective in cases of inflammatory myopathy complicated by interstitial lung disease. In one report, tacrolimus (0.075",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in two divided doses) was effective in a series of eight patients with refractory PM [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13065/abstract/13\">",
"     13",
"    </a>",
"    ]. Strength normalized in five of eight anti-Jo-1 antibody-positive patients and improved in the two anti-SRP positive patients. The mean CK declined from 3114 to 87 international",
"    <span class=\"nowrap\">",
"     units/mL.",
"    </span>",
"    Three of five patients with interstitial lung disease also showed improvement in pulmonary function.",
"   </p>",
"   <p>",
"    In a second series from the same authors with minor overlap, 13 patients with the antisynthetase syndrome and interstitial lung disease were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    for a mean duration of 51 months [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13065/abstract/14\">",
"     14",
"    </a>",
"    ]. Twelve of the patients had antibodies to Jo-1 and one had antibodies to PL-12. The following benefits were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum CK levels improved by 75 percent.",
"     </li>",
"     <li>",
"      Manual testing of muscle strength improved or remained stable in 10 of 13 patients.",
"     </li>",
"     <li>",
"      The mean",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      dose was tapered by 67 percent.",
"     </li>",
"     <li>",
"      There were substantial improvements in forced vital capacity (FVC), forced expiratory volume in one second (FEV1), and the diffusing capacity for carbon monoxide (DLCO).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In other small series of patients with interstitial lung disease,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    appeared to be beneficial in patients who were not controlled with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13065/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Summary of calcineurin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In summary,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    appear to have some role in the treatment of resistant DM and PM. The limited evidence available presently suggests that tacrolimus offers some advantage over cyclosporine in efficacy, but larger studies are required before definitive conclusions are possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24697?source=see_link\">",
"     \"Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data related to the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    and IVIG in interstitial lung disease are extremely limited. Some data suggest that calcineurin inhibitors are particularly effective in the treatment of the interstitial lung disease complication of DM or PM. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Cyclosporine'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H9\">",
"     'Tacrolimus'",
"    </a>",
"    above.) For interstitial lung disease that is refractory to glucocorticoids plus either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , we use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    as the next agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil has been used with some success in retrospective series of patients with inflammatory myopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13065/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. These case series suggest a role for mycophenolate mofetil in the treatment of resistant myositis. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective series included 10 DM patients with a history of refractory disease [",
"      <a class=\"abstract\" href=\"UTD.htm?12/48/13065/abstract/18\">",
"       18",
"      </a>",
"      ]. After initiation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil, manual muscle testing scores improved in five, and the glucocorticoid dose could be tapered in six. Serious opportunistic infections occurred in 3 of the 10 patients: a Mycobacterium xenopi abscess of the thigh; pulmonary blastomycosis; and Legionella pneumonia (fatal). However, it is likely that the patients' immunosuppressive regimens prior to the use of mycophenolate mofetil contributed to the development of opportunistic infections.",
"     </li>",
"     <li>",
"      In a second report, six patients with treatment-resistant myositis (two with DM, three with PM, one with overlap myositis) were treated for a mean of 22 months with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil (mean dose 1.6",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?12/48/13065/abstract/19\">",
"       19",
"      </a>",
"      ]. Both muscle strength and serum CK levels improved in all patients, and the mean",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      dose was tapered from 13.7 to 8.5",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinicians prescribing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil for inflammatory myopathy must be alert to the possibility of opportunistic infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    (which is infrequently used because of greater toxicity than cyclophosphamide) may be effective in treating myositis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13065/abstract/21,22\">",
"     21,22",
"    </a>",
"    ], but their utility is limited by their potential for toxicity, particularly the induction of malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One study evaluated the use of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) for progressive interstitial lung disease in 17 patients with DM or PM [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13065/abstract/23\">",
"     23",
"    </a>",
"    ]. The patients were treated with intravenous cyclophosphamide at doses ranging from 300 to 800",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every four weeks. All patients received at least six courses.",
"   </p>",
"   <p>",
"    The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eleven of the 17 patients showed improvement in their dyspnea.",
"     </li>",
"     <li>",
"      Six of the seven patients who required supplemental oxygen were able to discontinue supplemental oxygen use.",
"     </li>",
"     <li>",
"      Twelve of the patients had improvements in FVC of at least 10 percent. For the group overall, the mean FVC improved by 15 percent over baseline, from 68 to 83 percent predicted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the absence of aggressive interstitial lung disease or systemic vasculitis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    should be considered only in patients who fail to respond to multiple other second-line agents.",
"   </p>",
"   <p>",
"    Given the efficacy of alkylating agents in the treatment of vasculitides,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    may also be useful in patients with inflammatory myopathy who develop the complication of systemic vasculitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Tumor necrosis factor inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data related to the efficacy of tumor necrosis factor inhibition in DM and PM are mixed. Only small studies of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    have been reported, and further studies will be required to further define their role. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       Etanercept",
"      </a>",
"      (50 mg once weekly) showed benefit compared with placebo in a randomized, 52-week, pilot trial involving 16 patients with active DM [",
"      <a class=\"abstract\" href=\"UTD.htm?12/48/13065/abstract/24\">",
"       24",
"      </a>",
"      ]. The efficacy of etanercept, compared with placebo, was demonstrated using a standardized schedule for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      tapering; etanercept treatment resulted in a significantly lower median average prednisone dose after week 24 (1.2 versus 29.2",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      and significantly longer time to treatment failure (358 versus 148 days). Adverse event rates were similar.",
"     </li>",
"     <li>",
"      In a report of five patients with DM treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      (25 mg twice weekly), all five had disease exacerbations with increased muscle weakness, elevations in muscle enzymes, and failure of the cutaneous manifestations to improve [",
"      <a class=\"abstract\" href=\"UTD.htm?12/48/13065/abstract/25\">",
"       25",
"      </a>",
"      ]. All patients improved following treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Initial anecdotal reports suggested benefit from",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?12/48/13065/abstract/26-28\">",
"       26-28",
"      </a>",
"      ]. However, in the largest such series, even the responders to infliximab (six of eight patients) had only partial improvement in muscle enzyme elevations [",
"      <a class=\"abstract\" href=\"UTD.htm?12/48/13065/abstract/29\">",
"       29",
"      </a>",
"      ]. Furthermore, in a follow-up report of two patients in whom infliximab had appeared effective, subsequent courses to treat disease exacerbations were associated with anaphylaxis in one patient and the development of anti-dsDNA antibodies in the other [",
"      <a class=\"abstract\" href=\"UTD.htm?12/48/13065/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination therapy may be effective among those with resistant disease. One crossover study randomly assigned 30 patients with refractory myositis to a combination of weekly oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or to intravenous methotrexate with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    rescue every two weeks for six months [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13065/abstract/31\">",
"     31",
"    </a>",
"    ]. Twenty-five of the patients had had inadequate responses to previous cytotoxic therapies.",
"   </p>",
"   <p>",
"    The results were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the 15 patients initially assigned to oral",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"        methotrexate",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"        azathioprine",
"       </a>",
"       ,",
"      </span>",
"      eight improved with oral therapy, and one improved with intravenous methotrexate during the crossover period.",
"     </li>",
"     <li>",
"      Of the 15 patients initially assigned to intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      therapy, three improved with intravenous therapy and four with oral combination therapy during the crossover period.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This study did not have sufficient power to compare the two treatment regimens. However, the data indicate that either the combination of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or high dose intravenous methotrexate with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    rescue may benefit some patients with refractory disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Refractory rash",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some cases of DM, the cutaneous manifestations are more refractory to treatment than the muscle disease. A variety of approaches to the problem of refractory cutaneous DM have been taken. The management of the cutaneous manifestations of dermatomyositis, including initial management and the treatment of manifestations that are resistant to initial therapy, is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15513?source=see_link\">",
"     \"Initial management of cutaneous dermatomyositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/24/38281?source=see_link\">",
"     \"Management of refractory cutaneous dermatomyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/63/5106?source=see_link\">",
"       \"Patient information: Dermatomyositis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/47/30450?source=see_link\">",
"       \"Patient information: Polymyositis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    Many patients with dermatomyositis (DM) or polymyositis (PM) require intermittent or even continuous therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recurrent disease is defined as the occurrence of a disease flare following the achievement of disease control with treatment.",
"     </li>",
"     <li>",
"      Resistant disease does not respond sufficiently to the conventional approaches of glucocorticoids plus either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      . In such cases, alternative approaches to remission induction must be considered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Recurrent disease",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who experience disease flares after the achievement of disease control, there are four specific scenarios.",
"     </li>",
"     <li>",
"      For disease flares at more than 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      , we suggest the addition of either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (if not already used) or treatment of the patient as a case of resistant disease (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Resistant disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For disease flares at 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or less, we suggest increasing the prednisone to the lowest dose required to reestablish disease control",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      increasing the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      dose, if this has not been maximized already (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For disease flares off",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      but on a glucocorticoid-sparing drug, we suggest reinstituting prednisone at the lowest dose required to reestablish disease control",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      changing the glucocorticoid-sparing medication from",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      or vice versa (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      If the patient has already failed both azathioprine and methotrexate, treatment as a case of resistant disease is appropriate. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Resistant disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For flare off all immunosuppressive medication, we suggest reinstituting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      with an initial daily dose that varies according to relapse severity (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The minimum starting dose of prednisone is 20",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      In addition, a glucocorticoid-sparing drug should be resumed or started.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Resistant disease",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple options exist for treating patients who do not respond adequately to glucocorticoids plus either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      . Options for the treatment of resistant disease, each of which is described above, include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       Rituximab",
"      </a>",
"     </li>",
"     <li>",
"      Intravenous immune globulin (IVIG)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       Tacrolimus",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       Mycophenolate",
"      </a>",
"      mofetil",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       Cyclophosphamide",
"      </a>",
"     </li>",
"     <li>",
"      Tumor necrosis factor inhibitors",
"     </li>",
"     <li>",
"      Combination therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With the exception of IVIG for PM, none of these therapeutic options has been subjected to a randomized clinical trial in the treatment of DM or PM. Therefore, there is no single or definitive approach for managing refractory disease.",
"     </li>",
"     <li>",
"      Although the clinical data supporting its use are sparse, we suggest using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (1 g each week times two doses) in the treatment of resistant disease (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Rituximab'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      is not effective, we suggest IVIG as the second-line agent for the treatment of resistant DM (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Intravenous immune globulin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Data related to the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      and IVIG in interstitial lung disease are extremely limited. Some data suggest that calcineurin inhibitors are particularly effective in the treatment of the interstitial lung disease complication of DM or PM. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Cyclosporine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Tacrolimus'",
"      </a>",
"      above.) For interstitial lung disease that is refractory to glucocorticoids plus either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      (0.2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in divided doses) as the next agent (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In patients with inflammatory myopathy,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil (1 to 1.5 g twice daily) is a reasonable alternative if",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      and IVIG have failed. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Mycophenolate mofetil'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of their substantial side effect profiles, we suggest reserving alkylating agents (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      ) for patients whose disease has proven resistant to multiple other treatment options (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Cyclophosphamide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Combination therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      (up to 200",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (up to 25",
"      <span class=\"nowrap\">",
"       mg/week)",
"      </span>",
"      hold some potential for efficacy in patients with resistant disease. However, the risk of treatment-related morbidity when using both of these medications together mandates the utmost care in monitoring patients for cytopenias and other adverse effects. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Combination therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest not using tumor necrosis factor inhibitors in DM or PM, unless all other treatment options have failed (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Tumor necrosis factor inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Refractory rash",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In some cases of DM, the cutaneous findings are more refractory to treatment than is the muscle disease, and additional management approaches are required. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Refractory rash'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15513?source=see_link\">",
"       \"Initial management of cutaneous dermatomyositis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/24/38281?source=see_link\">",
"       \"Management of refractory cutaneous dermatomyositis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13065/abstract/1\">",
"      Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005; 52:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13065/abstract/2\">",
"      Brulhart L, Waldburger JM, Gabay C. Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis 2006; 65:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13065/abstract/3\">",
"      Noss EH, Hausner-Sypek DL, Weinblatt ME. Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 2006; 33:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13065/abstract/4\">",
"      Lambotte O, Kotb R, Maigne G, et al. Efficacy of rituximab in refractory polymyositis. J Rheumatol 2005; 32:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13065/abstract/5\">",
"      Mahler EA, Blom M, Voermans NC, et al. Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology (Oxford) 2011; 50:2206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13065/abstract/6\">",
"      Patwa HS, Chaudhry V, Katzberg H, et al. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2012; 78:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13065/abstract/7\">",
"      Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13065/abstract/8\">",
"      Cherin P, Pelletier S, Teixeira A, et al. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 2002; 46:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13065/abstract/9\">",
"      Grau JM, Herrero C, Casademont J, et al. Cyclosporine A as first choice therapy for dermatomyositis. J Rheumatol 1994; 21:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13065/abstract/10\">",
"      Vencovsk&yacute; J, Jarosov&aacute; K, Mach&aacute;cek S, et al. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 2000; 29:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13065/abstract/11\">",
"      Qushmaq KA, Chalmers A, Esdaile JM. Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review. J Rheumatol 2000; 27:2855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13065/abstract/12\">",
"      Maeda K, Kimura R, Komuta K, Igarashi T. Cyclosporine treatment for polymyositis/dermatomyositis: is it possible to rescue the deteriorating cases with interstitial pneumonitis? Scand J Rheumatol 1997; 26:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13065/abstract/13\">",
"      Oddis CV, Sciurba FC, Elmagd KA, Starzl TE. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 1999; 353:1762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13065/abstract/14\">",
"      Wilkes MR, Sereika SM, Fertig N, et al. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 2005; 52:2439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13065/abstract/15\">",
"      Takada K, Nagasaka K, Miyasaka N. Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity 2005; 38:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13065/abstract/16\">",
"      Ochi S, Nanki T, Takada K, et al. Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis. Clin Exp Rheumatol 2005; 23:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13065/abstract/17\">",
"      Schneider C, Gold R, Sch&auml;fers M, Toyka KV. Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome. Muscle Nerve 2002; 25:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13065/abstract/18\">",
"      Rowin J, Amato AA, Deisher N, et al. Mycophenolate mofetil in dermatomyositis: is it safe? Neurology 2006; 66:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13065/abstract/19\">",
"      Pisoni CN, Cuadrado MJ, Khamashta MA, et al. Mycophenolate mofetil treatment in resistant myositis. Rheumatology (Oxford) 2007; 46:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13065/abstract/20\">",
"      Majithia V, Harisdangkul V. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford) 2005; 44:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13065/abstract/21\">",
"      Bombardieri S, Hughes GR, Neri R, et al. Cyclophosphamide in severe polymyositis. Lancet 1989; 1:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13065/abstract/22\">",
"      Sinoway PA, Callen JP. Chlorambucil. An effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis. Arthritis Rheum 1993; 36:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13065/abstract/23\">",
"      Yamasaki Y, Yamada H, Yamasaki M, et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford) 2007; 46:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13065/abstract/24\">",
"      Muscle Study Group. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol 2011; 70:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13065/abstract/25\">",
"      Iannone F, Scioscia C, Falappone PC, et al. Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol 2006; 33:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13065/abstract/26\">",
"      Hengstman GJ, van den Hoogen FH, Barrera P, et al. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur Neurol 2003; 50:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13065/abstract/27\">",
"      Selva-O'Callaghan A, Mart&iacute;nez-Costa X, Solans-Laque R, et al. Refractory adult dermatomyositis with pneumatosis cystoides intestinalis treated with infliximab. Rheumatology (Oxford) 2004; 43:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13065/abstract/28\">",
"      Anandacoomarasamy A, Howe G, Manolios N. Advanced refractory polymyositis responding to infliximab. Rheumatology (Oxford) 2005; 44:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13065/abstract/29\">",
"      Efthimiou P, Schwartzman S, Kagen LJ. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis 2006; 65:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13065/abstract/30\">",
"      Hengstman GJ, van den Hoogen FH, van Engelen BG. Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up. Eur Neurol 2004; 52:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13065/abstract/31\">",
"      Villalba L, Hicks JE, Adams EM, et al. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 1998; 41:392.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5133 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-210.101.131.232-8FC26C7E2B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_48_13065=[""].join("\n");
var outline_f12_48_13065=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RECURRENT DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RESISTANT DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Intravenous immune globulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Summary: Rituximab versus IVIG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Calcineurin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Summary of calcineurin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Tumor necrosis factor inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Refractory rash",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Recurrent disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Resistant disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Refractory rash",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=related_link\">",
"      Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=related_link\">",
"      General principles in the use of immune globulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=related_link\">",
"      Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15513?source=related_link\">",
"      Initial management of cutaneous dermatomyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=related_link\">",
"      Initial treatment of dermatomyositis and polymyositis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24697?source=related_link\">",
"      Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/24/38281?source=related_link\">",
"      Management of refractory cutaneous dermatomyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29368?source=related_link\">",
"      Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/63/5106?source=related_link\">",
"      Patient information: Dermatomyositis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/47/30450?source=related_link\">",
"      Patient information: Polymyositis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21130?source=related_link\">",
"      Rituximab and other B cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/5/2138?source=related_link\">",
"      Treatment and prognosis of juvenile dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_48_13066="Overview of selective COX-2 inhibitors";
var content_f12_48_13066=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of selective COX-2 inhibitors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/48/13066/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/48/13066/contributors\">",
"     Daniel H Solomon, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/48/13066/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/48/13066/contributors\">",
"     Daniel E Furst, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/48/13066/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/48/13066/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/48/13066/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary effect of the nonsteroidal antiinflammatory drugs (NSAIDs) is to inhibit cyclooxygenase (COX or prostaglandin synthase [PGHS]), thereby impairing the ultimate transformation of arachidonic acid to prostaglandins, prostacyclin, and thromboxanes (",
"    <a class=\"graphic graphic_figure graphicRef66146 \" href=\"UTD.htm?33/29/34269\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/1\">",
"     1",
"    </a>",
"    ]. The extent of enzyme inhibition varies among the different NSAIDs, although there are no studies relating the degree of cyclooxygenase inhibition with antiinflammatory efficacy in individual patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1336?source=see_link\">",
"     \"NSAIDs: Mechanism of action\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two related isoforms of the COX enzyme have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]: COX-1 (PGHS-1) and COX-2 (PGHS-2). They possess 60 percent homology in those amino acid sequences apparently conserved for catalysis of arachidonic acid [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]. The most important differences between the two isoforms are the regulation and expression of the enzymes in various tissues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      COX-1 is expressed in most tissues, but variably. It is described as a \"housekeeping\" enzyme, regulating normal cellular processes (such as gastric cytoprotection, vascular homeostasis, platelet aggregation, and kidney function), and it is stimulated by hormones or growth factors.",
"     </li>",
"     <li>",
"      COX-2 is constitutively expressed in the brain, in the kidney, in bone, and probably in the female reproductive system [",
"      <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/11\">",
"       11",
"      </a>",
"      ]. Its expression at other sites is increased during states of inflammation or, experimentally, in response to mitogenic stimuli. As an example, growth factors, phorbol esters, and interleukin-1 stimulate the expression of COX-2 in fibroblasts, while endotoxin serves the same function in",
"      <span class=\"nowrap\">",
"       monocytes/macrophages",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/5,12\">",
"       5,12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Both COX isoforms are regulated by physiologic stimuli, including shear stress in the vasculature [",
"      <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/13\">",
"       13",
"      </a>",
"      ] and ovulation and implantation in the female reproductive tract of rodents [",
"      <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/14\">",
"       14",
"      </a>",
"      ]. In the human kidney, in non-physiologic states, such as diabetic nephropathy, hypertension, bone fracture, and heart failure, increased expression of COX-2 mRNA and protein has been noted [",
"      <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/15\">",
"       15",
"      </a>",
"      ]. The clinical relevance of this is not yet clear.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, differences in the extent with which a particular NSAID inhibits an isoform of cyclooxygenase may affect both its activity and toxicity. It has been proposed that the perfect NSAID would inhibit the inducible COX-2 isoform (thereby decreasing inflammation) without having any effect on the constitutive COX-1 isoform (thereby minimizing toxicity). Such an agent would maximize effectiveness without inducing toxicity, particularly gastroduodenal erosions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=see_link\">",
"     \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most traditional NSAIDs are nonselective inhibitors of both COX-1 and COX-2. Selective COX-2 inhibitors,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    (Celebrex&reg;), rofecoxib (Vioxx&reg;), and valdecoxib (Bextra&reg;), received approval from the Food and Drug Administration (FDA) in the United States. All three were approved for use in rheumatoid arthritis and osteoarthritis while rofecoxib and celecoxib were also approved for use in acute pain. Rofecoxib was withdrawn worldwide by the manufacturer due to an increased risk of adverse cardiovascular events seen in a placebo controlled trial. Valdecoxib was also withdrawn from the US and European Union markets in April 2005. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=see_link\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other selective COX-2 inhibitors that are being actively investigated include etoricoxib and lumiracoxib. Parecoxib, a water soluble prodrug that is metabolized to valdecoxib [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/16,17\">",
"     16,17",
"    </a>",
"    ], seems unlikely to be commercially developed following the withdrawal of valdecoxib.",
"   </p>",
"   <p>",
"    The selective COX-2 inhibitors demonstrate at least a 200- to 300-fold selectivity for inhibition of COX-2 over COX-1 at the defined therapeutic doses (",
"    <a class=\"graphic graphic_figure graphicRef82145 \" href=\"UTD.htm?5/51/5950\">",
"     figure 2",
"    </a>",
"    ). They provide comparable analgesia to the nonspecific NSAIDs among patients with rheumatoid arthritis and osteoarthritis and several benefits, particularly a reduction in gastroduodenal toxicity (since COX-1 is involved in gastric cytoprotection). However, the one remaining agent in this class,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    , never received approval from the FDA to be marketed as safer on the gastrointestinal system. Selective COX-2 inhibitors have not been approved for use in children.",
"   </p>",
"   <p>",
"    An overview of selective COX-2 inhibitors will be presented here. Detailed discussions of their use in selected diseases are discussed separately. (See appropriate topics).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BENEFITS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal benefit with the selective COX-2 inhibitors is the production of comparable analgesia and antiinflammatory effects to the nonselective NSAIDs, but with fewer symptomatic gastric and duodenal ulcers and a decrease in gastrointestinal symptoms. An additional possible benefit is protection against the development of colon cancer; this has yet to be clearly shown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Analgesia and antiinflammatory activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     Celecoxib",
"    </a>",
"    was approved based upon the results of five clinical trials (some of which have been published only in preliminary form) involving more than 5200 patients with osteoarthritis or rheumatoid arthritis in which its efficacy and toxicity were compared with nonselective NSAIDs and placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. One of the published studies included a total of 688 patients with rheumatoid arthritis who completed a controlled trial comparing various doses of celecoxib with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    or placebo for 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/18\">",
"     18",
"    </a>",
"    ]. All doses of celecoxib and naproxen improved signs and symptoms of arthritis compared with placebo. Similar results were found in a second study of 655 patients with rheumatoid arthritis, which compared the efficacy and gastrointestinal toxicity of celecoxib versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     Celecoxib",
"    </a>",
"    is also as efficacious as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/36/43592?source=see_link\">",
"     ketoprofen",
"    </a>",
"    in ankylosing spondylitis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35194?source=see_link\">",
"     \"Assessment and treatment of ankylosing spondylitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rofecoxib had equivalent efficacy in patients with osteoarthritis to that of nonselective NSAIDs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/23-25\">",
"     23-25",
"    </a>",
"    ], and to that of the selective COX-2 inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/26\">",
"     26",
"    </a>",
"    ]. Rofecoxib (12.5 mg daily) was both more efficacious and had a more rapid onset of action than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/18/39208?source=see_link\">",
"     nabumetone",
"    </a>",
"    (500 mg twice daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/27\">",
"     27",
"    </a>",
"    ]. Its efficacy was similar to that of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    for the treatment of rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/28\">",
"     28",
"    </a>",
"    ]. However, as noted above, rofecoxib was withdrawn worldwide by the manufacturer due to increased risk of adverse cardiovascular events.",
"   </p>",
"   <p>",
"    Valdecoxib had approximately the same efficacy in treating patients with rheumatoid arthritis as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    ; ACR-20 response rates of about 50 percent were noted for both agents from week 2 through week 12 compared with 30 to 36 percent for placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/29\">",
"     29",
"    </a>",
"    ]. Valdecoxib doses of 10, 20, and 40 mg per day were equally efficacious. Likewise, valdecoxib appears to be equivalent in efficacy to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    as assessed in a study of 722 patients with RA who were randomly assigned to valdecoxib (either 20 or 40",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or diclofenac (75 mg BID) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/30\">",
"     30",
"    </a>",
"    ]. However, like rofecoxib, valdecoxib has been removed from the market due to an apparent increase in the risk of cardiovascular events and of allergic reactions associated with its use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=see_link\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lumiracoxib is a highly selective COX-2 inhibitor that is efficacious at doses of 100 mg to 400 mg daily for osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. It does not contain a sulfonamide or sulfone moiety. It is approved for use in the UK.",
"   </p>",
"   <p>",
"    Etoricoxib is another highly selective COX-2 inhibitor. In a randomized trial that compared etoricoxib (30 mg daily) with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    (800 mg three times daily) and with placebo in 528 patients with osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/33\">",
"     33",
"    </a>",
"    ], a beneficial effect of treatment was apparent by two weeks of treatment. Etoricoxib was significantly more effective than placebo and similar to ibuprofen in the amount of pain relief and improvement in patient global assessment. Drug related adverse events were significantly more frequent in those receiving ibuprofen when compared with the placebo group, but there was no significant difference between the ibuprofen and etoricoxib groups. Larger long-term studies are underway to address the cardiovascular safety of etoricoxib.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Reduction in gastroduodenal toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many clinical trials have confirmed the efficacy and relative reduction in gastroduodenal toxicity of all of the selective COX-2 inhibitors when compared with nonselective NSAIDs. Detailed information regarding these trials is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10375?source=see_link\">",
"     \"COX-2 inhibitors and gastroduodenal toxicity &mdash; major clinical trials\"",
"    </a>",
"    .) The range of findings can be briefly summarized by the following observations, which address the relative frequency of ulceration detected by surveillance endoscopy and of adverse clinical gastrointestinal events:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Representative of the results from surveillance endoscopy is a trial in which 688 patients with rheumatoid arthritis were randomly assigned to various doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"       celecoxib",
"      </a>",
"      , to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      , or to placebo for 12 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/18\">",
"       18",
"      </a>",
"      ]. All doses of celecoxib and naproxen improved signs and symptoms of arthritis compared with placebo. The incidence of endoscopically determined gastroduodenal ulcers among patients taking celecoxib was similar to that of those taking placebo (approximately 4 percent) and was significantly lower than that of those taking naproxen (26 percent) (",
"      <a class=\"graphic graphic_figure graphicRef58850 \" href=\"UTD.htm?34/42/35501\">",
"       figure 3",
"      </a>",
"      ). However, it is not clear that endoscopic results are a surrogate for an endpoint that includes ulcer complications. In that this debate continues, there was a need to develop longer term GI outcome trials to define the effects of the COX-2 selective inhibitors in terms of ulcers and their complications of bleeding, perforation, obstruction, and death.",
"     </li>",
"     <li>",
"      Ulcer symptoms and complications were the focus of a prospective trial (CLASS study) involving 8059 patients that found",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"       celecoxib",
"      </a>",
"      to be significantly associated with a reduced incidence of a combined outcome (symptomatic ulcers and ulcer complications) compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"       diclofenac",
"      </a>",
"      at six months [",
"      <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/20\">",
"       20",
"      </a>",
"      ]. In addition, celecoxib was associated with a decrease in liver toxicity, hypertension, and edema compared with the nonselective NSAIDS. At the final study endpoint (one year), there was no statistically significant reduction in ulcers and their complications among patients taking celecoxib. There was substantial patient drop-out making the final study time point difficult to interpret.",
"     </li>",
"     <li>",
"      The effect of rofecoxib on adverse clinical gastrointestinal events (gastroduodenal perforation or obstruction, upper gastrointestinal bleeding, and symptomatic gastroduodenal ulcers) was evaluated in a trial (VIGOR study) of 8076 patients with rheumatoid arthritis who were randomly assigned to rofecoxib or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/28\">",
"       28",
"      </a>",
"      ]. At a median follow-up of nine months, significantly fewer events occurred in the rofecoxib group (2.1 versus 4.5 per 100 patient-years, relative risk 0.5, 95 % CI 0.3-0.6).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A possible concern of selective COX-2 inhibition is the potential to delay healing of gastric erosions or ulcers, an effect that has been observed in mouse models [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/34\">",
"     34",
"    </a>",
"    ]. Although neither a clinically significant nor statistically significant delay in healing of ulcers was observed in the clinical trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    , approximately 40 percent of the patients included in the trials were required to be free of ulcers prior to study entry. In addition, studies on rofecoxib excluded patients with active peptic ulcer disease. Thus, it is still unclear whether the COX-2 inhibitors may induce damage to the GI tract even though there may be no effects on COX-1 activity in vivo at any therapeutic dose. Instead, the observed GI effects of the COX-2 selective inhibitors may be due to the drug effect on healing of ulcers induced through other pathologic effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=see_link\">",
"     \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Effect of low-dose aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential gastroduodenal sparing effect with selective COX-2 agents may be counterbalanced by toxicity from concurrent low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy for primary or secondary prevention of cardiovascular or cerebrovascular disease. As an example, similar rates of ulcers and ulcer complications were noted among those receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    plus low dose aspirin as were those among patients receiving a nonselective NSAID plus aspirin (2.02 and 2.12 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/20\">",
"     20",
"    </a>",
"    ]. Thus, the value of selective COX-2 inhibitors in patients who require aspirin therapy for cardiovascular protection is less clear. If one decides to pursue use of an NSAID or selective COX-2 inhibitor in a patient requiring concomitant aspirin therapy, then consideration should be given to using a proton pump inhibitor prophylactically. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect of combining a COX-2 inhibitor with low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    was investigated in a large study that compared rofecoxib with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/35\">",
"     35",
"    </a>",
"    ]. The combination of rofecoxib (25",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and aspirin was not associated with an increased incidence of dyspepsia, nausea, vomiting, other gastrointestinal symptoms, or a significantly different rate of discontinuation when compared with the use of rofecoxib alone [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/35\">",
"     35",
"    </a>",
"    ]. Unfortunately, the relative risk of serious adverse side effects in those using the selective COX-2 inhibitor alone or with aspirin could not be definitively addressed due to the small number of such events (11 in 5557 patients followed for three months) and to the post-hoc nature of the analysis of the aspirin versus non-aspirin-using subgroups.",
"   </p>",
"   <p>",
"    A similar abrogation of the gastrointestinal sparing effect was seen when lumiracoxib was combined with low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Possible prevention of colon cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have documented an association between the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and other NSAIDs and a reduced risk of colorectal adenomas; this reduction in risk extends to colorectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/37\">",
"     37",
"    </a>",
"    ]. The evidence supporting these associations is provided elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22666?source=see_link\">",
"     \"NSAIDs (including aspirin): Role in prevention of cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One possible mechanism by which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    NSAIDs may prevent colon cancer is the inhibition of COX-2. Studies in human colon cancer have shown increased COX-2 expression when compared with the adjacent colonic mucosa; similar observations have been made in experimental models of colon cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. COX-2 expression may also increase the metastatic potential of colon cancer cells and possibly influence patient survival [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. In one study, for example, COX-2 expression was determined in 76 patients with a variety of stages of colorectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/42\">",
"     42",
"    </a>",
"    ]. Ten-year survival was significantly higher in patients with the lowest levels of COX-2 staining (68 versus 35 percent).",
"   </p>",
"   <p>",
"    These findings suggest that COX-2 activation may promote tumor growth. Consistent with this hypothesis is a study in which human colon cancer cells that expressed high levels of COX-2 were implanted into nude mice; treatment with a selective COX-2 inhibitor reduced tumor formation by 85 to 90 percent and inhibited colony formation of cultured cells [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/39\">",
"     39",
"    </a>",
"    ]. This benefit was not seen with tumor cells that lacked COX-2.",
"   </p>",
"   <p>",
"    There may also be an interaction between COX-2 inhibition and the induction of apoptosis. In one report, the ras mutation (found in 50 percent of colorectal carcinomas) made rat intestinal epithelial cells more resistant to spontaneous apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/43\">",
"     43",
"    </a>",
"    ]. The ras-transformed cells also had increased expression of COX-2. Administration of a COX-2 selective antagonist impaired the growth of these cells by both inhibition of cell proliferation and the induction of apoptosis. However, in another study, a different COX-2 selective antagonist induced apoptosis in a colorectal cancer cell line that lacked detectable COX-2 expression, suggesting that COX-2 selective NSAIDs may induce apoptosis via mechanisms that do not involve COX-2, or it may be the result of a combination of these effects [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A controlled trial involving 83 patients with familial adenomatous polyposis (FAP) suggested that one of the COX-2 inhibitors (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    400 mg twice daily) was associated with a 28 percent reduction in rectal polyps. These data led a FDA advisory panel to recommend the drug for approval in patients with phenotypic expression of FAP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=see_link\">",
"     \"Clinical manifestations and diagnosis of familial adenomatous polyposis\"",
"    </a>",
"    .) The data from the selective COX-2 inhibitor non-familial adenomatous polyp prevention trials APPROVe and APC are still awaited.",
"   </p>",
"   <p>",
"    However, increased rates of cardiovascular events have been noted in some primary prevention trials that utilized the selective COX-2 inhibitors",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    and rofecoxib. The cardiovascular risks associated with COX-2 selective agents, including the results of the polyp prevention trials, are presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=see_link\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Lack of effect upon platelets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generation of prostanoids by activated platelets plays an important role in platelet function and in promoting vasoconstriction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/32/3594?source=see_link&amp;anchor=H2#H2\">",
"     \"Effect of cardiac drugs on platelet function\", section on 'Normal platelet function'",
"    </a>",
"    .) Since production of the potent prostanoid, thromboxane A2, is dependent upon COX-1, inhibition of COX-2 alone should produce little or no effect upon platelet function. This has been substantiated in one study in which doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    that were much larger that those used in clinical practice were given to normal subjects for 10 days; platelet function was assessed with in vitro measures as well as measurement of bleeding time [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/45\">",
"     45",
"    </a>",
"    ]. Neither celecoxib at 600 mg BID (which is greater than the usual maximum dose of 200 mg BID) nor placebo had any measurable effect on platelet function, while",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    500 mg BID produced significant prolongation of the bleeding time and decreases in platelet aggregation and adhesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Reduced risk of bleeding in anticoagulated patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lack of an inhibitory effect on platelet function of the selective COX-2 inhibitors, as noted above, may be valuable when an antiinflammatory effect is needed for a patient who is receiving ongoing anticoagulation. This was illustrated by a case-control study of 1491 reported episodes of bleeding in patients anticoagulated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/46\">",
"     46",
"    </a>",
"    ]. Cases (154) were patients who bleed who reported use of an NSAID (COX-2 selective or not), and controls (183) were warfarin treated patients who reported NSAID use but who did not bleed.",
"   </p>",
"   <p>",
"    Cases more often used a nonselective NSAID than controls (96 versus 88 percent, respectively). The adjusted odds ratio (OR) for bleeding was approximately three-fold higher for those using nonselective agents compared to use of COX-2 inhibitors (OR 3.07, 95 % CI 1.18-8.03). Use of highly selective COX-2 inhibitors was infrequent, with most patients using somewhat selective agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/18/39208?source=see_link\">",
"     nabumetone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/38/35432?source=see_link\">",
"     meloxicam",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Other relatively selective COX-2 inhibitors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Lack of bronchoconstriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and some NSAIDs, selective COX-2 inhibitors appear to have little risk of precipitating bronchospasm in patients with aspirin induced asthma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39944?source=see_link\">",
"     \"Aspirin exacerbated respiratory disease\"",
"    </a>",
"    .) However, despite the reassuring data from clinical trials, it should be noted that the manufacturers' labeling for the coxibs in the United States includes a warning that they should not be given to patients who have experienced asthma, urticaria, or allergic reactions after taking aspirin or other NSAIDs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TOXICITIES AND POSSIBLE TOXICITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data are available concerning the toxicity associated with COX-2 inhibitors outside the gastrointestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/47\">",
"     47",
"    </a>",
"    ]. In addition, the long-term safety of this class of drugs has not been established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Acute renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies in vitro and in animals suggest that the COX-2 enzyme has a significant role in renal development and function [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/48-52\">",
"     48-52",
"    </a>",
"    ]. In mice, for example, deletion of the COX-2 gene is associated with aberrant kidney development after birth, resulting in marked diffuse tubular cysts, glomerular hypoplasia, interstitial fibrosis, and renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/48,53\">",
"     48,53",
"    </a>",
"    ]. The enzyme is also constitutively expressed and occasionally upregulated in the macula densa, cortical thick ascending limb, and cortical collecting duct [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/49\">",
"     49",
"    </a>",
"    ]. In rabbits, the functional effects of selective COX-2 inhibition include an enhanced pressor effect of angiotensin-2 and decreased renal medullary blood flow, urine output, and sodium excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these findings in animals, the clinical trials with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    and rofecoxib did not demonstrate significant changes in renal function associated with treatment at the approved doses for osteoarthritis and rheumatoid arthritis. However, these studies are limited since NSAIDs generally have little toxicity in the general population of patients with rheumatic diseases. The precipitation of hemodynamically-mediated acute renal failure is limited to selected patients in whom the secretion of vasodilator prostaglandins is increased in an attempt to counteract the effect of increased renal vasoconstrictors such as angiotensin II. Patients at risk include those with volume depletion, heart failure, cirrhosis, intrinsic renal disease (eg, diabetic nephropathy), and hypercalcemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=see_link\">",
"     \"NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is evidence that selective COX-2 inhibitors adversely affect renal function in such at risk patients. As examples [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/55-58\">",
"     55-58",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of the literature, acute renal failure",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      severe electrolyte disturbances (particularly hyperkalemia and metabolic acidosis) were clearly precipitated by either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"       celecoxib",
"      </a>",
"      or rofecoxib [",
"      <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/57\">",
"       57",
"      </a>",
"      ]. Clinical characteristics shared by almost all 14 patients included older age and one or more risk factor for NSAID-associated nephrotoxicity, such as baseline renal insufficiency, volume depletion, diabetic nephropathy, congestive heart failure,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      concurrent use of medications that impair renal potassium excretion. After discontinuation of selective COX-2 inhibitors and suspect agents in combination with aggressive supportive therapy, renal function returned to baseline within two days to three weeks. Acute hemodialysis was required in four patients.",
"     </li>",
"     <li>",
"      In another study, 60 elderly patients receiving a low-salt diet were administered rofecoxib (12.5 or 25",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      (50 mg three times per day) or placebo over five days [",
"      <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/56\">",
"       56",
"      </a>",
"      ]. Compared with placebo, 12.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of rofecoxib, 25",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of rofecoxib, and indomethacin significantly lowered the glomerular filtration rate by 8.4, 7.8, and 6.0",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      respectively. A companion study of 15 similar patients found that a single dose of high amounts of rofecoxib (250 mg) had significant and similarly detrimental effects on renal function as a single dose of indomethacin (75 mg) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations suggest that selective COX-2 inhibitors should be",
"    <strong>",
"     avoided",
"    </strong>",
"    in patients with chronic renal insufficiency, severe heart disease, volume depletion,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hepatic failure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/56,59\">",
"     56,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Discussions relating to acute interstitial nephritis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nephrotic syndrome occurring in association with these agents are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=see_link\">",
"     \"NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27209?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute interstitial nephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Sulfonamide allergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The molecular structures of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    and valdecoxib include a sulfonamide moiety, whereas rofecoxib contained a sulfone. The sulfur components are necessary for receptor binding, but their varying structures have different potentials for causing allergic reactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Celecoxib",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been recommended that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    not be given to patients who are allergic to sulfonamide antibiotics. However, studies that included a total of 151 patients with a history of allergy to a sulfonamide antibiotic found no allergic reactions to celecoxib [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. These observations suggest that the sulfonamide structure is different in antibiotics and celecoxib and thus allow cautious use of this agent in patients with a history of an allergic reaction to a sulfonamide antibiotic.",
"   </p>",
"   <p>",
"    One case of suspected allergic reaction with fatal leukocytoclastic vasculitis has been reported in a patient taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/62\">",
"     62",
"    </a>",
"    ]. Although there was no prior history of allergy to sulfonamide medications, the initial maculopapular rash, which evolved to urticaria, angioedema, palpable purpura, and then necrotic skin lesions, was suspicious for a hypersensitivity reaction. Rhabdomyolysis, acidosis, and multiple organ failure led to the patient's demise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Valdecoxib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial clinical trials of valdecoxib included patients with a history of sulfonamide allergy, and there was no higher incidence of allergic reactions noted. As a result, sulfonamide allergy was initially not considered a contraindication to the use of valdecoxib. However, postmarketing reports of serious anaphylactoid reactions in sulfonamide allergic patients who received valdecoxib led to relabeling with a caution against use of this agent in patients with an allergy to sulfonamide containing antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/63\">",
"     63",
"    </a>",
"    ]. In April 2005, the FDA recommended and the manufacturer agreed to a withdrawal of valdecoxib from the US and European Union markets.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Anaphylactoid reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have had anaphylactoid reactions to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or nonselective NSAIDs may be at risk for similar effects when challenged with COX-2 selective agents. This was illustrated by one patient with well documented anaphylactoid reactions to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/28/17864?source=see_link\">",
"     diclofenac-misoprostol",
"    </a>",
"    who had a similar reaction (shaking, flushing, and hypotension) when given rofecoxib [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/64\">",
"     64",
"    </a>",
"    ]. Rapid resolution of symptoms and hypotension followed subcutaneous epinephrine and intravenous administration of saline,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anaphylactoid reactions and angioedema have been reported in association with valdecoxib; serious skin reactions have also been noted, including exfoliative dermatitis, toxic epidermal necrolysis, and the Stevens-Johnson syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A discussion of adverse cardiovascular effects that may occur with some selective COX-2 inhibitors is presented in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=see_link\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Aseptic meningitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postmarketing surveillance has identified at least five cases of aseptic meningitis in patients treated with rofecoxib [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/66\">",
"     66",
"    </a>",
"    ]. This uncommon side effect also occurs in patients treated with nonselective NSAIDs. The incidence of aseptic meningitis in patients receiving rofecoxib is estimated to be less than 2 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Possible proinflammatory activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a large body of evidence suggests that COX-2 is induced in inflammation, the effect of COX-2 inhibition on inflammation is not completely understood:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      COX-2 knockout mice are as susceptible to inflammation as intact mice [",
"      <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/48,67\">",
"       48,67",
"      </a>",
"      ]. Paradoxically, COX-1 knockout mice show less gastric inflammation and ulceration after the administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      than intact mice even though their gastric prostaglandin E2 levels are reduced by 99 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      COX-2 may have antiinflammatory properties. Using an animal model of inflammation and carrageenin-induced pleurisy, one study showed that maximal COX-2 expression coincided with inflammatory resolution and was associated with minimal prostaglandin E2 synthesis [",
"      <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Human T lymphocytes express the COX-2 isoenzyme where it may serve a role in both the early and late events of T cell activation, such as the production of interleukin-2, tumor necrosis factor-alpha, and interferon-gamma [",
"      <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Healing of musculoskeletal injury",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Possible effect on fracture healing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small increased risk of nonunion in patients with bone fractures has been reported with the use of nonselective NSAIDs or COX-2 selective agents. However, a causal relationship has not been proven, and the effect of these drugs on fracture healing in humans is uncertain. At present, we would not avoid the use of these agents in patients with fractures, given the very small absolute risk. This is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link&amp;anchor=H23#H23\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\", section on 'Possible effect on fracture healing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Possible effect on tendon injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Possible effects on tendon and ligament injury are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link&amp;anchor=H24#H24\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\", section on 'Possible effect on tendon injury'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Effects on vision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Irreversible blindness, temporary loss of vision, chromatopsia, and other visual abnormalities have occurred in patients taking selective COX-2 inhibitors. A postmarketing surveillance program in New Zealand identified seven cases of visual disturbances in patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    or rofecoxib; in the six cases where the outcome was known, vision recovered after the selective COX-2 inhibitor was stopped [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/71\">",
"     71",
"    </a>",
"    ]. As of May 2003, reports to the World Health Organization's Collaborating Center for International Drug Monitoring included 37 cases of blindness and 14 cases of temporary blindness associated with use of selective COX-2 inhibitors. However, a possible association with temporary or permanent visual loss was also noted with nonselective NSAIDs.",
"   </p>",
"   <p>",
"    It is difficult, from postmarketing reports, to conclude that there is a clear causal relationship between use of COX-2 inhibitors or NSAIDs and vision problems. Although the issue of causality deserves further study, occurrence of otherwise unexplained loss of vision, blurred vision, color vision changes, or scotomata should lead to discontinuation of an NSAID or selective COX-2 inhibitor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4966756\">",
"    <span class=\"h2\">",
"     Pregnancy and lactation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety of NSAIDs during pregnancy and lactation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link&amp;anchor=H7#H7\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'NSAIDs and aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     OTHER RELATIVELY SELECTIVE COX-2 INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some older NSAIDs are also relatively selective for the COX-2 receptor at low doses.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/18/39208?source=see_link\">",
"     Nabumetone",
"    </a>",
"    , for example, appears to be a more effective inhibitor of COX-2 than COX-1 in some experimental systems [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/72\">",
"     72",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/35/13881?source=see_link\">",
"     Etodolac",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/38/35432?source=see_link\">",
"     meloxicam",
"    </a>",
"    also inhibit the COX-2 isoform more than COX-1 (10 to 1 ratio) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/73,74\">",
"     73,74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Nabumetone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited clinical data suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/18/39208?source=see_link\">",
"     nabumetone",
"    </a>",
"    may be less likely to induce gastric ulcers than other NSAIDs. However, relative inhibition of COX-2 decreases and the risk of ulcer disease increases when higher doses of nabumetone are used. In one report, for example, the administration of nabumetone to healthy human volunteers at an adequate antiinflammatory dose inhibited COX-2 and COX-1 to the same degree [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/72\">",
"     72",
"    </a>",
"    ]. Use of an in vitro model showed that 6-MNA (the active metabolite of nabumetone) also equally inhibited both COX isoforms in a whole blood system consisting of inducible mononuclear cells. These results were supported by a second study that found that most NSAIDs did not spare COX-1 activity at therapeutic concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/75\">",
"     75",
"    </a>",
"    ]. Thus, rather than a selective effect on COX-2, the relative gastric protection observed with nabumetone may be due to the neutral state of its prodrug formulation and the fact that 6-MNA is not a powerful inhibitor of COX at low doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Meloxicam",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/38/35432?source=see_link\">",
"     Meloxicam",
"    </a>",
"    , an NSAID with similar properties as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/35/13881?source=see_link\">",
"     etodolac",
"    </a>",
"    , is approved by the Federal Drug Administration of the United States for the treatment of osteoarthritis at a starting dose of 7.5 mg per day. This agent has been available in Europe and elsewhere at doses of 7.5 and 15 mg once per day. As with etodolac, meloxicam principally inhibits the activity of COX-2 at low doses, while it has more effects upon COX-1 at higher doses. This loss of COX-2 selectivity with higher doses is mirrored in an increase in the rate of serious gastrointestinal adverse events when a dose of 15",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    is compared with 7.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, this agent has similar effects when used clinically to those of the other NSAIDs. As an example, a double blind randomized trial of 774 patients with OA compared various doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/38/35432?source=see_link\">",
"     meloxicam",
"    </a>",
"    (3.75 mg, 7.5 mg, and 15 mg per day) with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    50 mg BID and placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/77\">",
"     77",
"    </a>",
"    ]. The 7.5 and 15 mg per day doses of meloxicam and diclofenac were approximately equal in efficacy and were superior to placebo. Meloxicam was associated with more adverse events than placebo but fewer than diclofenac (58, 48, and 66 percent, respectively). Rates of serious adverse drug related reactions were less than 3 percent for patients receiving either diclofenac or meloxicam versus 1.3 percent for placebo. Mild adverse gastrointestinal side effects occurred in 17, 17, and 19 percent of placebo, meloxicam 15 mg per day, and diclofenac treated patients, respectively.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/38/35432?source=see_link\">",
"     Meloxicam",
"    </a>",
"    is also more efficacious than placebo in patients with rheumatoid arthritis. A randomized trial compared three different daily doses of meloxicam (7.5 mg, 15 mg, and 22.5 mg) with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    150 mg per day and with placebo in 894 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/78\">",
"     78",
"    </a>",
"    ]. The 15 and 22.5 mg daily doses of meloxicam and diclofenac had similar efficacy and were significantly superior to placebo. Elevation of liver enzymes was more frequent with diclofenac than meloxicam or placebo, while gastrointestinal adverse event rates were similar in the three groups. Greater than 0.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (26",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    increases in serum creatinine were more frequent in the highest dose meloxicam and diclofenac groups when compared with placebo (9.5, 8.5, and 3.4 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     CLINICAL ROLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for an NSAID (selective or nonselective), as opposed to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , should be assessed in any patient for whom prescription of a selective COX-2 inhibitor is being considered. In the absence of clinically apparent inflammation, a simple analgesic may be sufficient. As an example, use of acetaminophen may suffice for some patients with osteoarthritis and is a safe and less costly alternative than a selective COX-2 inhibitor. For other patients, use of a low-potency opioid analgesic alone or in combination with acetaminophen may be preferred to an NSAID. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14714?source=see_link\">",
"     \"Pharmacologic therapy of osteoarthritis\"",
"    </a>",
"    .) These suggestions are similar to the recommendations of the American Heart Association for patients with known, or at high risk for, cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A patient who requires an antiinflammatory agent for a well established indication (eg, rheumatoid arthritis) and who is at high risk for gastroduodenal damage (ie, has one or more risk factors for developing NSAID-associated gastroduodenal ulcer and complications, such as a prior history of ulcer disease or gastrointestinal bleeding; age &gt;65; and concomitant use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , or glucocorticoids) may be treated with a selective COX-2 inhibitor or a nonselective NSAID plus a gastroprotective agent (ie, a proton pump inhibitor or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/58/12197?source=see_link\">",
"     \"NSAIDs (including aspirin): Secondary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, additional testing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    and other selective COX-2 inhibitor in patients at high risk for ischemic heart and cerebrovascular disease will be necessary before the safety of this approach can be fully evaluated. Pending these data, patients should be informed of the potential concern, and selective COX-2 inhibitor should be avoided in the setting of acute ST elevation (Q wave) myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/80-82\">",
"     80-82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     Celecoxib",
"    </a>",
"    at 100 to 200 mg once per day appears to be the safest dose. Higher doses are clearly associated with an increased cardiovascular risk and should be avoided, especially in patients with known cardiovascular risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/48/13066/abstract/83\">",
"     83",
"    </a>",
"    ]. However, the 400 mg twice daily dose is reserved for patients with familial colonic adenomatous polyposis, and this dose has been shown to decrease both the incidence and size of these polyps. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22666?source=see_link\">",
"     \"NSAIDs (including aspirin): Role in prevention of cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients beginning treatment with an NSAID or a selective COX-2 inhibitor who require use of low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for another indication (most often for known ischemic cardiovascular disease), the lowest effective dose of aspirin should be used (typically 81 mg daily for cardiovascular prevention), and concomitant use of a proton pump inhibitor may be necessary to mitigate the risk conferred by aspirin use alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"       \"Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who require chronic use of NSAIDs, one must first consider their risk of NSAID-related gastroduodenal toxicity (",
"    <a class=\"graphic graphic_algorithm graphicRef81893 \" href=\"UTD.htm?24/35/25150\">",
"     algorithm 1",
"    </a>",
"    ). Risk factors for NSAID-related gastroduodenal toxicity include age &gt;65 years, use of an anticoagulant (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , direct thrombin inhibitors, factor Xa inhibitors, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ), prior gastrointestinal bleed, active peptic ulcer disease, and concomitant use of oral glucocorticoids. If any of these risk factors are present, then one should reconsider whether NSAID therapy is advised and consider other analgesic options (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , low potency opioids, joint protection with a cane or brace, musculoskeletal injections, or orthopedic interventions). If NSAID therapy is being considered in a patient with risk factors for NSAID-related gastroduodenal toxicity, there are three safer options: an NSAID with a proton pump inhibitor, an NSAID with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    , or a selective COX-2 inhibitor (with or without a proton pump inhibitor). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with known coronary heart disease or cerebrovascular disease who require concomitant therapy with low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    should only receive a selective COX-2 inhibitor after full disclosure of their possible cardiovascular risks. The safety of nonselective NSAIDs in this patient group has not been established, but they may pose similar cardiovascular risks to the selective COX-2 inhibitors. Patients receiving low dose aspirin may require prophylaxis to prevent gastroduodenal damage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/1\">",
"      Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/2\">",
"      Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs--differences and similarities. N Engl J Med 1991; 324:1716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/3\">",
"      Abramson SB, Weissmann G. The mechanisms of action of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1989; 32:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/4\">",
"      Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993; 268:6610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/5\">",
"      DeWitt DL, Meade EA, Smith WL. PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal antiinflammatory drugs. Am J Med 1993; 95:40S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/6\">",
"      DeWitt DL, el-Harith EA, Kraemer SA, et al. The aspirin and heme-binding sites of ovine and murine prostaglandin endoperoxide synthases. J Biol Chem 1990; 265:5192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/7\">",
"      Shimokawa T, Smith WL. Prostaglandin endoperoxide synthase. The aspirin acetylation region. J Biol Chem 1992; 267:12387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/8\">",
"      Shimokawa T, Smith WL. Essential histidines of prostaglandin endoperoxide synthase. His-309 is involved in heme binding. J Biol Chem 1991; 266:6168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/9\">",
"      Shimokawa T, Kulmacz RJ, DeWitt DL, Smith WL. Tyrosine 385 of prostaglandin endoperoxide synthase is required for cyclooxygenase catalysis. J Biol Chem 1990; 265:20073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/10\">",
"      Toh H. Prostaglandin endoperoxide synthase contains an EGF-like domain. FEBS Lett 1989; 258:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/11\">",
"      Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 1998; 12:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/12\">",
"      Lee SH, Soyoola E, Chanmugam P, et al. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem 1992; 267:25934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/13\">",
"      Doroudi R, Gan LM, Selin Sj&ouml;gren L, Jern S. Effects of shear stress on eicosanoid gene expression and metabolite production in vascular endothelium as studied in a novel biomechanical perfusion model. Biochem Biophys Res Commun 2000; 269:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/14\">",
"      Lim H, Paria BC, Das SK, et al. Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell 1997; 91:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/15\">",
"      Khan KN, Stanfield KM, Harris RK, Baron DA. Expression of cyclooxygenase-2 in the macula densa of human kidney in hypertension, congestive heart failure, and diabetic nephropathy. Ren Fail 2001; 23:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/16\">",
"      Cheer SM, Goa KL. Parecoxib (parecoxib sodium). Drugs 2001; 61:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/17\">",
"      Stoltz RR, Harris SI, Kuss ME, et al. Upper GI mucosal effects of parecoxib sodium in healthy elderly subjects. Am J Gastroenterol 2002; 97:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/18\">",
"      Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999; 282:1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/19\">",
"      Emery P, Zeidler H, Kvien TK, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999; 354:2106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/20\">",
"      Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/21\">",
"      Bensen WG, Fiechtner JJ, McMillen JI, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999; 74:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/22\">",
"      Dougados M, B&eacute;hier JM, Jolchine I, et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 2001; 44:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/23\">",
"      Saag K, van der Heijde D, Fisher C, et al. Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group. Arch Fam Med 2000; 9:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/24\">",
"      Cannon GW, Caldwell JR, Holt P, et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group. Arthritis Rheum 2000; 43:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/25\">",
"      Day R, Morrison B, Luza A, et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group. Arch Intern Med 2000; 160:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/26\">",
"      Gibofsky A, Williams GW, McKenna F, Fort JG. Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial. Arthritis Rheum 2003; 48:3102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/27\">",
"      Kivitz AJ, Greenwald MW, Cohen SB, et al. Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial. J Am Geriatr Soc 2004; 52:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/28\">",
"      Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/29\">",
"      Bensen W, Weaver A, Espinoza L, et al. Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen. Rheumatology (Oxford) 2002; 41:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/30\">",
"      Pavelka K, Recker DP, Verburg KM. Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial. Rheumatology (Oxford) 2003; 42:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/31\">",
"      Tannenbaum H, Berenbaum F, Reginster JY, et al. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib. Ann Rheum Dis 2004; 63:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/32\">",
"      Schnitzer TJ, Beier J, Geusens P, et al. Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 51:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/33\">",
"      Wiesenhutter CW, Boice JA, Ko A, et al. Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005; 80:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/34\">",
"      Mizuno H, Sakamoto C, Matsuda K, et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 1997; 112:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/35\">",
"      Lisse JR, Perlman M, Johansson G, et al. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Ann Intern Med 2003; 139:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/36\">",
"      Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004; 364:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/37\">",
"      Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995; 333:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/38\">",
"      Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/39\">",
"      Sheng H, Shao J, Kirkland SC, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997; 99:2254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/40\">",
"      DuBois RN, Radhika A, Reddy BS, Entingh AJ. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 1996; 110:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/41\">",
"      Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 1997; 94:3336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/42\">",
"      Sheehan KM, Sheahan K, O'Donoghue DP, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 1999; 282:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/43\">",
"      Sheng GG, Shao J, Sheng H, et al. A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells. Gastroenterology 1997; 113:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/44\">",
"      Elder DJ, Halton DE, Hague A, Paraskeva C. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin Cancer Res 1997; 3:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/45\">",
"      Leese PT, Hubbard RC, Karim A, et al. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol 2000; 40:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/46\">",
"      Knijff-Dutmer EA, Van der Palen J, Schut G, Van de Laar MA. The influence of cyclo-oxygenase specificity of non-steroidal anti-inflammatory drugs on bleeding complications in concomitant coumarine users. QJM 2003; 96:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/47\">",
"      Lipsky PE, Brooks P, Crofford LJ, et al. Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease. Arch Intern Med 2000; 160:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/48\">",
"      Morham SG, Langenbach R, Loftin CD, et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995; 83:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/49\">",
"      Ferguson S, H&eacute;bert RL, Laneuville O. NS-398 upregulates constitutive cyclooxygenase-2 expression in the M-1 cortical collecting duct cell line. J Am Soc Nephrol 1999; 10:2261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/50\">",
"      K&ouml;mhoff M, Wang JL, Cheng HF, et al. Cyclooxygenase-2-selective inhibitors impair glomerulogenesis and renal cortical development. Kidney Int 2000; 57:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/51\">",
"      Harris RC. Cyclooxygenase-2 in the kidney. J Am Soc Nephrol 2000; 11:2387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/52\">",
"      Khan KN, Paulson SK, Verburg KM, et al. Pharmacology of cyclooxygenase-2 inhibition in the kidney. Kidney Int 2002; 61:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/53\">",
"      Norwood VF, Morham SG, Smithies O. Postnatal development and progression of renal dysplasia in cyclooxygenase-2 null mice. Kidney Int 2000; 58:2291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/54\">",
"      Qi Z, Hao CM, Langenbach RI, et al. Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest 2002; 110:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/55\">",
"      Perazella MA, Eras J. Are selective COX-2 inhibitors nephrotoxic? Am J Kidney Dis 2000; 35:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/56\">",
"      Swan SK, Rudy DW, Lasseter KC, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med 2000; 133:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/57\">",
"      Perazella MA, Tray K. Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs. Am J Med 2001; 111:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/58\">",
"      Braden GL, O'Shea MH, Mulhern JG, Germain MJ. Acute renal failure and hyperkalaemia associated with cyclooxygenase-2 inhibitors. Nephrol Dial Transplant 2004; 19:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/59\">",
"      Dunn MJ. Are COX-2 selective inhibitors nephrotoxic? Am J Kidney Dis 2000; 35:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/60\">",
"      Patterson R, Bello AE, Lefkowith J. Immunologic tolerability profile of celecoxib. Clin Ther 1999; 21:2065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/61\">",
"      Shapiro LE, Knowles SR, Weber E, et al. Safety of celecoxib in individuals allergic to sulfonamide: a pilot study. Drug Saf 2003; 26:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/62\">",
"      Schneider F, Meziani F, Chartier C, et al. Fatal allergic vasculitis associated with celecoxib. Lancet 2002; 359:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/63\">",
"      New treatment for hemophilia. FDA Consum 2003; 37:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/64\">",
"      Schellenberg RR, Isserow SH. Anaphylactoid reaction to a cyclooxygenase-2 inhibitor in a patient who had a reaction to a cyclooxygenase-1 inhibitor. N Engl J Med 2001; 345:1856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/65\">",
"      \"The Pink Sheet\" FDC Reports. Chevy Chase, MD 2002; 64(45):19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/66\">",
"      Bonnel RA, Villalba ML, Karwoski CB, Beitz J. Aseptic meningitis associated with rofecoxib. Arch Intern Med 2002; 162:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/67\">",
"      Dinchuk JE, Car BD, Focht RJ, et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995; 378:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/68\">",
"      Langenbach R, Morham SG, Tiano HF, et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995; 83:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/69\">",
"      Gilroy DW, Colville-Nash PR, Willis D, et al. Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 1999; 5:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/70\">",
"      I&ntilde;iguez MA, Punz&oacute;n C, Fresno M. Induction of cyclooxygenase-2 on activated T lymphocytes: regulation of T cell activation by cyclooxygenase-2 inhibitors. J Immunol 1999; 163:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/71\">",
"      Coulter DM, Clark DW, Savage RL. Celecoxib, rofecoxib, and acute temporary visual impairment. BMJ 2003; 327:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/72\">",
"      Roth SH. NSAID gastropathy. A new understanding. Arch Intern Med 1996; 156:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/73\">",
"      Patrignani P, Panara MR, Greco A, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 1994; 271:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/74\">",
"      Glaser K, Sung ML, O'Neill K, et al. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. Eur J Pharmacol 1995; 281:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/75\">",
"      Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/76\">",
"      Singh G, Lanes S, Triadafilopoulos G. Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. Am J Med 2004; 117:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/77\">",
"      Yocum D, Fleischmann R, Dalgin P, et al. Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, multiple-dose, placebo-controlled trial. The Meloxicam Osteoarthritis Investigators. Arch Intern Med 2000; 160:2947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/78\">",
"      Furst DE, Kolba KS, Fleischmann R, et al. Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double blind, dose response study versus placebo and diclofenac. J Rheumatol 2002; 29:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/79\">",
"      Bennett JS, Daugherty A, Herrington D, et al. The use of nonsteroidal anti-inflammatory drugs (NSAIDs): a science advisory from the American Heart Association. Circulation 2005; 111:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/80\">",
"      Solomon DH. Selective cyclooxygenase 2 inhibitors and cardiovascular events. Arthritis Rheum 2005; 52:1968.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Public Health Advisory: FDA Announces Important Changes and Additional Warnings for COX-2 Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) www.fda.gov/cder/drug/advisory/COX2.htm (Accessed on August 23, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/82\">",
"      Canadian Cardiovascular Society, American Academy of Family Physicians, American College of Cardiology, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008; 51:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/48/13066/abstract/83\">",
"      Solomon SD, Wittes J, Finn PV, et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 2008; 117:2104.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7992 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-0B2EC3AACF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_48_13066=[""].join("\n");
var outline_f12_48_13066=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BENEFITS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Analgesia and antiinflammatory activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Reduction in gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Effect of low-dose aspirin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Possible prevention of colon cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Lack of effect upon platelets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Reduced risk of bleeding in anticoagulated patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Lack of bronchoconstriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TOXICITIES AND POSSIBLE TOXICITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Acute renal failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Sulfonamide allergy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Celecoxib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Valdecoxib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Anaphylactoid reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Aseptic meningitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Possible proinflammatory activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Healing of musculoskeletal injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Possible effect on fracture healing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Possible effect on tendon injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Effects on vision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4966756\">",
"      Pregnancy and lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      OTHER RELATIVELY SELECTIVE COX-2 INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Nabumetone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Meloxicam",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      CLINICAL ROLE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7992\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7992|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?24/35/25150\" title=\"algorithm 1\">",
"      Choosing an antiinflammatory",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7992|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/29/34269\" title=\"figure 1\">",
"      Prostaglandin synthesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/51/5950\" title=\"figure 2\">",
"      COX 1 versus COX 2 inhibition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/42/35501\" title=\"figure 3\">",
"      Fewer ulcers with celecoxib",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39944?source=related_link\">",
"      Aspirin exacerbated respiratory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35194?source=related_link\">",
"      Assessment and treatment of ankylosing spondylitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10375?source=related_link\">",
"      COX-2 inhibitors and gastroduodenal toxicity &mdash; major clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=related_link\">",
"      COX-2 selective inhibitors: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27209?source=related_link\">",
"      Clinical manifestations and diagnosis of acute interstitial nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=related_link\">",
"      Clinical manifestations and diagnosis of familial adenomatous polyposis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/32/3594?source=related_link\">",
"      Effect of cardiac drugs on platelet function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=related_link\">",
"      NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22666?source=related_link\">",
"      NSAIDs (including aspirin): Role in prevention of cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/58/12197?source=related_link\">",
"      NSAIDs (including aspirin): Secondary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=related_link\">",
"      NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1336?source=related_link\">",
"      NSAIDs: Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14714?source=related_link\">",
"      Pharmacologic therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_48_13067="Causes of thrombocytopenia during pregnancy";
var content_f12_48_13067=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62669&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62669&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major causes of thrombocytopenia during pregnancy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Spurious, due to EDTA-induced platelet aggregation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gestational thrombocytopenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preeclampsia-eclampsia, including HELLP syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autoimmune thrombocytopenia (idiopathic or related to drugs, systemic lupus erythematosus, antiphospholipid antibodies, or HIV)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disseminated intravascular coagulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome or, rarely, congenital TTP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital platelet disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bone marrow disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypersplenism",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Guidelines for the investigation and Management of Idiopathic Tnrombocytopenic Purpura in Adults, Children and in Pregnancy. Br J Haematol 2003; 120:574.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_48_13067=[""].join("\n");
var outline_f12_48_13067=null;
var title_f12_48_13068="Comparison conization technique";
var content_f12_48_13068=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61097&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61097&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of different techniques for cervical (uterine cervix) conization",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Advantages",
"      </td>",
"      <td class=\"subtitle1\">",
"       Disadvantages",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"       Cold knife conization",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Technical simplicity",
"      </td>",
"      <td>",
"       General or regional anesthetic required",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Excellent specimen quality",
"      </td>",
"      <td>",
"       Distortion after healing",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Complication rate higher",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"       Laser conization",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Good specimen quality",
"      </td>",
"      <td>",
"       Technically difficult",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Good hemostasis",
"      </td>",
"      <td>",
"       Expense and upkeep of equipment",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Healing with minimal distortion",
"      </td>",
"      <td>",
"       Some thermal damage",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Low complication rate",
"      </td>",
"      <td>",
"       A narrow deep cone is difficult",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Can be done in an office setting",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Flexible treatment of endocervix",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"       Large loop excision of the transformation zone",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Easily done in the office setting",
"      </td>",
"      <td>",
"       Some thermal damage",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Rapid performance",
"      </td>",
"      <td>",
"       A large or deep cone may be difficult to perform in the office and result in more thermal damage if a second loop excision is required",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Technically easy",
"      </td>",
"      <td colspan=\"1\" rowspan=\"5\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Equipment inexpensive",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Low complication rate",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Good specimen quality",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Healing with minimal distortion",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_48_13068=[""].join("\n");
var outline_f12_48_13068=null;
var title_f12_48_13069="Causes of an elevated CA 125";
var content_f12_48_13069=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F81621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F81621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Conditions associated with an elevated serum CA 125 concentration",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Gynecologic malignancies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Epithelial ovarian, fallopian tube, and primary peritoneal cancers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Endometrial cancer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Benign gynecologic conditions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Benign ovarian neoplasms",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Functional ovarian cysts",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Endometriosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Meig syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Adenomyosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Uterine leiomyomas",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pelvic inflammatory disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ovarian hyperstimulation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pregnancy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Menstruation",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Nongynecologic conditions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cirrhosis and other liver disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ascites",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Colitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diverticulitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Appendicular abscess",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tuberculosis peritonitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pancreatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pleural effusion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pulmonary embolism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pneumonia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cystic fibrosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Heart failure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Myocardiopathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Myocardial infarction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pericardial disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Renal insufficiency",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Urinary tract infection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Recent surgery",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Systemic lupus erythematosus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sarcoidosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Nongynecologic cancers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Breast",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Colon",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Liver",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gallbladder",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pancreas",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lung",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hematologic malignancies",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Buamah P. J Surg Oncol 2000; 75:264.",
"      </li>",
"      <li>",
"       Miralles C, et. al. Ann Surg Oncol 2003; 10:150.",
"      </li>",
"      <li>",
"       Moss EL, et al. J Clin Pathol 2005; 58:308.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_48_13069=[""].join("\n");
var outline_f12_48_13069=null;
var title_f12_48_13070="Miscarriage rates by age";
var content_f12_48_13070=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F81823&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F81823&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 539px\">",
"   <div class=\"ttl\">",
"    Percentages of ART cycles using fresh nondonor eggs or embryos that resulted in miscarriage, by age of woman, 2006",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 519px; height: 401px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A woman's age not only affects the chance for pregnancy when her own eggs are used, but also affects her risk for miscarriage. The above figure shows the percentages of ART cycles started in 2006 that resulted in miscarriage for women of different ages. The percentages of ART cycles that resulted in miscarriage were below 14 percent among women younger than 35. The percentages of ART cycles that resulted in miscarriages began to increase among women in their mid- to late 30s and continued to increase with age, reaching 28 percent at age 40 and 56 percent among women older than 43.",
"    <br>",
"     The risk for miscarriage observed among women undergoing ART procedures using fresh nondonor eggs or embryos appear to be similar to those reported in various studies of other pregnant women in the United States.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced from: Centers for Disease Control and Prevention, American Society for Reproductive Medicine, Society for Assisted Reproductive Technology. 2006 Assisted Reproductive Technology Success Rates: National Summary and Fertility Clinic Reports, Atlanta: Centers for Disease Control and Prevention, 2008.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_48_13070=[""].join("\n");
var outline_f12_48_13070=null;
var title_f12_48_13071="Osteoarthritis following ankle fracture";
var content_f12_48_13071=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Osteoarthritis following ankle fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 238px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ankle osteoarthritis developed in this 41-year-old male after an ankle injury with ligamentous damage and distal fibular fracture. Callus at the distal fibular fracture site, several centimeters above the joint line (upper arrow), and medial joint line narrowing with sclerotic changes (lower arrow), suggestive of osteoarthritis, can be seen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott M Koehler, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_48_13071=[""].join("\n");
var outline_f12_48_13071=null;
